<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d13" for="edge" attr.name="truncate" attr.type="string" />
  <key id="d12" for="edge" attr.name="created_at" attr.type="long" />
  <key id="d11" for="edge" attr.name="file_path" attr.type="string" />
  <key id="d10" for="edge" attr.name="source_id" attr.type="string" />
  <key id="d9" for="edge" attr.name="keywords" attr.type="string" />
  <key id="d8" for="edge" attr.name="description" attr.type="string" />
  <key id="d7" for="edge" attr.name="weight" attr.type="double" />
  <key id="d6" for="node" attr.name="truncate" attr.type="string" />
  <key id="d5" for="node" attr.name="created_at" attr.type="long" />
  <key id="d4" for="node" attr.name="file_path" attr.type="string" />
  <key id="d3" for="node" attr.name="source_id" attr.type="string" />
  <key id="d2" for="node" attr.name="description" attr.type="string" />
  <key id="d1" for="node" attr.name="entity_type" attr.type="string" />
  <key id="d0" for="node" attr.name="entity_id" attr.type="string" />
  <graph edgedefault="undirected">
    <node id="Biosci Trends">
      <data key="d0">Biosci Trends</data>
      <data key="d1">organization</data>
      <data key="d2">Biosci Trends is a publication that featured research findings related to medical science.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Polymerase">
      <data key="d0">SARS-CoV-2 Polymerase</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 polymerase is an enzyme involved in the replication of the SARS-CoV-2 virus, which was studied for its mechanism of stalling influenced by remdesivir.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="Kalil AC">
      <data key="d0">Kalil AC</data>
      <data key="d1">person</data>
      <data key="d2">Kalil AC is a researcher associated with the ACTT-2 Study Group, focusing on treatments for COVID-19.&lt;SEP&gt;Kalil AC is a researcher associated with the ACTT-2 Study group investigating treatments for COVID-19.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="Baricitinib">
      <data key="d0">Baricitinib</data>
      <data key="d1">drug</data>
      <data key="d2">Baricitinib is a Janus-kinase STAT signalling inhibitor used in combination with Remdesivir to reduce recovery time in hospitalized COVID-19 pneumonia patients.&lt;SEP&gt;Baricitinib is a medication evaluated in combination with remdesivir for treating hospitalized adults with COVID-19.&lt;SEP&gt;Baricitinib is a Janus-kinase inhibitor evaluated in combination with Remdesivir for reducing recovery time in COVID-19 patients.&lt;SEP&gt;Baricitinib is a medication used in conjunction with remdesivir for treating hospitalized adults with COVID-19.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="N Engl J Med">
      <data key="d0">N Engl J Med</data>
      <data key="d1">organization</data>
      <data key="d2">N Engl J Med is a prestigious medical journal that published significant research on COVID-19 treatments.&lt;SEP&gt;N Engl J Med is a medical journal that published findings related to the importation and transmission of a novel coronavirus in Vietnam.&lt;SEP&gt;The New England Journal of Medicine (N Engl J Med) is a prestigious medical journal featuring articles on clinical trials and vaccine research.&lt;SEP&gt;The New England Journal of Medicine is a prestigious journal publishing findings related to COVID-19 vaccines.&lt;SEP&gt;N Engl J Med is a journal that published findings related to the transmission of the novel coronavirus.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="Lopinavir-Ritonavir">
      <data key="d0">Lopinavir-Ritonavir</data>
      <data key="d1">drug</data>
      <data key="d2">Lopinavir-Ritonavir is an antiviral drug combination that has been studied in the context of treating SARS and COVID-19.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="Hydroxychloroquine">
      <data key="d0">Hydroxychloroquine</data>
      <data key="d1">drug</data>
      <data key="d2">Hydroxychloroquine is an anti-malarial drug that was recently trialed for preventing SARS-CoV-2 infection but proved ineffective in healthy exposed individuals.&lt;SEP&gt;Hydroxychloroquine is an anti-malarial drug studied for its potential role in preventing COVID-19.&lt;SEP&gt;Hydroxychloroquine is a derivative of chloroquine evaluated for its effectiveness in preventing SARS-CoV-2 infection after exposure.&lt;SEP&gt;Hydroxychloroquine is a drug that was assessed for post-exposure therapy against SARS-CoV-2 but found ineffective in preventing infection.&lt;SEP&gt;Hydroxychloroquine is a derivative of chloroquine examined in trials for the prevention of COVID-19.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="BCN-PEP-CoV2 Research Group">
      <data key="d0">BCN-PEP-CoV2 Research Group</data>
      <data key="d1">organization</data>
      <data key="d2">BCN-PEP-CoV2 Research Group is a collaborative group involved in researching COVID-19 prevention strategies.&lt;SEP&gt;The BCN-PEP-CoV2 Research Group is involved in a trial concerning the prevention of COVID-19 using hydroxychloroquine.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791237</data>
      <data key="d6" />
    </node>
    <node id="ACTT-2 Study Group Members">
      <data key="d0">ACTT-2 Study Group Members</data>
      <data key="d1">organization</data>
      <data key="d2">The ACTT-2 Study Group Members are a collective of researchers involved in studies assessing COVID-19 treatments.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="Cao B">
      <data key="d0">Cao B</data>
      <data key="d1">person</data>
      <data key="d2">Cao B is a researcher who participated in the trial of Lopinavir-Ritonavir for adults hospitalized with severe COVID-19.&lt;SEP&gt;Cao B is a researcher involved in trials using Lopinavir-Ritonavir for severe COVID-19.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="Wang Y">
      <data key="d0">Wang Y</data>
      <data key="d1">person</data>
      <data key="d2">Wang Y is a researcher associated with studies related to COVID-19 treatments, including Lopinavir-Ritonavir.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="Mehta AK">
      <data key="d0">Mehta AK</data>
      <data key="d1">person</data>
      <data key="d2">Mehta AK is a researcher involved in the ACTT-2 Study Group focusing on COVID-19.&lt;SEP&gt;Mehta AK is a member of the ACTT-2 Study group, involved in research on COVID-19 therapies.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="OVID-Vac">
      <data key="d0">OVID-Vac</data>
      <data key="d1">organization</data>
      <data key="d2">OVID-Vac is a vaccine that efficiently neutralized the spike protein from B.1.1.7 and B.1.351 strains, suggesting potential protection against SARS-CoV-2 variants.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="mRNA Vaccines">
      <data key="d0">mRNA Vaccines</data>
      <data key="d1">method</data>
      <data key="d2">mRNA vaccines are a type of therapeutic that induces immune reactions against various viral infections and are noted for their effectiveness against SARS-CoV-2.&lt;SEP&gt;mRNA vaccines are a novel approach to vaccine development, classified under a new era in vaccinology.&lt;SEP&gt;mRNA vaccines are a type of vaccine technology that utilizes messenger RNA to elicit an immune response, with notable examples being mRNA-1273 and BNT162b2.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="BNT162b2">
      <data key="d0">BNT162b2</data>
      <data key="d1">vaccine</data>
      <data key="d2">BNT162b2 is an mRNA vaccine developed by Pfizer-BioNTech, approved for emergency use to prevent SARS-CoV-2 infection.&lt;SEP&gt;BNT162b2 is a COVID-19 vaccine associated with the development of neutralizing antibodies in patients with cancer.&lt;SEP&gt;BNT162b2 is an mRNA vaccine developed by Pfizer-BioNTech approved by the FDA for emergency use against COVID-19.&lt;SEP&gt;BNT162b2 is an mRNA vaccine developed by Pfizer-BioNTech, approved for emergency use to prevent COVID-19.&lt;SEP&gt;BNT162b2 is an mRNA vaccine that induces a broad immune response with SARS-CoV-2 spike-specific neutralizing antibodies and T cells.&lt;SEP&gt;BNT162b2 is one of the vaccines that have been administered to patients, including those with cancers, to induce neutralizing antibodies against COVID-19.&lt;SEP&gt;BNT162b2 is a COVID-19 vaccine developed by Pfizer-BioNTech, authorized for emergency use in adolescents.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="mRNA-1273">
      <data key="d0">mRNA-1273</data>
      <data key="d1">vaccine</data>
      <data key="d2">mRNA-1273 is an mRNA vaccine developed by Moderna, which has demonstrated efficacy in preventing SARS-CoV-2 infection.&lt;SEP&gt;mRNA-1273 is an mRNA vaccine developed by Moderna Biotechnologies Inc., also approved for emergency use against COVID-19.&lt;SEP&gt;mRNA-1273 is an mRNA vaccine developed by Moderna Biotechnologies Inc., approved for emergency use to prevent COVID-19.&lt;SEP&gt;mRNA-1273 is an mRNA vaccine that demonstrated robust immune response in a phase I clinical trial involving 47 participants.&lt;SEP&gt;mRNA-1273 is a COVID-19 vaccine developed by Moderna, and a preliminary report discusses its effectiveness.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="COVE Study Group">
      <data key="d0">COVE Study Group</data>
      <data key="d1">organization</data>
      <data key="d2">The COVE Study Group in the USA reported on the efficacy of the mRNA-1273 vaccine in preventing COVID-19.&lt;SEP&gt;The COVE Study Group is involved in clinical trials for COVID-19 vaccines, reporting on their efficacy and safety.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791238</data>
      <data key="d6" />
    </node>
    <node id="Rabies">
      <data key="d0">Rabies</data>
      <data key="d1">concept</data>
      <data key="d2">Rabies is a viral infection against which mRNA vaccines have been shown to induce immune reactions.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Zika">
      <data key="d0">Zika</data>
      <data key="d1">concept</data>
      <data key="d2">Zika is a viral infection for which mRNA vaccines have been found effective in inducing immune responses.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Influenza A">
      <data key="d0">Influenza A</data>
      <data key="d1">concept</data>
      <data key="d2">Influenza A is a viral infection against which mRNA vaccines are reported to be effective in animal models and humans.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Angiotensin-Converting Enzyme 2">
      <data key="d0">Angiotensin-Converting Enzyme 2</data>
      <data key="d1">protein</data>
      <data key="d2">Angiotensin-Converting Enzyme 2 (ACE2) is a receptor that the SARS-CoV-2 virus utilizes to enter host cells and is relevant in research on SARS pathogenesis.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Wuhan">
      <data key="d0">Wuhan</data>
      <data key="d1">location</data>
      <data key="d2">Wuhan is the capital city of Hubei Province in China, where the outbreak of pneumonia leading to the identification of SARS-CoV-2 began in December 2019.&lt;SEP&gt;Wuhan is a city in China known for being the initial epicenter of the COVID-19 outbreak and was involved in several studies related to the disease.&lt;SEP&gt;Wuhan is the capital city of Hubei Province, China, and is notably associated with the outbreak of pneumonia linked to the novel coronavirus that began in December 2019.&lt;SEP&gt;Wuhan is a city in China where significant early cases of COVID-19 were reported.&lt;SEP&gt;Wuhan is a city in China known for being associated with studies of hospitalized COVID-19 patients.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Severe Acute Respiratory Syndrome">
      <data key="d0">Severe Acute Respiratory Syndrome</data>
      <data key="d1">disease</data>
      <data key="d2">Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the SARS-CoV virus, which was studied for its clinical pathology and tissue distribution.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Neuroinvasive Potential">
      <data key="d0">Neuroinvasive Potential</data>
      <data key="d1">concept</data>
      <data key="d2">Neuroinvasive potential refers to the ability of SARS-CoV-2 to affect the nervous system, contributing to symptoms such as respiratory failure in COVID-19 patients.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Family Cluster Study">
      <data key="d0">Family Cluster Study</data>
      <data key="d1">study</data>
      <data key="d2">A family cluster study investigates person-to-person transmission of the 2019 novel coronavirus, providing insights into its spread within households.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="J Chem Inf Model">
      <data key="d0">J Chem Inf Model</data>
      <data key="d1">content</data>
      <data key="d2">The Journal of Chemical Information and Modeling publishes articles related to the field of chemistry and computational modeling.&lt;SEP&gt;J Chem Inf Model is a scientific journal documenting studies on SARS-CoV-2 spike protein mutations and their implications.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="J Med Virol">
      <data key="d0">J Med Virol</data>
      <data key="d1">content</data>
      <data key="d2">J Med Virol is a journal in which research on CRISPR-Cas13-based diagnosis was published.&lt;SEP&gt;The Journal of Medical Virology focuses on research articles in the field of medical virology, including studies on coronaviruses.&lt;SEP&gt;J Med Virol is a journal that has published various studies related to the clinical pathology and neurological impacts of coronaviruses.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="J Pathol">
      <data key="d0">J Pathol</data>
      <data key="d1">content</data>
      <data key="d2">The Journal of Pathology publishes research on pathological studies, including research related to severe acute respiratory syndrome (SARS).</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791239</data>
      <data key="d6" />
    </node>
    <node id="Adv Exp Med Biol">
      <data key="d0">Adv Exp Med Biol</data>
      <data key="d1">content</data>
      <data key="d2">Advances in Experimental Medicine and Biology publishes research articles bridging medicine, biology, and molecular aspects of various diseases.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="J Virol">
      <data key="d0">J Virol</data>
      <data key="d1">content</data>
      <data key="d2">The Journal of Virology publishes research on viruses and viral diseases, including studies on human coronaviruses.</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="B.1.1.7 Variant">
      <data key="d0">B.1.1.7 Variant</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.1.7 is a variant of SARS-CoV-2 that has been studied for its genetic variations and response to treatments like Remdesivir.&lt;SEP&gt;The B.1.1.7 variant is a variant of SARS-CoV-2 that has been studied concerning rapid detection methods and surveillance.&lt;SEP&gt;The B.1.1.7 variant is a strain of SARS-CoV-2 against which the effectiveness of the BNT162b2 vaccine was evaluated.&lt;SEP&gt;The B.1.1.7 variant of SARS-CoV-2 displays low genetic variation in its RNA replication complex and numerous mutations in the spike protein.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="B.1.351 Variant">
      <data key="d0">B.1.351 Variant</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.351 is another variant of SARS-CoV-2 that has been researched regarding its mutations in treatment response.&lt;SEP&gt;The B.1.351 variant is another strain of SARS-CoV-2 against which the BNT162b2 vaccine's effectiveness was assessed.&lt;SEP&gt;The B.1.351 variant of SARS-CoV-2 is noted for low genetic variation in the RNA replication complex and several spike protein mutations compared to early strains.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="Amino Acid Sequences">
      <data key="d0">Amino Acid Sequences</data>
      <data key="d1">data</data>
      <data key="d2">Amino acid sequences of variants B.1.1.7 and B.1.351 have numerous mutations when compared to early SARS-CoV-2 strains.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="Nsp12 P323L">
      <data key="d0">Nsp12 P323L</data>
      <data key="d1">data</data>
      <data key="d2">Nsp12 P323L is a frequently observed substitution in the RNA replication complex of SARS-CoV-2 variants.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="Molnupiravir">
      <data key="d0">Molnupiravir</data>
      <data key="d1">drug</data>
      <data key="d2">Molnupiravir is an FDA approved antiviral drug targeting SARS-CoV-2 by misdirecting the viral polymerase during replication.&lt;SEP&gt;Molnupiravir is a recently FDA-approved antiviral drug designed to target viral polymerase during SARS-CoV-2 replication.&lt;SEP&gt;Molnupiravir is an antiviral drug that promotes mutagenesis of the SARS-CoV-2 virus via the RNA template.&lt;SEP&gt;Molnupiravir is a recently FDA approved antiviral drug that interferes with the viral polymerase and leads to fatal errors in viral replication.&lt;SEP&gt;Molnupiravir is an antiviral drug that induces mutagenesis in SARS-CoV-2 by using the RNA template during replication.&lt;SEP&gt;Molnupiravir is an antiviral medication known for inducing mutagenesis in SARS-CoV-2.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="Paxlovid">
      <data key="d0">Paxlovid</data>
      <data key="d1">drug</data>
      <data key="d2">Paxlovid is a recent FDA approved antiviral medication that is recommended for use against existing VOCs, including the omicron variant.&lt;SEP&gt;Paxlovid is an orally bioavailable broad-spectrum antiviral that raises hopes for COVID-19 recovery during the Omicron variant outbreak.&lt;SEP&gt;Paxlovid is another FDA approved antiviral drug claimed to be effective against existing SARS-CoV-2 variants, including the omicron variant.&lt;SEP&gt;Paxlovid is an orally bioavailable antiviral that offers hope for COVID-19 recovery.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccines">
      <data key="d0">COVID-19 Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 vaccines are essential for prevention and protection against SARS-CoV-2 infection, with ongoing development and research.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="RNA-Dependent RNA Polymerase">
      <data key="d0">RNA-Dependent RNA Polymerase</data>
      <data key="d1">protein</data>
      <data key="d2">RNA-Dependent RNA Polymerase is a protein target for Remdesivir in the treatment of Covid-19.&lt;SEP&gt;RNA-Dependent RNA Polymerase is highlighted as an effective target for COVID-19 treatments against SARS-CoV-2 variants.&lt;SEP&gt;RNA-Dependent RNA Polymerase is an enzyme that plays a crucial role in the replication of RNA viruses, including SARS-CoV-2.&lt;SEP&gt;RNA-Dependent RNA Polymerase (RdRP) is the main target for antiviral drugs like remdesivir and molnupiravir in SARS-CoV-2 variants.&lt;SEP&gt;RNA-Dependent RNA Polymerase is a critical target for therapeutic intervention against SARS-CoV-2 variants.</data>
      <data key="d3">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="Omicron Variant">
      <data key="d0">Omicron Variant</data>
      <data key="d1">variant</data>
      <data key="d2">The Omicron variant represents the most recent variant of SARS-CoV-2, which has key mutations in its spike protein.&lt;SEP&gt;The Omicron variant is a specific mutation of the SARS-CoV-2 virus, notable for its key mutations in the spike protein.&lt;SEP&gt;The Omicron variant is a notable variant of SARS-CoV-2 that has been the subject of research for detection methods.&lt;SEP&gt;The Omicron variant is a strain of SARS-CoV-2 that has raised concerns in the context of COVID-19.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791240</data>
      <data key="d6" />
    </node>
    <node id="PCR Primers">
      <data key="d0">PCR Primers</data>
      <data key="d1">method</data>
      <data key="d2">PCR primers are specific sequences used in tests for the rapid detection of SARS-CoV-2 variants.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Multi-Target Assays">
      <data key="d0">Multi-Target Assays</data>
      <data key="d1">method</data>
      <data key="d2">Multi-target assays are techniques employed to detect multiple targets in a single test, facilitating the identification of variants.&lt;SEP&gt;Multi-Target Assays are experimental approaches aiming to address challenges in the detection of viral mutations.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Genome Sequencing">
      <data key="d0">Genome Sequencing</data>
      <data key="d1">method</data>
      <data key="d2">Genome sequencing is a comprehensive method for identifying viral strains but is slower and requires specialized equipment.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Loop-Mediated Isothermal Amplification (LAMP)">
      <data key="d0">Loop-Mediated Isothermal Amplification (LAMP)</data>
      <data key="d1">method</data>
      <data key="d2">LAMP is a rapid, robust, and cost-effective technique considered a reliable alternative to traditional PCR-based diagnostics.&lt;SEP&gt;LAMP is a rapid and robust diagnostic technique considered a reliable alternative to traditional RT-PCR for SARS-CoV-2 detection.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)">
      <data key="d0">Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)</data>
      <data key="d1">method</data>
      <data key="d2">CRISPR is a novel technology utilized for specific viral gene targeting in SARS-CoV-2 diagnostics.&lt;SEP&gt;CRISPR is a novel assay technology targeting genes of SARS-CoV-2 that shows high sensitivity and specificity in detection.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Microarray-Based Technology">
      <data key="d0">Microarray-Based Technology</data>
      <data key="d1">method</data>
      <data key="d2">Microarray-based technology facilitates the detection of viral RNA through hybridization and quantification methods.&lt;SEP&gt;Microarray-based technology is used to detect viral RNA through hybridization and quantification of labelled cDNA.&lt;SEP&gt;Microarray-Based Technology is utilized for detecting viral RNA through labeled cDNA molecules synthesized from viral RNA.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383&lt;SEP&gt;chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Next-Generation Gene Sequencing (NGS)">
      <data key="d0">Next-Generation Gene Sequencing (NGS)</data>
      <data key="d1">method</data>
      <data key="d2">NGS methods allow for the detection of viral presence and contribute to epidemiological studies of SARS-CoV-2.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="Antigen-Based Immuno-Assays">
      <data key="d0">Antigen-Based Immuno-Assays</data>
      <data key="d1">method</data>
      <data key="d2">Antigen-based immuno-assays are diagnostic tests that detect proteins associated with SARS-CoV-2 infection.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="VOCs">
      <data key="d0">VOCs</data>
      <data key="d1">concept</data>
      <data key="d2">VOCs, or Variants of Concern, refer to specific strains of SARS-CoV-2 that are monitored for their impact and significance in the pandemic.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Variants">
      <data key="d0">SARS-CoV-2 Variants</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 variants are different strains of the virus that have undergone mutations, impacting their detection and behavior.&lt;SEP&gt;SARS-CoV-2 variants, including VOCs, are versions of the virus that may pose different challenges for antiviral drug efficacy.&lt;SEP&gt;SARS-CoV-2 Variants refer to different strains of the virus that have emerged and are evaluated for treatment efficacy.&lt;SEP&gt;SARS-CoV-2 variants refer to the different forms of the virus that have emerged over time, each with distinct characteristics and impacts on transmissibility and treatment.&lt;SEP&gt;SARS-CoV-2 variants refer to different strains of the virus, including the most recent omicron variant, known for distinct mutations.&lt;SEP&gt;SARS-CoV-2 variants are mutated forms of the virus that can evade immunity provided by vaccines.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383&lt;SEP&gt;chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="PCR-Based Tests">
      <data key="d0">PCR-Based Tests</data>
      <data key="d1">method</data>
      <data key="d2">PCR-based tests are diagnostic assays designed for the detection of SARS-CoV-2 and its variants, specifically developed to be simpler and faster.</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791241</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV">
      <data key="d0">SARS-CoV</data>
      <data key="d1">virus</data>
      <data key="d2">SARS-CoV is a zoonotic coronavirus that is part of the same family as SARS-CoV-2 and is known for contributing to respiratory outbreaks.&lt;SEP&gt;SARS-CoV is a virus similar to SARS-CoV-2 and is noted for its ability to infect host cells, similar to its variant counterpart.&lt;SEP&gt;SARS-CoV is a virus that, like SARS-CoV-2, is known to enter host cells through ACE2 and has similar neuro-invasive potential.&lt;SEP&gt;SARS-CoV is a previous zoonotic coronavirus outbreak that serves as a point of comparison for SARS-CoV-2's impact.&lt;SEP&gt;SARS-CoV is a coronavirus known to infect respiratory cells and is implicated in severe respiratory illnesses.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416&lt;SEP&gt;chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="MERS-CoV">
      <data key="d0">MERS-CoV</data>
      <data key="d1">virus</data>
      <data key="d2">MERS-CoV is another zoonotic coronavirus, similar to SARS-CoV and SARS-CoV-2, that causes severe respiratory diseases.&lt;SEP&gt;MERS-CoV is a virus that, alongside SARS-CoV, can enter the central nervous system despite low levels of ACE2.&lt;SEP&gt;MERS-CoV is another prior zoonotic coronavirus outbreak, relevant for understanding the context of SARS-CoV-2.&lt;SEP&gt;MERS-CoV is a coronavirus related to SARS-CoV, known for its severe health implications.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="ACE2">
      <data key="d0">ACE2</data>
      <data key="d1">protein</data>
      <data key="d2">ACE2 is a receptor expressed in lung cells, which allows the entry of SARS-CoV-2 and SARS-CoV into host cells.&lt;SEP&gt;ACE2 is a receptor that plays a role in the entry of coronaviruses like SARS-CoV and SARS-CoV-2 into host cells.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="DDP430">
      <data key="d0">DDP430</data>
      <data key="d1">protein</data>
      <data key="d2">DDP430 is another receptor involved in the entry of coronaviruses into cells, although present at low levels in certain tissues.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Pandemic">
      <data key="d0">COVID-19 Pandemic</data>
      <data key="d1">event</data>
      <data key="d2">The COVID-19 pandemic refers to the global outbreak of the SARS-CoV-2 virus, impacting health systems, economies, and daily life worldwide.&lt;SEP&gt;The COVID-19 Pandemic refers to the global outbreak of the SARS-CoV-2 virus, impacting health and safety regulations worldwide.&lt;SEP&gt;The COVID-19 pandemic is a global health crisis caused by the SARS-CoV-2 virus, leading to widespread illness and significant public health challenges.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Central Nervous System">
      <data key="d0">Central Nervous System</data>
      <data key="d1">anatomicalstructure</data>
      <data key="d2">The Central Nervous System (CNS) is a critical part of the body where SARS-CoV and potentially SARS-CoV-2 have been shown to invade.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Neuro-invasive Potential">
      <data key="d0">Neuro-invasive Potential</data>
      <data key="d1">concept</data>
      <data key="d2">Neuro-invasive potential refers to the ability of certain viruses, including SARS-CoV-2, to infect the nervous system.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Healthcare Workers">
      <data key="d0">Healthcare Workers</data>
      <data key="d1">person</data>
      <data key="d2">Healthcare Workers are individuals who may be at risk of SARS-CoV-2 infection, especially in medical settings.&lt;SEP&gt;Healthcare workers are medical personnel who are at high risk of infection during the COVID-19 pandemic due to human-to-human transmission of the virus.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Qatar National Library">
      <data key="d0">Qatar National Library</data>
      <data key="d1">organization</data>
      <data key="d2">The Qatar National Library supports research publications and provides funding for Open Access.&lt;SEP&gt;Qatar National Library is recognized for its support in the publication of the manuscript discussed.&lt;SEP&gt;The Qatar National Library provided Open Access funding for the publication.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Authors of the Manuscript">
      <data key="d0">Authors of the Manuscript</data>
      <data key="d1">person</data>
      <data key="d2">The authors are responsible for the initial draft and revision of the manuscript, contributing collectively to its development.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Medullary Neurons">
      <data key="d0">Medullary Neurons</data>
      <data key="d1">naturalobject</data>
      <data key="d2">Medullary neurons are specialized nerve cells located in the medulla, which may be affected by the invasion of SARS-CoV-2 during the COVID-19 pandemic.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791242</data>
      <data key="d6" />
    </node>
    <node id="Neurologic Symptoms">
      <data key="d0">Neurologic Symptoms</data>
      <data key="d1">concept</data>
      <data key="d2">Neurologic Symptoms include headaches, nausea, and impaired consciousness experienced by some COVID-19 patients.&lt;SEP&gt;Neurologic symptoms refer to health issues such as headaches and nausea observed in some COVID-19 patients, indicating the virus's potential impact on the nervous system.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="Acute Cerebrovascular Disease">
      <data key="d0">Acute Cerebrovascular Disease</data>
      <data key="d1">medicalcondition</data>
      <data key="d2">Acute cerebrovascular disease is a serious neurologic manifestation reported in some severe COVID-19 cases, affecting blood flow to the brain.</data>
      <data key="d3">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.1.7">
      <data key="d0">B.1.1.7</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.1.7 is classified as a VOC Alpha variant that originated in the United Kingdom in December 2020.&lt;SEP&gt;B.1.1.7 is a variant of SARS-CoV-2 mentioned in the study of RNA-Dependent RNA Polymerase.&lt;SEP&gt;B.1.1.7 is a variant of SARS-CoV-2 classified as Alpha, first detected in the United Kingdom in December 2020.&lt;SEP&gt;B.1.1.7 is a variant of SARS-CoV-2 against which NVX-CoV2373 has demonstrated strong efficacy.&lt;SEP&gt;B.1.1.7 is a variant of SARS-CoV-2 first detected in the United Kingdom, impacting vaccine efficacy.&lt;SEP&gt;B.1.1.7 is a variant of SARS-CoV-2 that is subject to therapeutic intervention analysis.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.351">
      <data key="d0">B.1.351</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.351 is classified as a VOC Beta variant that originated in South Africa in December 2020.&lt;SEP&gt;B.1.351 is another variant of SARS-CoV-2 discussed in regard to therapeutic targets for COVID-19.&lt;SEP&gt;B.1.351 is a variant classified as Beta, identified in South Africa in December 2020.&lt;SEP&gt;B.1.351 is a variant of SARS-CoV-2 first identified in South Africa, raising concerns over vaccine effectiveness.&lt;SEP&gt;B.1.351 is another variant of SARS-CoV-2 addressed in therapeutic research concerning COVID-19 treatment outcomes.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.351.2">
      <data key="d0">B.1.351.2</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.351.2 is a variant associated with B.1.351.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.351.3">
      <data key="d0">B.1.351.3</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.351.3 is another variant associated with B.1.351.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="P.1">
      <data key="d0">P.1</data>
      <data key="d1">variant</data>
      <data key="d2">P.1 is classified as a VOC Gamma variant that originated in Brazil in January 2021.&lt;SEP&gt;P.1 is a variant of SARS-CoV-2 classified as Gamma, identified in Brazil in January 2021.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="Remdesivir">
      <data key="d0">Remdesivir</data>
      <data key="d1">drug</data>
      <data key="d2">Remdesivir is an antiviral drug specifically utilized for the treatment of COVID-19, particularly in patients experiencing pneumonia. The drug has been approved by the FDA and is recognized for its effectiveness in managing viral load associated with the disease. It predominantly targets the RNA-Dependent RNA Polymerase (RdRP) protein sequence of the SARS-CoV-2 virus, thereby interrupting the viral replication process.

Research on Remdesivir has evaluated its efficacy against various emerging SARS-CoV-2 variants, known as variants of concern (VOCs). While the drug is noted for its ability to target a broad range of viruses, it has been reported to encounter resistance issues with some VOCs. Despite this, studies indicate that Remdesivir shows minimal pre-existing resistance among circulating virus variants, suggesting its ongoing relevance in the treatment landscape.

In some treatment protocols, Remdesivir is used in combination with other medications, such as Baricitinib, to enhance therapeutic outcomes for patients suffering from COVID-19. Overall, Remdesivir remains a critical component in managing COVID-19, particularly for patients presenting with pneumonia and requiring urgent antiviral intervention.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-90dfb33ebd8b6695b6eb243fc4a55781&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.617.2">
      <data key="d0">B.1.617.2</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.617.2 is classified as a VOI Delta variant that originated in India in May 2021.&lt;SEP&gt;B.1.617.2 is a variant of SARS-CoV-2 classified as Delta, first detected in India in May 2021.&lt;SEP&gt;B.1.617.2 is a variant of SARS-CoV-2 that emerged in India, showing reduced vaccine effectiveness.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="AY.1">
      <data key="d0">AY.1</data>
      <data key="d1">variant</data>
      <data key="d2">AY.1 is a variant classification associated with B.1.617.2.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="AY.2">
      <data key="d0">AY.2</data>
      <data key="d1">variant</data>
      <data key="d2">AY.2 is another variant classification associated with B.1.617.2.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791243</data>
      <data key="d6" />
    </node>
    <node id="B.1.427">
      <data key="d0">B.1.427</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.427 is classified as a VOC Epsilon variant that originated in California in July 2020.&lt;SEP&gt;B.1.427 is a variant of SARS-CoV-2 classified as Epsilon, first detected in California in July 2020.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="B.1.429">
      <data key="d0">B.1.429</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.429 is associated with B.1.427.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="B.1.1.529">
      <data key="d0">B.1.1.529</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.1.529 is classified as a VOC Omicron variant that originated in South Africa in November 2021.&lt;SEP&gt;B.1.1.529 is a variant classified as Omicron, first identified in South Africa in November 2021.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="Spike Protein Substitutions">
      <data key="d0">Spike Protein Substitutions</data>
      <data key="d1">concept</data>
      <data key="d2">Spike protein substitutions refer to mutations affecting transmissibility and severity in SARS-CoV-2 variants.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="E484K">
      <data key="d0">E484K</data>
      <data key="d1">mutation</data>
      <data key="d2">E484K is a spike protein mutation that has implications for strain severity and antibody response.&lt;SEP&gt;E484K is a mutation in the spike protein of SARS-CoV-2 that impacts antibody neutralization.&lt;SEP&gt;E484K is a mutation associated with SARS-CoV-2 that may reduce the effectiveness of neutralizing antibodies.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="N501Y">
      <data key="d0">N501Y</data>
      <data key="d1">mutation</data>
      <data key="d2">N501Y is a spike protein mutation associated with increased transmissibility.&lt;SEP&gt;N501Y is a mutation in the spike protein of SARS-CoV-2 linked to susceptibility to infection.&lt;SEP&gt;N501Y is a mutation that has implications for susceptibility to infection from SARS-CoV-2.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="D614G">
      <data key="d0">D614G</data>
      <data key="d1">mutation</data>
      <data key="d2">D614G is a spike protein mutation noted for its prevalence in various COVID-19 variants.&lt;SEP&gt;D614G is a spike protein mutation in SARS-CoV-2 associated with susceptibility and transmissibility.&lt;SEP&gt;D614G is a specific mutation of the spike protein of SARS-CoV-2 linked to increased transmissibility.&lt;SEP&gt;D614G is a significant mutation in SARS-CoV-2 associated with transmissibility and infection susceptibility.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="T20N">
      <data key="d0">T20N</data>
      <data key="d1">mutation</data>
      <data key="d2">T20N is a spike protein mutation impacting susceptibility to monoclonal antibody treatments.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="K417N">
      <data key="d0">K417N</data>
      <data key="d1">mutation</data>
      <data key="d2">K417N is a spike protein mutation that affects neutralization by post-vaccination sera.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="B.1.525">
      <data key="d0">B.1.525</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.525 is classified as a Variant of Interest (VOI) identified in the United Kingdom and Nigeria in December 2020.&lt;SEP&gt;B.1.525 is classified as a VOI Eta variant that originated in the United Kingdom and Nigeria in December 2020.&lt;SEP&gt;B.1.525 is a variant of interest (VOI) classified as Eta, originating from the United Kingdom and Nigeria in December 2020.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="B.1.526">
      <data key="d0">B.1.526</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.526 is classified as a Variant of Interest (VOI) detected in the United States in November 2020.&lt;SEP&gt;B.1.526 is classified as a VOI Iota variant that originated in the United States in November 2020.&lt;SEP&gt;B.1.526 is a variant of interest (VOI) classified as Iota, originating from the United States in November 2020.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791244</data>
      <data key="d6" />
    </node>
    <node id="B.1.617.1">
      <data key="d0">B.1.617.1</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.617.1 is a Variant of Interest (VOI) identified in India in December 2020.&lt;SEP&gt;B.1.617.1 is classified as a VOI Kappa variant that originated in India in December 2020.&lt;SEP&gt;B.1.617.1 is a variant of interest (VOI) classified as Kappa, originating from India in December 2020.</data>
      <data key="d3">chunk-011e180e8a15a1d31d1e61e1c124eb17&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="COVE Study">
      <data key="d0">COVE Study</data>
      <data key="d1">event</data>
      <data key="d2">The COVE Study is a phase 3 clinical trial focused on evaluating the efficacy of COVID-19 vaccine candidates, including interim analyses and effectiveness estimates.&lt;SEP&gt;The COVE Study is a phase 3 clinical trial evaluating the efficacy of a COVID-19 vaccine candidate.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Moderna COVID-19 Vaccine Candidate">
      <data key="d0">Moderna COVID-19 Vaccine Candidate</data>
      <data key="d1">product</data>
      <data key="d2">The Moderna COVID-19 vaccine candidate met its primary efficacy endpoint in the first interim analysis of the COVE study.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="SIREN Study">
      <data key="d0">SIREN Study</data>
      <data key="d1">event</data>
      <data key="d2">The SIREN Study investigates COVID-19 vaccine coverage and effectiveness among health care workers in England.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccine Effectiveness Network">
      <data key="d0">COVID-19 Vaccine Effectiveness Network</data>
      <data key="d1">organization</data>
      <data key="d2">The COVID-19 Vaccine Effectiveness Network is a collaborative network monitoring vaccine effectiveness in the U.S.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Thompson MG">
      <data key="d0">Thompson MG</data>
      <data key="d1">person</data>
      <data key="d2">Thompson MG is listed as an author in the context of vaccine effectiveness studies.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Burgess JL">
      <data key="d0">Burgess JL</data>
      <data key="d1">person</data>
      <data key="d2">Burgess JL is listed as an author in research related to COVID-19 vaccines.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Naleway AL">
      <data key="d0">Naleway AL</data>
      <data key="d1">person</data>
      <data key="d2">Naleway AL is listed as an author in studies examining vaccine effectiveness against COVID-19.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Hall VJ">
      <data key="d0">Hall VJ</data>
      <data key="d1">person</data>
      <data key="d2">Hall VJ is one of the authors involved in a study assessing COVID-19 vaccine coverage and effectiveness.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Foulkes S">
      <data key="d0">Foulkes S</data>
      <data key="d1">person</data>
      <data key="d2">Foulkes S is an author in the context of COVID-19 vaccine studies.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Saei A">
      <data key="d0">Saei A</data>
      <data key="d1">person</data>
      <data key="d2">Saei A is an author associated with research on COVID-19 vaccine effectiveness.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791245</data>
      <data key="d6" />
    </node>
    <node id="Lopez Bernal J">
      <data key="d0">Lopez Bernal J</data>
      <data key="d1">person</data>
      <data key="d2">Lopez Bernal J is an author of studies assessing the effectiveness of COVID-19 vaccines.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Andrews N">
      <data key="d0">Andrews N</data>
      <data key="d1">person</data>
      <data key="d2">Andrews N is an author involved in evaluating the effectiveness of COVID-19 vaccines.</data>
      <data key="d3">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="C.37">
      <data key="d0">C.37</data>
      <data key="d1">variant</data>
      <data key="d2">C.37 is classified as a Variant of Interest (VOI) discovered in Peru in August 2020.&lt;SEP&gt;C.37 is a variant of interest (VOI) classified as Lambda, originating from Peru in August 2020.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="B.1.621">
      <data key="d0">B.1.621</data>
      <data key="d1">variant</data>
      <data key="d2">B.1.621 is classified as a Variant of Interest (VOI) detected in Colombia in January 2021.&lt;SEP&gt;B.1.621 is a variant of interest (VOI) classified as Mu, originating from Colombia in January 2021.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="P.3">
      <data key="d0">P.3</data>
      <data key="d1">variant</data>
      <data key="d2">P.3 is classified as a Variant of Interest (VOI) identified in the Philippines in January 2021.&lt;SEP&gt;P.3 is a variant of interest (VOI) classified as Theta, originating from the Philippines in January 2021.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Nucleic Acid-Based Detection">
      <data key="d0">Nucleic Acid-Based Detection</data>
      <data key="d1">method</data>
      <data key="d2">Nucleic acid-based detection is a method used for clinical identification of SARS-CoV-2 infection through various sample types.&lt;SEP&gt;Nucleic acid-based detection is a widely used method for clinically identifying SARS-CoV-2 infections through various sample types.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Nasopharyngeal Swab">
      <data key="d0">Nasopharyngeal Swab</data>
      <data key="d1">sample</data>
      <data key="d2">Nasopharyngeal swab samples are recognized as the most reliable source for detecting SARS-CoV-2 infection.&lt;SEP&gt;Nasopharyngeal swabs are samples obtained from the nasopharynx, considered the most reliable for detecting SARS-CoV-2 due to their high sensitivity.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="COVID-19">
      <data key="d0">COVID-19</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 is the infectious disease caused by the SARS-CoV-2 virus. It is characterized by a range of symptoms, including respiratory issues, fevers, coughs, fatigue, pneumonia, and muscle pain. The disease can manifest in varying severities, from mild respiratory problems to severe pneumonia and respiratory failure, and, in some cases, it has neurological manifestations as well.

COVID-19 has resulted in a global pandemic, prompting widespread public health initiatives due to its high transmissibility and the emergence of various variants that have impacted vaccine effectiveness. The World Health Organization (WHO) formally named the disease COVID-19. Extensive research and treatment trials have been conducted to understand the disease better and to develop effective responses.

Vaccines, such as NVX-CoV2373 and AZD1222, have been developed specifically to induce an immune response against COVID-19. These vaccines aim to mitigate the spread and effects of the disease, as well as to reduce the severity of symptoms in infected individuals. Despite the availability of vaccines, COVID-19 continues to pose diagnostic challenges and requires numerous preventive and therapeutic strategies to manage its impact on public health. Overall, COVID-19 remains a significant health crisis globally, prompting ongoing efforts to combat the virus and its effects.</data>
      <data key="d3">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd&lt;SEP&gt;chunk-90dfb33ebd8b6695b6eb243fc4a55781&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Real-Time PCR Technology">
      <data key="d0">Real-Time PCR Technology</data>
      <data key="d1">method</data>
      <data key="d2">Real-time PCR technology is a detection method based on identifying specific viral RNA regions in SARS-CoV-2.&lt;SEP&gt;Real-Time PCR Technology is used for detecting the presence of specific viral RNA in samples.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="P681H">
      <data key="d0">P681H</data>
      <data key="d1">mutation</data>
      <data key="d2">P681H is a mutation associated with the spike protein of SARS-CoV-2 and is noted for its impact on transmissibility.</data>
      <data key="d3">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Aza-\nNavir">
      <data key="d0">Aza-\nNavir</data>
      <data key="d1">concept</data>
      <data key="d2">Aza-\nNavir is noted as not being a main protease inhibitor for SARS-CoV-2.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Proc Natl Acad Sci USA">
      <data key="d0">Proc Natl Acad Sci USA</data>
      <data key="d1">organization</data>
      <data key="d2">Proc Natl Acad Sci USA is a scientific journal that published findings about Aza-\nNavir.&lt;SEP&gt;Proceedings of the National Academy of Sciences USA is a journal that publishes research, including those on antiviral agents.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Brown MJ">
      <data key="d0">Brown MJ</data>
      <data key="d1">person</data>
      <data key="d2">Brown MJ is an author contributing to research on interleukin-6 receptor antagonists in critically ill patients with COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Alazawi W">
      <data key="d0">Alazawi W</data>
      <data key="d1">person</data>
      <data key="d2">Alazawi W is an author associated with the study of interleukin-6 receptor antagonists in the treatment of COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Kanoni S">
      <data key="d0">Kanoni S</data>
      <data key="d1">person</data>
      <data key="d2">Kanoni S is an author contributing to the research regarding interleukin-6 receptor antagonists in critically ill COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Tocilizumab">
      <data key="d0">Tocilizumab</data>
      <data key="d1">drug</data>
      <data key="d2">Tocilizumab is a monoclonal antibody approved by the FDA as an immunotherapy for treating cytokine storms in critical COVID-19 infections.&lt;SEP&gt;Tocilizumab is a drug that improved survival rates and reduced mortality in hospitalized Covid-19 patients according to the trial results.&lt;SEP&gt;Tocilizumab is an interleukin-6 receptor antagonist mentioned in treatment protocols for COVID-19.&lt;SEP&gt;Tocilizumab is a monoclonal antibody used to treat rheumatoid arthritis that has been repurposed for treating COVID-19 related complications.&lt;SEP&gt;Tocilizumab is an interleukin-6 receptor antagonist studied for critically ill COVID-19 patients.&lt;SEP&gt;Tocilizumab is a monoclonal antibody used to treat cytokine release syndrome in patients with moderate to severe COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="COVINTOC">
      <data key="d0">COVINTOC</data>
      <data key="d1">trial</data>
      <data key="d2">COVINTOC is a phase 3 clinical trial comparing tocilizumab plus standard care to standard care alone in patients with COVID-19.&lt;SEP&gt;COVINTOC is a study assessing the efficacy of Tocilizumab in patients with COVID-19-associated cytokine release syndrome in India.&lt;SEP&gt;COVINTOC is an open-label, multicentre, randomized controlled phase 3 trial assessing the efficacy of tocilizumab in COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Lancet Respir Med">
      <data key="d0">Lancet Respir Med</data>
      <data key="d1">organization</data>
      <data key="d2">The Lancet Respir Med is a medical journal that published the findings of the COVINTOC trial.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791246</data>
      <data key="d6" />
    </node>
    <node id="Zhang S">
      <data key="d0">Zhang S</data>
      <data key="d1">person</data>
      <data key="d2">Zhang S is an author discussing the rational use of tocilizumab in treating novel coronavirus pneumonia.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Li L">
      <data key="d0">Li L</data>
      <data key="d1">person</data>
      <data key="d2">Li L is an author involved in the study of tocilizumab for COVID-19 treatment.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Shen A">
      <data key="d0">Shen A</data>
      <data key="d1">person</data>
      <data key="d2">Shen A is a contributor to the discussion surrounding tocilizumab usage in the context of COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Pharm J">
      <data key="d0">Pharm J</data>
      <data key="d1">organization</data>
      <data key="d2">Pharm J is a publication that encouraged clinicians to consider tocilizumab for hospitalized COVID-19 patients.&lt;SEP&gt;Pharm J published insights on COVID-19 therapy trials beneficial for understanding treatment options.&lt;SEP&gt;Pharm J is a journal that encourages clinicians to consider certain medications, such as tocilizumab or sarilumab, for treating hospitalized COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Biospace">
      <data key="d0">Biospace</data>
      <data key="d1">organization</data>
      <data key="d2">Biospace reported on a phase 3 trial that showed the efficacy of the REGEN-COV antibody cocktail for COVID-19 treatment.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="REGEN-COV">
      <data key="d0">REGEN-COV</data>
      <data key="d1">drug</data>
      <data key="d2">REGEN-COV is a monoclonal antibody cocktail that decreased hospitalization or death by 70% in non-hospitalized Covid-19 patients.&lt;SEP&gt;REGEN-COV is an antibody cocktail that reduced hospitalization or death in non-hospitalized COVID-19 patients.&lt;SEP&gt;REGEN-COV is a monoclonal antibody cocktail consisting of Casirivimab and Imdevimab, approved for treating mild to moderate COVID-19 cases.&lt;SEP&gt;REGEN-COV is an antibody cocktail of casirivimab and imdevimab that has shown to reduce hospitalization or death in non-hospitalized COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Martin R">
      <data key="d0">Martin R</data>
      <data key="d1">person</data>
      <data key="d2">Martin R is an author studying the genetic conservation of the SARS-CoV-2 RNA replication complex.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Li J">
      <data key="d0">Li J</data>
      <data key="d1">person</data>
      <data key="d2">Li J is a contributor to research on SARS-CoV-2 RNA replication complexities.&lt;SEP&gt;Li J is an author of a referenced study characterizing the genomic epidemiology of the novel coronavirus.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Parvangada A">
      <data key="d0">Parvangada A</data>
      <data key="d1">person</data>
      <data key="d2">Parvangada A is an author of research on SARS-CoV-2 RNA replication issues.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Gordon CJ">
      <data key="d0">Gordon CJ</data>
      <data key="d1">person</data>
      <data key="d2">Gordon CJ is an author discussing the effects of molnupiravir on SARS-CoV-2.&lt;SEP&gt;Gordon CJ is an author involved in the analysis of SARS-CoV-2 mutations and the study of Molnupiravir.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Tchesnokov EP">
      <data key="d0">Tchesnokov EP</data>
      <data key="d1">person</data>
      <data key="d2">Tchesnokov EP is a researcher involved in studying molnupiravir's effects on SARS-CoV-2.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Schinazi RF">
      <data key="d0">Schinazi RF</data>
      <data key="d1">person</data>
      <data key="d2">Schinazi RF is an author focused on the implications of molnupiravir in laboratory studies of SARS-CoV-2.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="TMPRSS2">
      <data key="d0">TMPRSS2</data>
      <data key="d1">gene</data>
      <data key="d2">TMPRSS2 is a target for therapeutic intervention in SARS-CoV-2 treatment discussed in the context of COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Soin AS">
      <data key="d0">Soin AS</data>
      <data key="d1">person</data>
      <data key="d2">Soin AS is an author involved in the COVINTOC trial comparing tocilizumab plus standard care versus standard care in COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="FDA">
      <data key="d0">FDA</data>
      <data key="d1">organization</data>
      <data key="d2">The FDA, or Food and Drug Administration, is the U.S. government agency responsible for regulating food and drug products, including the approval and oversight of medications and vaccines, particularly in the context of public health crises, such as the COVID-19 pandemic. 

The FDA has played a crucial role in approving treatments and vaccines for COVID-19, including the antiviral drug Remdesivir, which was authorized for the treatment of patients with the virus. Additionally, the FDA approved the REGEN-COV treatment for high-risk COVID-19 patients and authorized the emergency use of the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 vaccines. It further provided specific authorization for the BNT162b2 vaccine to be administered in adolescents. 

In its regulatory capacity, the FDA is also responsible for monitoring the safety of these vaccines and medications, which includes overseeing the reporting of suspected adverse reactions among those receiving COVID-19 vaccinations in the United States. The agency ensures that public health remains a priority by maintaining rigorous standards for the approval and continuous evaluation of therapeutic products. 

Overall, the FDA's comprehensive oversight encompasses patient safety, the regulation of drug therapy, and the emergency use of vaccines, reflecting its essential role in managing health crises and protecting public health.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Kumar K">
      <data key="d0">Kumar K</data>
      <data key="d1">person</data>
      <data key="d2">Kumar K is an author associated with the research on tocilizumab in patients with COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Choudhary NS">
      <data key="d0">Choudhary NS</data>
      <data key="d1">person</data>
      <data key="d2">Choudhary NS is an author involved in the study of tocilizumab for treating COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791247</data>
      <data key="d6" />
    </node>
    <node id="Interleukin-6 Receptor Antagonists">
      <data key="d0">Interleukin-6 Receptor Antagonists</data>
      <data key="d1">drug</data>
      <data key="d2">Interleukin-6 receptor antagonists are drugs discussed as potential treatments for critically ill patients with COVID-19.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Phase 3 Trial">
      <data key="d0">Phase 3 Trial</data>
      <data key="d1">category</data>
      <data key="d2">Phase 3 trial refers to the stage of clinical testing for treatments like tocilizumab in COVID-19 patients.</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="mRNA-1273 Vaccine">
      <data key="d0">mRNA-1273 Vaccine</data>
      <data key="d1">artifact</data>
      <data key="d2">The mRNA-1273 vaccine is an approved vaccine for individuals aged 18 and older and is known to potentially induce immunogenic responses against COVID-19 variants.&lt;SEP&gt;The mRNA-1273 vaccine is another COVID-19 vaccine candidate studied for its effects against SARS-CoV-2 infections.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="BNT162b2 Vaccine">
      <data key="d0">BNT162b2 Vaccine</data>
      <data key="d1">artifact</data>
      <data key="d2">The BNT162b2 vaccine is recently authorized by the FDA for use in adolescents aged 12 to 15 years and has shown strong protection against COVID-19 variants.&lt;SEP&gt;The BNT162b2 vaccine is a COVID-19 vaccine being studied for its effectiveness among health care personnel and against specific variants.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="UK Variant (B.1.1.7)">
      <data key="d0">UK Variant (B.1.1.7)</data>
      <data key="d1">concept</data>
      <data key="d2">The UK variant B.1.1.7 is a strain of COVID-19 that has been studied for its impact on vaccine efficacy.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="South Africa Variant (B.1.351)">
      <data key="d0">South Africa Variant (B.1.351)</data>
      <data key="d1">concept</data>
      <data key="d2">The South Africa variant B.1.351 is another COVID-19 strain that affects the performance of vaccines.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="India Variant (B.1.617.2)">
      <data key="d0">India Variant (B.1.617.2)</data>
      <data key="d1">concept</data>
      <data key="d2">The India variant B.1.617.2 is a recent strain of COVID-19 that has shown reduced vaccine effectiveness.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Phase I Clinical Trial">
      <data key="d0">Phase I Clinical Trial</data>
      <data key="d1">event</data>
      <data key="d2">The Phase I clinical trial involves testing the mRNA-1273 vaccine on participants to assess its immune response and safety.&lt;SEP&gt;Phase I Clinical Trial refers to the initial stage where the COVID-19 Vaccine (Vero Cell) Inactivated was tested on 144 healthy participants to evaluate safety.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Spike-Specific Neutralizing Antibodies">
      <data key="d0">SARS-CoV-2 Spike-Specific Neutralizing Antibodies</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 spike-specific neutralizing antibodies are immune responses developed in reaction to the BNT162b2 vaccine.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Inactivated Virus Vaccines">
      <data key="d0">Inactivated Virus Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Inactivated virus vaccines are produced from whole viral inactivation and are used to prevent various viral diseases.&lt;SEP&gt;Inactivated virus vaccines contain killed pathogens, posing fewer safety concerns compared to live vaccines.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Live Attenuated Virus Vaccines">
      <data key="d0">Live Attenuated Virus Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Live attenuated virus vaccines contain weakened versions of the virus, raising safety concerns as they can revert to the original pathogenic form.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 mRNA Vaccines">
      <data key="d0">COVID-19 mRNA Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 mRNA vaccines refer to a class of vaccines, including the mRNA-1273 and BNT162b2 vaccines, designed to elicit an immune response against the COVID-19 virus.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="47 Participants">
      <data key="d0">47 Participants</data>
      <data key="d1">data</data>
      <data key="d2">The number of participants involved in the Phase I clinical trial for the mRNA-1273 vaccine was 47, indicating the scale of initial testing.</data>
      <data key="d3">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Cui J">
      <data key="d0">Cui J</data>
      <data key="d1">person</data>
      <data key="d2">Cui J is an author who contributed to the study on the origin and evolution of pathogenic coronaviruses, published in 2019.&lt;SEP&gt;Cui J is an author contributing to the research on the origin and evolution of pathogenic coronaviruses.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Li F">
      <data key="d0">Li F</data>
      <data key="d1">person</data>
      <data key="d2">Li F is an author who collaborated on the research regarding pathogenic coronaviruses, published in 2019.&lt;SEP&gt;Li F is an author involved in the study of coronaviruses alongside Cui J.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Shi ZL">
      <data key="d0">Shi ZL</data>
      <data key="d1">person</data>
      <data key="d2">Shi ZL is a co-author involved in the study of the origin and evolution of pathogenic coronaviruses, published in 2019.&lt;SEP&gt;Shi ZL is an author who co-authored research on the origin and evolution of coronaviruses.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Chan JF">
      <data key="d0">Chan JF</data>
      <data key="d1">person</data>
      <data key="d2">Chan JF is an author of a study detailing a pneumonia cluster associated with the 2019 novel coronavirus, published in 2020.&lt;SEP&gt;Chan JF is an author of a referenced study characterizing the genomic composition of a novel human-pathogenic coronavirus.&lt;SEP&gt;Chan JF is an author who studied a familial cluster of pneumonia associated with the novel coronavirus.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Yuan S">
      <data key="d0">Yuan S</data>
      <data key="d1">person</data>
      <data key="d2">Yuan S is a co-author of the study discussing the familial cluster of pneumonia tied to the 2019 novel coronavirus, published in 2020.&lt;SEP&gt;Yuan S is an author collaborating with Chan JF on research regarding pneumonia and coronavirus transmission.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Kok KH">
      <data key="d0">Kok KH</data>
      <data key="d1">person</data>
      <data key="d2">Kok KH is an author who contributed to the study on pneumonia associated with the 2019 novel coronavirus, published in 2020.&lt;SEP&gt;Kok KH is an author of a referenced study characterizing the genomic composition of a novel human-pathogenic coronavirus.&lt;SEP&gt;Kok KH is an author who contributed to the study of person-to-person transmission of the coronavirus.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Phan LT">
      <data key="d0">Phan LT</data>
      <data key="d1">person</data>
      <data key="d2">Phan LT is an author of a study concerning the human-to-human transmission of a novel coronavirus in Vietnam, published in 2020.&lt;SEP&gt;Phan LT is an author involved in the research on the importation and transmission of the novel coronavirus in Vietnam.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Nguyen TV">
      <data key="d0">Nguyen TV</data>
      <data key="d1">person</data>
      <data key="d2">Nguyen TV is a co-author involved in the study of novel coronavirus transmission in Vietnam, published in 2020.&lt;SEP&gt;Nguyen TV is an author who collaborated with Phan LT on studying the coronavirus in Vietnam.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Luong QC">
      <data key="d0">Luong QC</data>
      <data key="d1">person</data>
      <data key="d2">Luong QC is an author who collaborated on the research regarding the importation and transmission of a novel coronavirus, published in 2020.&lt;SEP&gt;Luong QC is an author participating in research about human-to-human transmission of the coronavirus.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2">
      <data key="d0">SARS-CoV-2</data>
      <data key="d1">virus</data>
      <data key="d2">SARS-CoV-2 is the virus responsible for the COVID-19 pandemic, known to cause severe respiratory illnesses and other symptoms, including Acute Respiratory Distress Syndrome (ARDS). As a novel strain of the coronavirus, SARS-CoV-2 has been the central focus of extensive research and review, especially concerning diagnostics, variants, and vaccine development. The virus is characterized as an enveloped, single-stranded RNA virus belonging to the Betacoronavirus genus.

The emergence of SARS-CoV-2 has led to the identification of various variants that influence the effectiveness of diagnostic methods and therapeutic approaches. These variants pose challenges as they may exhibit mutations, particularly in the spike protein, which is crucial for vaccine development. Such mutations raise concerns regarding the virus's ability to evade antibodies and impact treatment efficacy.

Detection of SARS-CoV-2 is primarily conducted using nucleic acid-based methods, with several diagnostic assays specifically developed to identify antibodies against its antigens. Multiple vaccines targeting SARS-CoV-2 have been developed, including NVX-CoV2373, AZD1222, Gam-COVID-Vac, and BBIBP-CorV, which aim to provide immunity and mitigate the impact of the pandemic. Vaccines like ChAdOx1 nCoV-19 and Sinovac's inactivated viral vaccine have also been highlighted in studies.

Research on SARS-CoV-2 extends to its potential neuro-invasive properties, which, combined with its rapid mutation rates, underline the ongoing challenges faced in managing the virus. Given its widespread implications for public health, SARS-CoV-2 remains a subject of extensive study, focusing on its clinical effects, vaccine responses, and the evolving landscape of variants.</data>
      <data key="d3">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-0a60b0692db3daf8de021fda40a42927&lt;SEP&gt;chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8&lt;SEP&gt;chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-90dfb33ebd8b6695b6eb243fc4a55781&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-1c7d4256e04a0834c64b7e62ef5d3416&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d&lt;SEP&gt;chunk-42afc66a510e32c7e7356f907c3ef8fb&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791248</data>
      <data key="d6" />
    </node>
    <node id="Wang D">
      <data key="d0">Wang D</data>
      <data key="d1">person</data>
      <data key="d2">Wang D is an author who researched the clinical characteristics of patients infected with the 2019 novel coronavirus in Wuhan, China, in 2020.&lt;SEP&gt;Wang D is an author contributing to research on clinical characteristics of COVID-19 patients in Wuhan.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Hu B">
      <data key="d0">Hu B</data>
      <data key="d1">person</data>
      <data key="d2">Hu B is a co-author on the study detailing hospitalized patients with the novel coronavirus in Wuhan, China, in 2020.&lt;SEP&gt;Hu B is an author who collaborated with Wang D in researching COVID-19 in Wuhan, China.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Hu C">
      <data key="d0">Hu C</data>
      <data key="d1">person</data>
      <data key="d2">Hu C is a co-author involved in the clinical study of 2019 novel coronavirus-infected pneumonia in Wuhan, published in 2020.&lt;SEP&gt;Hu C is an author who co-authored a study on COVID-19 patient characteristics in Wuhan.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="JAMA">
      <data key="d0">JAMA</data>
      <data key="d1">organization</data>
      <data key="d2">JAMA is a medical journal that published research regarding the clinical characteristics of hospitalized patients with pneumonia caused by the novel coronavirus in Wuhan, China.&lt;SEP&gt;JAMA is a prominent medical journal that published research findings related to COVID-19 patient characteristics.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Nat Rev Microbiol">
      <data key="d0">Nat Rev Microbiol</data>
      <data key="d1">organization</data>
      <data key="d2">Nat Rev Microbiol is a journal that published the research on the origin and evolution of pathogenic coronaviruses.&lt;SEP&gt;Nat Rev Microbiol is a journal that published research on the origin and evolution of pathogenic coronaviruses.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="2020 Novel Coronavirus">
      <data key="d0">2020 Novel Coronavirus</data>
      <data key="d1">concept</data>
      <data key="d2">The 2020 novel coronavirus refers to the virus that emerged and caused a global pandemic, impacting health systems worldwide.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Variants">
      <data key="d0">COVID-19 Variants</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 variants refer to the novel strains of SARS-CoV-2 that have emerged and pose challenges to diagnosis and treatment.&lt;SEP&gt;COVID-19 variants refer to the emerging and evolving strains of SARS-CoV-2, which pose challenges in diagnostics and vaccine development.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Dina Moustafa Abo El-Ella">
      <data key="d0">Dina Moustafa Abo El-Ella</data>
      <data key="d1">person</data>
      <data key="d2">Dina Moustafa Abo El-Ella is a contributor to the review article regarding emerging COVID-19 variants.&lt;SEP&gt;Dina Moustafa Abo El-Ella is an author affiliated with the Translational Cancer Research Facility, involved in research related to COVID-19 variants and SARS-CoV-2.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Takwa Bedhiafi">
      <data key="d0">Takwa Bedhiafi</data>
      <data key="d1">person</data>
      <data key="d2">Takwa Bedhiafi is a contributor to the review article analyzing COVID-19 diagnostics and vaccines.&lt;SEP&gt;Takwa Bedhiafi is a co-author involved in the research on COVID-19 variants and their impact on SARS-CoV-2 diagnostics and therapeutics.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Afsheen Raza">
      <data key="d0">Afsheen Raza</data>
      <data key="d1">person</data>
      <data key="d2">Afsheen Raza is a contributor to the review article discussing COVID-19 diagnosis and treatment.&lt;SEP&gt;Afsheen Raza is a co-author who contributed to the study regarding COVID-19 variants and their implications for diagnostics and vaccines.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Mariam Ali Yousuf Al-Nesf">
      <data key="d0">Mariam Ali Yousuf Al-Nesf</data>
      <data key="d1">person</data>
      <data key="d2">Mariam Ali Yousuf Al-Nesf is a contributor to the review article on the impact of COVID-19 variants.&lt;SEP&gt;Mariam Ali Yousuf Al-Nesf is a co-author associated with the research on the impact of COVID-19 variants on diagnostics and therapeutic approaches.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Ali Ait Hssain">
      <data key="d0">Ali Ait Hssain</data>
      <data key="d1">person</data>
      <data key="d2">Ali Ait Hssain is a contributor mentioned in the article related to COVID-19 diagnostics and vaccines.&lt;SEP&gt;Ali Ait Hssain is a co-author involved in the study reviewing COVID-19 variants and their effects on healthcare.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Shahab Uddin">
      <data key="d0">Shahab Uddin</data>
      <data key="d1">person</data>
      <data key="d2">Shahab Uddin is a contributor to the review discussing emerging COVID-19 variants.&lt;SEP&gt;Shahab Uddin contributed intellectual input and is associated with an ORCID identifier for academic recognition.&lt;SEP&gt;Shahab Uddin is a co-author affiliated with the Allergy and Immunology Section of Hamad General Hospital, involved in researching COVID-19 variants.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Said Dermime">
      <data key="d0">Said Dermime</data>
      <data key="d1">person</data>
      <data key="d2">Said Dermime is a contributor to the review article on COVID-19 variants and diagnostics.&lt;SEP&gt;Said Dermime is also a contributor to the manuscript and has a corresponding ORCID identifier.&lt;SEP&gt;Said Dermime is a contact associated with the Hamad Medical Corporation, mentioned in the context of health research.&lt;SEP&gt;Said Dermime is a co-author associated with the research on the impact of COVID-19 variants on diagnostics and therapeutics in Qatar.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="NVX-CoV2373">
      <data key="d0">NVX-CoV2373</data>
      <data key="d1">vaccine</data>
      <data key="d2">NVX-CoV2373 is a SARS-CoV-2 subunit vaccine developed from the spike glycoprotein, produced in insect cell systems.&lt;SEP&gt;NVX-CoV2373 is a vaccine with a reported efficacy of 89.7%, known to induce robust humoral and T cell immune responses in vaccinated participants.&lt;SEP&gt;NVX-CoV2373 is a COVID-19 vaccine candidate that has shown immunogenicity in baboons and protection in mice.&lt;SEP&gt;NVX-CoV2373 is a SARS-CoV-2 subunit vaccine developed by Novavax, formulated using nanoparticles containing the full-length spike glycoprotein.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Novavax">
      <data key="d0">Novavax</data>
      <data key="d1">organization</data>
      <data key="d2">Novavax is a company that developed NVX-CoV2373, a vaccine targeting the SARS-CoV-2 virus.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Matrix-M">
      <data key="d0">Matrix-M</data>
      <data key="d1">adjuvant</data>
      <data key="d2">Matrix-M is an adjuvant used in the formulation of NVX-CoV2373 vaccine to enhance immune responses.&lt;SEP&gt;Matrix-M is a saponin-based adjuvant used in the NVX-CoV2373 vaccine to enhance immune responses.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Nonhuman Primate Models">
      <data key="d0">Nonhuman Primate Models</data>
      <data key="d1">method</data>
      <data key="d2">Nonhuman primate models, including baboons and cynomolgus macaque, were used to initially test the safety and immunogenicity of the NVX-CoV2373 vaccine.&lt;SEP&gt;Nonhuman primate models, including baboons and cynomolgus macaques, were used to initially test the safety and immunogenicity of NVX-CoV2373.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791249</data>
      <data key="d6" />
    </node>
    <node id="Phase 1-2 Clinical Trial">
      <data key="d0">Phase 1-2 Clinical Trial</data>
      <data key="d1">event</data>
      <data key="d2">Phase 1-2 clinical trials evaluated the safety and immunogenicity of the SARS-CoV-2 vaccine in humans.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="United Kingdom">
      <data key="d0">United Kingdom</data>
      <data key="d1">location</data>
      <data key="d2">The United Kingdom is one of the countries where phase 3 trials for NVX-CoV2373 vaccine are ongoing.&lt;SEP&gt;The United Kingdom is one of the countries where ongoing trials for NVX-CoV2373 are being conducted.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="Northern Ireland">
      <data key="d0">Northern Ireland</data>
      <data key="d1">location</data>
      <data key="d2">Northern Ireland is one of the locations participating in the phase 3 trials of the NVX-CoV2373 vaccine.&lt;SEP&gt;Northern Ireland is one of the countries participating in the ongoing trials for NVX-CoV2373.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="Mexico">
      <data key="d0">Mexico</data>
      <data key="d1">location</data>
      <data key="d2">Mexico is included among the countries where the NVX-CoV2373 vaccine is currently in phase 3 trials.&lt;SEP&gt;Mexico is one of the countries involved in the ongoing trials for NVX-CoV2373.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="Puerto Rico">
      <data key="d0">Puerto Rico</data>
      <data key="d1">location</data>
      <data key="d2">Puerto Rico is part of the multi-country phase 3 trials for the NVX-CoV2373 vaccine.&lt;SEP&gt;Puerto Rico is participating in the ongoing trials for NVX-CoV2373.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="United States of America">
      <data key="d0">United States of America</data>
      <data key="d1">location</data>
      <data key="d2">The United States of America is participating in the phase 3 trials for the NVX-CoV2373 vaccine.&lt;SEP&gt;The United States of America is one of the countries conducting trials for NVX-CoV2373.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="Protein Subunit Vaccines">
      <data key="d0">Protein Subunit Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Protein subunit vaccines refer to a class of vaccines, including NVX-CoV2373, that use harmless pieces of the virus to stimulate an immune response.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="Baculovirus-Spodoptera Frugiperda (Sf9)">
      <data key="d0">Baculovirus-Spodoptera Frugiperda (Sf9)</data>
      <data key="d1">method</data>
      <data key="d2">Baculovirus-Spodoptera Frugiperda (Sf9) is an insect cell expression system used for producing the NVX-CoV2373 vaccine.&lt;SEP&gt;The Baculovirus-Spodoptera frugiperda (Sf9) insect cell expression system is used to produce the NVX-CoV2373 vaccine.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="T Cell Response">
      <data key="d0">T Cell Response</data>
      <data key="d1">immuneresponse</data>
      <data key="d2">T cell response refers to the immune response elicited by the NVX-CoV2373 vaccine, specifically targeting the cellular immunity aspect.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="B Cell Response">
      <data key="d0">B Cell Response</data>
      <data key="d1">immuneresponse</data>
      <data key="d2">B cell response refers to the antibody production elicited by the NVX-CoV2373 vaccine, crucial for humoral immunity.</data>
      <data key="d3">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="QF">
      <data key="d0">QF</data>
      <data key="d1">person</data>
      <data key="d2">QF is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;QF is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="MM">
      <data key="d0">MM</data>
      <data key="d1">person</data>
      <data key="d2">MM is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;MM is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="SM">
      <data key="d0">SM</data>
      <data key="d1">person</data>
      <data key="d2">SM is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;SM is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="NT">
      <data key="d0">NT</data>
      <data key="d1">person</data>
      <data key="d2">NT is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;NT is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="DM">
      <data key="d0">DM</data>
      <data key="d1">person</data>
      <data key="d2">DM is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;DM is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="TB">
      <data key="d0">TB</data>
      <data key="d1">person</data>
      <data key="d2">TB is one of the authors who contributed to the initial draft of the manuscript.&lt;SEP&gt;TB is an author who contributed to the initial draft of the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="VP">
      <data key="d0">VP</data>
      <data key="d1">person</data>
      <data key="d2">VP prepared the figures for graphical illustration in the manuscript.&lt;SEP&gt;VP is an author who prepared the figures for the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="AR">
      <data key="d0">AR</data>
      <data key="d1">person</data>
      <data key="d2">AR critically revised and organized the manuscript.&lt;SEP&gt;AR is an author who critically revised and organized the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="LZ">
      <data key="d0">LZ</data>
      <data key="d1">person</data>
      <data key="d2">LZ provided intellectual input and reviewed the manuscript.&lt;SEP&gt;LZ is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791250</data>
      <data key="d6" />
    </node>
    <node id="MOM">
      <data key="d0">MOM</data>
      <data key="d1">person</data>
      <data key="d2">MOM provided intellectual input and reviewed the manuscript.&lt;SEP&gt;MOM is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="MAN">
      <data key="d0">MAN</data>
      <data key="d1">person</data>
      <data key="d2">MAN provided intellectual input and reviewed the manuscript.&lt;SEP&gt;MAN is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="AA">
      <data key="d0">AA</data>
      <data key="d1">person</data>
      <data key="d2">AA provided intellectual input and reviewed the manuscript.&lt;SEP&gt;AA is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="HM">
      <data key="d0">HM</data>
      <data key="d1">person</data>
      <data key="d2">HM provided intellectual input and reviewed the manuscript.&lt;SEP&gt;HM is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="MB">
      <data key="d0">MB</data>
      <data key="d1">person</data>
      <data key="d2">MB provided intellectual input and reviewed the manuscript.&lt;SEP&gt;MB is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="SU">
      <data key="d0">SU</data>
      <data key="d1">person</data>
      <data key="d2">SU provided intellectual input and reviewed the manuscript.&lt;SEP&gt;SU is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="SD">
      <data key="d0">SD</data>
      <data key="d1">person</data>
      <data key="d2">SD provided intellectual input and reviewed the manuscript.&lt;SEP&gt;SD is an author who provided intellectual input and reviewed the manuscript.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Disclosure Statement">
      <data key="d0">Disclosure Statement</data>
      <data key="d1">concept</data>
      <data key="d2">The disclosure statement indicates that no potential conflict of interest was reported by the authors.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Funding">
      <data key="d0">Funding</data>
      <data key="d1">concept</data>
      <data key="d2">Funding refers to the financial support provided for the publication by the Qatar National Library.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Gorbalenya AE">
      <data key="d0">Gorbalenya AE</data>
      <data key="d1">person</data>
      <data key="d2">Gorbalenya AE is an author of a referenced study about severe acute respiratory syndrome-related coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Baker SC">
      <data key="d0">Baker SC</data>
      <data key="d1">person</data>
      <data key="d2">Baker SC is an author of a referenced study about severe acute respiratory syndrome-related coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Baric RS">
      <data key="d0">Baric RS</data>
      <data key="d1">person</data>
      <data key="d2">Baric RS is an author of a referenced study about severe acute respiratory syndrome-related coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Zhu N">
      <data key="d0">Zhu N</data>
      <data key="d1">person</data>
      <data key="d2">Zhu N is an author of a referenced study concerning a novel coronavirus from pneumonia patients in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Zhang D">
      <data key="d0">Zhang D</data>
      <data key="d1">person</data>
      <data key="d2">Zhang D is an author of a referenced study concerning a novel coronavirus from pneumonia patients in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Wang W">
      <data key="d0">Wang W</data>
      <data key="d1">person</data>
      <data key="d2">Wang W is an author of a referenced study concerning a novel coronavirus from pneumonia patients in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Guan WJ">
      <data key="d0">Guan WJ</data>
      <data key="d1">person</data>
      <data key="d2">Guan WJ is an author of a referenced study discussing the clinical characteristics of coronavirus disease 2019 in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Ni ZY">
      <data key="d0">Ni ZY</data>
      <data key="d1">person</data>
      <data key="d2">Ni ZY is an author of a referenced study discussing the clinical characteristics of coronavirus disease 2019 in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Hu Y">
      <data key="d0">Hu Y</data>
      <data key="d1">person</data>
      <data key="d2">Hu Y is an author of a referenced study discussing the clinical characteristics of coronavirus disease 2019 in China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Huang C">
      <data key="d0">Huang C</data>
      <data key="d1">person</data>
      <data key="d2">Huang C is an author of a referenced study discussing clinical features of patients infected with the novel coronavirus in Wuhan, China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791251</data>
      <data key="d6" />
    </node>
    <node id="Li X">
      <data key="d0">Li X</data>
      <data key="d1">person</data>
      <data key="d2">Li X is an author of a referenced study discussing clinical features of patients infected with the novel coronavirus in Wuhan, China.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Zhu Z">
      <data key="d0">Zhu Z</data>
      <data key="d1">person</data>
      <data key="d2">Zhu Z is an author of a referenced study characterizing the genomic composition of a novel human-pathogenic coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Lu R">
      <data key="d0">Lu R</data>
      <data key="d1">person</data>
      <data key="d2">Lu R is an author of a referenced study characterizing the genomic epidemiology of the novel coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Zhao X">
      <data key="d0">Zhao X</data>
      <data key="d1">person</data>
      <data key="d2">Zhao X is an author of a referenced study characterizing the genomic epidemiology of the novel coronavirus.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Tyrrell DA">
      <data key="d0">Tyrrell DA</data>
      <data key="d1">person</data>
      <data key="d2">Tyrrell DA is an author associated with research on the cultivation of viruses from patients with colds.&lt;SEP&gt;Tyrrell DA is an author of a referenced study about the cultivation of viruses from cold patients.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Bynoe ML">
      <data key="d0">Bynoe ML</data>
      <data key="d1">person</data>
      <data key="d2">Bynoe ML is a co-author of a study on the cultivation of viruses from patients with colds alongside Tyrrell DA.&lt;SEP&gt;Bynoe ML is an author of a referenced study about the cultivation of viruses from cold patients.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Perlman S">
      <data key="d0">Perlman S</data>
      <data key="d1">person</data>
      <data key="d2">Perlman S is an author who wrote about coronaviruses in the New England Journal of Medicine in 2020.&lt;SEP&gt;Perlman S is an author of a referenced study discussing coronaviruses over the decades.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Martin MA">
      <data key="d0">Martin MA</data>
      <data key="d1">person</data>
      <data key="d2">Martin MA is an author who contributed to research on SARS-CoV-2 sequences.&lt;SEP&gt;Martin MA is an author of a referenced study about insights from SARS-CoV-2 sequences.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="VanInsberghe D">
      <data key="d0">VanInsberghe D</data>
      <data key="d1">person</data>
      <data key="d2">VanInsberghe D is a co-author alongside Martin MA in the research regarding SARS-CoV-2 sequences.&lt;SEP&gt;VanInsberghe D is an author of a referenced study about insights from SARS-CoV-2 sequences.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Koelle K">
      <data key="d0">Koelle K</data>
      <data key="d1">person</data>
      <data key="d2">Koelle K is a co-author with Martin MA and VanInsberghe D on a study focused on SARS-CoV-2 sequences.&lt;SEP&gt;Koelle K is an author of a referenced study about insights from SARS-CoV-2 sequences.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="CDC">
      <data key="d0">CDC</data>
      <data key="d1">organization</data>
      <data key="d2">The Centers for Disease Control and Prevention is a national public health institute providing information on SARS-CoV-2 variant classifications.&lt;SEP&gt;The Centers for Disease Control and Prevention is a national public health agency in the United States that addresses SARS-CoV-2 variant classifications and definitions.&lt;SEP&gt;The CDC is a national public health agency involved in defining SARS-CoV-2 variant classifications.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="World Health Organization">
      <data key="d0">World Health Organization</data>
      <data key="d1">organization</data>
      <data key="d2">The World Health Organization (WHO) is an international public health agency that officially named the viral illness caused by SARS-CoV-2 as COVID-19 and declared it a public health emergency.&lt;SEP&gt;The World Health Organization is a global health agency involved in public health initiatives, including vaccine tracking.&lt;SEP&gt;The World Health Organization is an international public health agency that formally named COVID-19 and is involved in global health response efforts.&lt;SEP&gt;The World Health Organization is the international health agency that approved the AZD1222 vaccine for public use.&lt;SEP&gt;The World Health Organization oversees global health issues, including vaccination strategies during COVID-19.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Hubei Province">
      <data key="d0">Hubei Province</data>
      <data key="d1">location</data>
      <data key="d2">Hubei Province is a region in China where the outbreak of COVID-19 was first identified in December 2019.&lt;SEP&gt;Hubei Province is located in China and is notable for being the origin of the SARS-CoV-2 outbreak.&lt;SEP&gt;Hubei Province is a region in China where Wuhan is located and where the COVID-19 outbreak was initially identified.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Tyrell and Bynoe">
      <data key="d0">Tyrell and Bynoe</data>
      <data key="d1">person</data>
      <data key="d2">Tyrell and Bynoe are researchers known for first identifying the Coronaviridae family of viruses in 1965.&lt;SEP&gt;Tyrell and Bynoe were researchers credited with the first identification of a family of viruses that includes coronaviruses.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="International Committee on Taxonomy of Viruses">
      <data key="d0">International Committee on Taxonomy of Viruses</data>
      <data key="d1">organization</data>
      <data key="d2">The International Committee on Taxonomy of Viruses is responsible for formally naming and classifying viruses, including SARS-CoV-2.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Acute Respiratory Syndrome">
      <data key="d0">Acute Respiratory Syndrome</data>
      <data key="d1">concept</data>
      <data key="d2">Acute Respiratory Syndrome refers to the severe respiratory infections caused by certain strains of coronaviruses, including SARS-CoV-2.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Viral Epidemic">
      <data key="d0">Viral Epidemic</data>
      <data key="d1">concept</data>
      <data key="d2">A viral epidemic refers to an outbreak of infectious disease caused by a virus, such as the COVID-19 outbreak declared a public health emergency of international concern.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Nucleocapsid Protein">
      <data key="d0">Nucleocapsid Protein</data>
      <data key="d1">protein</data>
      <data key="d2">Nucleocapsid protein (N) is a viral structural protein that plays a role in the virulence and function of the SARS-CoV-2 virus.&lt;SEP&gt;The nucleocapsid protein (N) is one of the primary structural proteins of the SARS-CoV-2 virus that plays a critical role in virulence and function.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Membrane Glycoprotein">
      <data key="d0">Membrane Glycoprotein</data>
      <data key="d1">protein</data>
      <data key="d2">Membrane glycoprotein (M) is a structural protein involved in the functionality of the SARS-CoV-2 virus.&lt;SEP&gt;Membrane glycoprotein (M) is a structural protein of SARS-CoV-2 involved in the virus's functionality and virulence.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791252</data>
      <data key="d6" />
    </node>
    <node id="Spike Glycoprotein">
      <data key="d0">Spike Glycoprotein</data>
      <data key="d1">protein</data>
      <data key="d2">Spike glycoprotein (S) is a crucial structural component of SARS-CoV-2 responsible for initiating infection.&lt;SEP&gt;Spike glycoprotein (S) is a critical structural protein on the SARS-CoV-2 virus that facilitates entry into host cells.</data>
      <data key="d3">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Chung JR">
      <data key="d0">Chung JR</data>
      <data key="d1">person</data>
      <data key="d2">Chung JR is one of the authors involved in multiple studies related to vaccine effectiveness and safety.&lt;SEP&gt;Chung JR is an author involved in influenza clinical research and the Influenza Incidence Surveillance Project.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Flannery B">
      <data key="d0">Flannery B</data>
      <data key="d1">person</data>
      <data key="d2">Flannery B is a co-author in studies addressing influenza vaccination effectiveness and safety.&lt;SEP&gt;Flannery B is an author associated with influenza vaccine effectiveness studies.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Ambrose CS">
      <data key="d0">Ambrose CS</data>
      <data key="d1">person</data>
      <data key="d2">Ambrose CS is an author part of the research team for influenza clinical investigations.&lt;SEP&gt;Ambrose CS is an author working with the Influenza Clinical Investigation for Children Study Team.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Influenza Incidence Surveillance Project">
      <data key="d0">Influenza Incidence Surveillance Project</data>
      <data key="d1">organization</data>
      <data key="d2">The Influenza Incidence Surveillance Project is a study monitoring influenza incidence and vaccine effectiveness.&lt;SEP&gt;The Influenza Incidence Surveillance Project aims to monitor influenza cases in the population.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="US Influenza Vaccine Effectiveness Network">
      <data key="d0">US Influenza Vaccine Effectiveness Network</data>
      <data key="d1">organization</data>
      <data key="d2">The US Influenza Vaccine Effectiveness Network is a collective effort documenting the effectiveness of influenza vaccines in the United States.&lt;SEP&gt;The US Influenza Vaccine Effectiveness Network evaluates the effectiveness of influenza vaccines.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Pediatrics">
      <data key="d0">Pediatrics</data>
      <data key="d1">content</data>
      <data key="d2">Pediatrics is a journal that published a study on influenza vaccine effectiveness.&lt;SEP&gt;Pediatrics is a medical journal where relevant studies about influenza vaccine effectiveness were published.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Jiang R">
      <data key="d0">Jiang R</data>
      <data key="d1">person</data>
      <data key="d2">Jiang R is an author who contributed to research on the immunogenicity and safety of vaccines.&lt;SEP&gt;Jiang R is an author who contributed to research on the inactivated poliomyelitis vaccine.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Liu X">
      <data key="d0">Liu X</data>
      <data key="d1">person</data>
      <data key="d2">Liu X is a co-author in the research regarding the inactivated poliomyelitis vaccine.&lt;SEP&gt;Liu X is an author involved in the safety and immunogenicity study of the poliomyelitis vaccine.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Sun X">
      <data key="d0">Sun X</data>
      <data key="d1">person</data>
      <data key="d2">Sun X is involved in studies assessing the immunogenicity of a vaccine candidate.&lt;SEP&gt;Sun X is an author who participated in the phase IV clinical trial for vaccination against poliomyelitis.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Human Papillomavirus Vaccines">
      <data key="d0">Human Papillomavirus Vaccines</data>
      <data key="d1">content</data>
      <data key="d2">Human Papillomavirus Vaccines are the focus of a safety review published in Drug Safety.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Drug Safety">
      <data key="d0">Drug Safety</data>
      <data key="d1">content</data>
      <data key="d2">Drug safety encompasses the monitoring and evaluation of adverse drug reactions and effectiveness of medications.&lt;SEP&gt;Drug Safety is a journal that reviews the safety of various medical treatments, including vaccines.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="VPBM">
      <data key="d0">VPBM</data>
      <data key="d1">content</data>
      <data key="d2">VPBM is a publication that includes research findings on immunity in HIV-infected adults.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Candidate Vaccines">
      <data key="d0">COVID-19 Candidate Vaccines</data>
      <data key="d1">content</data>
      <data key="d2">COVID-19 candidate vaccines refer to the various vaccines developed to combat the COVID-19 pandemic, tracked by the World Health Organization.&lt;SEP&gt;COVID-19 Candidate Vaccines are the focus of a draft landscape report by the World Health Organization.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="CoronaVac">
      <data key="d0">CoronaVac</data>
      <data key="d1">vaccine</data>
      <data key="d2">CoronaVac is an inactivated vaccine candidate developed for SARS-CoV-2.&lt;SEP&gt;CoronaVac (formerly PiCoVacc) is an inactivated COVID-19 vaccine developed by Sinovac Biotech Ltd.&lt;SEP&gt;CoronaVac is an inactivated vaccine candidate developed to combat SARS-CoV-2.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Lancet Infectious Diseases">
      <data key="d0">Lancet Infectious Diseases</data>
      <data key="d1">content</data>
      <data key="d2">Lancet Infectious Diseases is a journal where significant clinical trial findings related to SARS-CoV-2 vaccines are published.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="medRxiv">
      <data key="d0">medRxiv</data>
      <data key="d1">content</data>
      <data key="d2">medRxiv is a preprint server where the study on the PCR-based detection method for Omicron was published in 2021.&lt;SEP&gt;medRxiv is a preprint server for health sciences that includes research on PCR-based methods for COVID-19 variant detection.&lt;SEP&gt;medRxiv is a repository for preprints related to health sciences, including vaccine studies.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791253</data>
      <data key="d6" />
    </node>
    <node id="Sinovac Vaccine">
      <data key="d0">Sinovac Vaccine</data>
      <data key="d1">product</data>
      <data key="d2">Sinovac Vaccine is an inactivated vaccine used in China to combat COVID-19 and is discussed in the context of phase-iii trial results.&lt;SEP&gt;The Sinovac Vaccine is a COVID-19 vaccine developed by Sinovac Biotech and tested in clinical trials.&lt;SEP&gt;Sinovac Vaccine is a COVID-19 vaccine candidate with studies reported in various publications.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Influenza Vaccine Effectiveness">
      <data key="d0">Influenza Vaccine Effectiveness</data>
      <data key="d1">concept</data>
      <data key="d2">Influenza Vaccine Effectiveness refers to how well influenza vaccines prevent infection, as studied by various research teams.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Immunogenicity">
      <data key="d0">Immunogenicity</data>
      <data key="d1">concept</data>
      <data key="d2">Immunogenicity is the ability of a vaccine to provoke an immune response, particularly studied in vaccine trials.&lt;SEP&gt;Immunogenicity refers to the ability of a vaccine to provoke an immune response, specifically related to COVID-19 vaccines in transplant recipients.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Phase IV Clinical Trial">
      <data key="d0">Phase IV Clinical Trial</data>
      <data key="d1">method</data>
      <data key="d2">A Phase IV clinical trial is a study conducted after a vaccine or medication has been approved to assess its long-term effectiveness and safety in the general population.&lt;SEP&gt;A Phase IV Clinical Trial involves post-marketing studies conducted to assess the long-term effectiveness and safety of a vaccine in a large population.</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="PCR Fragment">
      <data key="d0">PCR Fragment</data>
      <data key="d1">concept</data>
      <data key="d2">A PCR fragment that can identify and distinguish all known SARS-CoV-2 variants of concern (VOCs).</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Immuno-Assay">
      <data key="d0">Immuno-Assay</data>
      <data key="d1">method</data>
      <data key="d2">Immuno-assays, including various types, are reliable methods for detecting SARS-CoV-2 infections through antigens.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Enzyme Linked Immunosorbent Assays (ELISA)">
      <data key="d0">Enzyme Linked Immunosorbent Assays (ELISA)</data>
      <data key="d1">method</data>
      <data key="d2">ELISA is a specific type of immuno-assay used for detecting the presence of SARS-CoV-2 antigens.&lt;SEP&gt;Enzyme Linked Immunosorbent Assays (ELISA) are immunoassays used for the detection of SARS-CoV-2 infections.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781&lt;SEP&gt;chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Anti-SARS-CoV-2 Antibody">
      <data key="d0">Anti-SARS-CoV-2 Antibody</data>
      <data key="d1">concept</data>
      <data key="d2">Anti-SARS-CoV-2 antibodies are produced following infection and are used for detection but are not suitable for early diagnosis.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="IgM">
      <data key="d0">IgM</data>
      <data key="d1">data</data>
      <data key="d2">Immunoglobulin M (IgM) is an antibody measured in kits that detect humoral immune responses to SARS-CoV-2.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="IgG">
      <data key="d0">IgG</data>
      <data key="d1">data</data>
      <data key="d2">Immunoglobulin G (IgG) is an antibody that, along with IgM, is used to measure immune response in blood samples.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Variants of Concern (VOCs)">
      <data key="d0">SARS-CoV-2 Variants of Concern (VOCs)</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 Variants of Concern (VOCs) are the different strains of the virus that have been identified and are of particular interest due to their potential impact on infection spread and vaccine effectiveness.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Clinical Specimens">
      <data key="d0">Clinical Specimens</data>
      <data key="d1">data</data>
      <data key="d2">Clinical specimens include various sample types like nasopharyngeal swabs, nasal swabs, and saliva used in tests for SARS-CoV-2 detection.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Novel Sensor and Biosensor Technologies">
      <data key="d0">Novel Sensor and Biosensor Technologies</data>
      <data key="d1">concept</data>
      <data key="d2">Novel sensor and biosensor technologies are being researched to enhance the sensitivity of antigen-based immuno-assays for SARS-CoV-2.</data>
      <data key="d3">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Central Immune Cells">
      <data key="d0">Central Immune Cells</data>
      <data key="d1">naturalobject</data>
      <data key="d2">Central immune cells play a role in the immune response and can be activated without antigen presence, induced by TM Matrix-M adjuvant.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Cynomolgus Macaque">
      <data key="d0">Cynomolgus Macaque</data>
      <data key="d1">creature</data>
      <data key="d2">Cynomolgus macaques are a species of monkey used in vaccine studies to evaluate the protection of the upper and lower airways against SARS-CoV-2.&lt;SEP&gt;Cynomolgus macaques were utilized in studies to assess the effectiveness of NVX-CoV2373 against SARS-CoV-2.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="ChAdOx1 nCoV-19">
      <data key="d0">ChAdOx1 nCoV-19</data>
      <data key="d1">content</data>
      <data key="d2">ChAdOx1 nCoV-19 is a COVID-19 vaccine that has undergone safety and immunogenicity assessments in preliminary reports.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Lancet">
      <data key="d0">Lancet</data>
      <data key="d1">organization</data>
      <data key="d2">The Lancet is a prestigious and reputable medical journal known for publishing significant research and studies in the fields of health and medicine. It has a long-standing reputation for disseminating valuable information and findings regarding various medical topics, with a particular emphasis on vaccine efficacy and safety.

The journal has published numerous crucial articles, including studies on vaccines, notably those related to COVID-19, where it provided insights on the coverage and effectiveness of vaccines among healthcare workers. In addition, The Lancet has been instrumental in reporting on the rAd26 and rAd5 COVID-19 vaccine, contributing to the understanding of these vital medical interventions.

Furthermore, The Lancet has addressed public health concerns through its publications on infectious diseases. For example, it reported on a pneumonia cluster linked to the 2019 novel coronavirus, highlighting the journals commitment to informing the medical community about emerging health threats.

As a leading medical journal, The Lancet remains a foundational resource for medical professionals, researchers, and policymakers, continuing to shape the discourse around vital health issues through its rigorous peer-reviewed studies and articles.</data>
      <data key="d3">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2&lt;SEP&gt;chunk-ad9d995908432109592f45ab0eade340&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Keech CMD">
      <data key="d0">Keech CMD</data>
      <data key="d1">person</data>
      <data key="d2">Keech CMD is a researcher who has published work on SARS-CoV-2 recombinant spike protein nanoparticle vaccines and their trials.&lt;SEP&gt;Keech CMD is a lead researcher discussing the NVX-CoV2373 vaccine trials.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="Heath PT">
      <data key="d0">Heath PT</data>
      <data key="d1">person</data>
      <data key="d2">Heath PT is an author who collaborated on the safety and efficacy study of the NVX-CoV2373 COVID-19 vaccine.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="BioRxiv">
      <data key="d0">BioRxiv</data>
      <data key="d1">organization</data>
      <data key="d2">BioRxiv is a preprint repository for biology research where various studies, including those on SARS-CoV-2, are published.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791254</data>
      <data key="d6" />
    </node>
    <node id="J Biological Chemistry">
      <data key="d0">J Biological Chemistry</data>
      <data key="d1">content</data>
      <data key="d2">J Biological Chemistry is a scientific journal that published research on the effects of Molnupiravir on SARS-CoV-2.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Nature Structural &amp; Molecular Biology">
      <data key="d0">Nature Structural &amp; Molecular Biology</data>
      <data key="d1">content</data>
      <data key="d2">Nature Structural &amp; Molecular Biology is a journal that featured research on the mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Science Translational Medicine">
      <data key="d0">Science Translational Medicine</data>
      <data key="d1">content</data>
      <data key="d2">Science Translational Medicine is a journal that reported on broad-spectrum antivirals inhibiting SARS-CoV-2 in vitro and in animal models.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="New England Journal of Medicine">
      <data key="d0">New England Journal of Medicine</data>
      <data key="d1">organization</data>
      <data key="d2">The New England Journal of Medicine is a prominent medical journal that published a study on the safety and efficacy of the NVX-CoV2373 vaccine.&lt;SEP&gt;The New England Journal of Medicine is a highly regarded medical journal that published Perlman S's paper on coronaviruses.</data>
      <data key="d3">chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Sinovac">
      <data key="d0">Sinovac</data>
      <data key="d1">organization</data>
      <data key="d2">Sinovac is a pharmaceutical company from China that has developed an inactivated viral vaccine for COVID-19, currently in clinical trials.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Sinopharm">
      <data key="d0">Sinopharm</data>
      <data key="d1">organization</data>
      <data key="d2">Sinopharm is a pharmaceutical company from China that produces inactivated viral vaccines, which are undergoing clinical trials.&lt;SEP&gt;Sinopharm is the organization that developed the BBIBP-CorV vaccine.&lt;SEP&gt;Sinopharm commenced a phase III trial of its COVID-19 vaccine in several countries across Africa, Asia, and Europe.&lt;SEP&gt;Sinopharm is a pharmaceutical company that developed the BBIBP-CorV vaccine and is conducting clinical trials for its safety and efficacy.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccine (Vero Cell) Inactivated">
      <data key="d0">COVID-19 Vaccine (Vero Cell) Inactivated</data>
      <data key="d1">artifact</data>
      <data key="d2">COVID-19 Vaccine (Vero Cell) Inactivated, also known as CoronaVac, is a vaccine developed by Sinovac consisting of an inactivated SARS-CoV-2 virus.&lt;SEP&gt;The COVID-19 Vaccine (Vero Cell) Inactivated is a vaccine evaluated for its efficacy in preventing COVID-19.&lt;SEP&gt;COVID-19 Vaccine (Vero Cell) Inactivated is a specific formulation of the COVID-19 vaccine developed by Sinovac Biotech Ltd and based on the inactivated SARS-CoV-2 virus.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Brazil">
      <data key="d0">Brazil</data>
      <data key="d1">location</data>
      <data key="d2">Brazil is one of the seven countries where clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated have been launched.&lt;SEP&gt;Brazil is a country where trials for the vaccine were conducted, reporting an efficacy rate for COVID-19 prevention.&lt;SEP&gt;Brazil is one of the countries where clinical trials for the COVID-19 Vaccine (Vero Cell) were conducted, assessing its efficacy rate.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Indonesia">
      <data key="d0">Indonesia</data>
      <data key="d1">location</data>
      <data key="d2">Indonesia is one of the countries participating in the clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Turkey">
      <data key="d0">Turkey</data>
      <data key="d1">location</data>
      <data key="d2">Turkey is involved in both the clinical trials and placebo control studies for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Turkey is another country where vaccine trials were conducted, showing a different efficacy rate.&lt;SEP&gt;Turkey is another country involved in clinical trials for the COVID-19 Vaccine (Vero Cell), reporting a high efficacy rate.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="China">
      <data key="d0">China</data>
      <data key="d1">location</data>
      <data key="d2">China is the country where Sinovac and Sinopharm are located and where their COVID-19 vaccine candidates are developed.&lt;SEP&gt;China is the country where the Sinovac vaccine is administered and where phase-iii results are reported.&lt;SEP&gt;China is the country that provided anti-COVID-19 vaccine donations to both Algeria and Serbia.&lt;SEP&gt;China is a country referenced in the context of COVID-19 vaccine research and reporting results.&lt;SEP&gt;China is the source of the donation of anti-COVID-19 vaccine doses to Algeria.&lt;SEP&gt;China is the country where significant research and clinical case studies on SARS and COVID-19 have been conducted.&lt;SEP&gt;China is the country where Wuhan is located and significant research on the coronavirus outbreak occurred.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c&lt;SEP&gt;chunk-aca59a50b858aa1e41e7e9acf7e566d2&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Philippines">
      <data key="d0">Philippines</data>
      <data key="d1">location</data>
      <data key="d2">The Philippines is one of the seven countries that conduct clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Philippines is a country mentioned in the context of vaccine trials.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Hong Kong">
      <data key="d0">Hong Kong</data>
      <data key="d1">location</data>
      <data key="d2">Hong Kong is one of the locations participating in the clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Hong Kong is a location mentioned in the context of vaccine trials.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Chile">
      <data key="d0">Chile</data>
      <data key="d1">location</data>
      <data key="d2">Chile is included among the countries involved in the clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Chile is a country mentioned in the context of vaccine trials.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Macaca Mulatta">
      <data key="d0">Macaca Mulatta</data>
      <data key="d1">creature</data>
      <data key="d2">Macaca mulatta, commonly known as rhesus macaques, are used in the vaccine's safety evaluation as they mimic COVID-19-like symptoms.</data>
      <data key="d3">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Hamad Medical Corporation">
      <data key="d0">Hamad Medical Corporation</data>
      <data key="d1">organization</data>
      <data key="d2">Hamad Medical Corporation is involved in healthcare research and treatment related to COVID-19 variants.&lt;SEP&gt;Hamad Medical Corporation is a healthcare organization in Qatar associated with health sciences and research.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Hamad Bin Khalifa University">
      <data key="d0">Hamad Bin Khalifa University</data>
      <data key="d1">organization</data>
      <data key="d2">Hamad Bin Khalifa University is an academic institution in Doha, Qatar, focusing on health and life sciences.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="University of Bern">
      <data key="d0">University of Bern</data>
      <data key="d1">organization</data>
      <data key="d2">The University of Bern is a higher education institution in Switzerland with a focus on biomedical research.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="University of Oxford">
      <data key="d0">University of Oxford</data>
      <data key="d1">organization</data>
      <data key="d2">The University of Oxford is a prestigious university in the United Kingdom, known for its medical and biomedical research.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="Omicron">
      <data key="d0">Omicron</data>
      <data key="d1">concept</data>
      <data key="d2">Omicron is a variant of SARS-CoV-2, noted for its emergence and implications for diagnostics and vaccination strategies.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791255</data>
      <data key="d6" />
    </node>
    <node id="2019 Novel Coronavirus">
      <data key="d0">2019 Novel Coronavirus</data>
      <data key="d1">concept</data>
      <data key="d2">The 2019 Novel Coronavirus, initially identified as a new virus causing a pneumonia outbreak, was later renamed SARS-CoV-2.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Maysaloun Merhi">
      <data key="d0">Maysaloun Merhi</data>
      <data key="d1">person</data>
      <data key="d2">Maysaloun Merhi is one of the authors associated with the biomedical research and immunology discussed in the text.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Sarra Mestiri">
      <data key="d0">Sarra Mestiri</data>
      <data key="d1">person</data>
      <data key="d2">Sarra Mestiri is an author mentioned in the context of the biomedical research associated with COVID-19.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Nassiba Taib">
      <data key="d0">Nassiba Taib</data>
      <data key="d1">person</data>
      <data key="d2">Nassiba Taib is an author involved in the research related to COVID-19 immunological responses.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Lobna Al-Zaidan">
      <data key="d0">Lobna Al-Zaidan</data>
      <data key="d1">person</data>
      <data key="d2">Lobna Al-Zaidan is one of the authors contributing to the research on COVID-19 discussed in the text.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Mona O. Mohsen">
      <data key="d0">Mona O. Mohsen</data>
      <data key="d1">person</data>
      <data key="d2">Mona O. Mohsen is mentioned as an author in the context of the biomedical research concerning COVID-19.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Hadi Mohamad Yassine">
      <data key="d0">Hadi Mohamad Yassine</data>
      <data key="d1">person</data>
      <data key="d2">Hadi Mohamad Yassine is another author involved in the study of COVID-19 and its immunological impact.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Martin F. Bachmann">
      <data key="d0">Martin F. Bachmann</data>
      <data key="d1">person</data>
      <data key="d2">Martin F. Bachmann is listed as an author associated with immunology research related to COVID-19.</data>
      <data key="d3">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Spike Glycoprotein">
      <data key="d0">SARS-CoV-2 Spike Glycoprotein</data>
      <data key="d1">concept</data>
      <data key="d2">The SARS-CoV-2 spike glycoprotein is a target for vaccine development and an important part of the virus's structure used in research and vaccine efficacy studies.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Chimpanzee Vectors">
      <data key="d0">Chimpanzee Vectors</data>
      <data key="d1">method</data>
      <data key="d2">Chimpanzee vectors are biological tools employed in human vaccine development due to their high immunogenicity and genome stability.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Ebola Vaccine">
      <data key="d0">Ebola Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The Ebola vaccine is among the vaccines developed using chimpanzee vectors, demonstrating efficacy in clinical trials.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Malaria Vaccine">
      <data key="d0">Malaria Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The malaria vaccine is another vaccine developed utilizing chimpanzee vectors in clinical trials for inducing immune responses.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="HIV Vaccine">
      <data key="d0">HIV Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The HIV vaccine is also developed with chimpanzee vectors, showcasing the versatility of this method in vaccine development.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Crohn Disease Vaccine">
      <data key="d0">Crohn Disease Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The Crohn disease vaccine is included in the range of vaccines tested through chimpanzee vector methods to generate immune responses.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="AZD1222 Vaccine">
      <data key="d0">AZD1222 Vaccine</data>
      <data key="d1">artifact</data>
      <data key="d2">The AZD1222 vaccine is a COVID-19 vaccine approved by the WHO and used in 102 countries, showing a well-tolerated safety profile.&lt;SEP&gt;The AZD1222 vaccine has been linked to episodes of thrombocytopenia and bleeding, resulting in its suspension in several European countries.&lt;SEP&gt;The AZD1222 vaccine is a specific vaccine developed for COVID-19, using adenovirus vectors and has received WHO approval for use in multiple countries.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Clinical Trials">
      <data key="d0">Clinical Trials</data>
      <data key="d1">event</data>
      <data key="d2">Clinical trials for the AZD1222 vaccine tested over 60,000 adult participants across various countries to assess its safety and efficacy.&lt;SEP&gt;Clinical trials are conducted to assess the safety and immunogenicity of the vaccine formulations in healthy adult volunteers.&lt;SEP&gt;Clinical trials of the AZD1222 vaccine tested the safety and efficacy of the vaccine on a large number of participants.&lt;SEP&gt;Clinical trials of the COVID-19 Vaccine (Vero Cell) were conducted to evaluate safety and efficacy among participants over various phases.&lt;SEP&gt;Clinical trials are research studies conducted to evaluate the safety and efficacy of vaccines or treatments in human participants.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f&lt;SEP&gt;chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="European Countries">
      <data key="d0">European Countries</data>
      <data key="d1">location</data>
      <data key="d2">European countries are the locations where the use of the AZD1222 vaccine was suspended due to reported adverse events.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Spike Protein">
      <data key="d0">Spike Protein</data>
      <data key="d1">concept</data>
      <data key="d2">The Spike Protein is a component of SARS-CoV-2 that undergoes mutations and is critical for virus infectivity.&lt;SEP&gt;The spike protein is a structural protein of SARS-CoV-2 critical for viral entry into host cells and a focus of vaccine research.&lt;SEP&gt;The spike protein of SARS-CoV-2 is crucial for the virus's ability to infect host cells and is a target for antibody response.</data>
      <data key="d3">chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c&lt;SEP&gt;chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Falzone L">
      <data key="d0">Falzone L</data>
      <data key="d1">person</data>
      <data key="d2">Falzone L is an author who wrote a review on current and innovative methods for the diagnosis of COVID-19 infection.&lt;SEP&gt;Falzone L is an author involved in reviewing current and innovative methods for diagnosing COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Gattuso G">
      <data key="d0">Gattuso G</data>
      <data key="d1">person</data>
      <data key="d2">Gattuso G is a co-author with Falzone L in the review concerning COVID-19 diagnostic methods.&lt;SEP&gt;Gattuso G is a co-author who contributed to the review of innovative methods for diagnosing COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791256</data>
      <data key="d6" />
    </node>
    <node id="Tsatsakis A">
      <data key="d0">Tsatsakis A</data>
      <data key="d1">person</data>
      <data key="d2">Tsatsakis A is also a co-author along with Falzone L and Gattuso G on the COVID-19 diagnostic methods review.&lt;SEP&gt;Tsatsakis A is a co-author in the study focusing on diagnosis methods for COVID-19 infection.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Alpdagtas S">
      <data key="d0">Alpdagtas S</data>
      <data key="d1">person</data>
      <data key="d2">Alpdagtas S is an author who conducted an evaluation of diagnostic methods for COVID-19.&lt;SEP&gt;Alpdagtas S is an author evaluating current diagnostic methods for COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Ilhan E">
      <data key="d0">Ilhan E</data>
      <data key="d1">person</data>
      <data key="d2">Ilhan E is a co-author with Alpdagtas S in the evaluation of current COVID-19 diagnostic methods.&lt;SEP&gt;Ilhan E is a co-author examining current diagnostic methods for COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Uysal E">
      <data key="d0">Uysal E</data>
      <data key="d1">person</data>
      <data key="d2">Uysal E is another co-author with Alpdagtas S and Ilhan E focusing on COVID-19 diagnostic methods.&lt;SEP&gt;Uysal E is involved in the evaluation of current diagnostic methods for COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Tsang NNY">
      <data key="d0">Tsang NNY</data>
      <data key="d1">person</data>
      <data key="d2">Tsang NNY is an author who conducted a systematic review on the diagnostic performance of different sampling approaches for SARS-CoV-2 testing.&lt;SEP&gt;Tsang NNY is an author who conducted a systematic review on diagnostic approaches for SARS-CoV-2 RT-PCR testing.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="So HC">
      <data key="d0">So HC</data>
      <data key="d1">person</data>
      <data key="d2">So HC is a co-author with Tsang NNY in the systematic review focused on sampling approaches for SARS-CoV-2 RT-PCR testing.&lt;SEP&gt;So HC is a co-author involved in researching the diagnostic performance of SARS-CoV-2 testing.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Ng KY">
      <data key="d0">Ng KY</data>
      <data key="d1">person</data>
      <data key="d2">Ng KY is also a co-author with Tsang NNY and So HC on the review of SARS-CoV-2 testing methods.&lt;SEP&gt;Ng KY is a co-author contributing to the study on testing methodologies for SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Tahan S">
      <data key="d0">Tahan S</data>
      <data key="d1">person</data>
      <data key="d2">Tahan S is an author of a study discussing the SARS-CoV-2 E gene variant and its impact on viral detection.&lt;SEP&gt;Tahan S is an author investigating the impact of the SARS-CoV-2 E gene variant on detection sensitivity.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Parikh BA">
      <data key="d0">Parikh BA</data>
      <data key="d1">person</data>
      <data key="d2">Parikh BA is a co-author with Tahan S in the study regarding the SARS-CoV-2 E gene variant.&lt;SEP&gt;Parikh BA is a co-author involved in the study of the SARS-CoV-2 E gene variant.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Droit L">
      <data key="d0">Droit L</data>
      <data key="d1">person</data>
      <data key="d2">Droit L is another co-author with Tahan S and Parikh BA focusing on SARS-CoV-2 viral detection methods.&lt;SEP&gt;Droit L is a co-author analyzing the impact of SARS-CoV-2 variants on diagnostic assays.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Mautner L">
      <data key="d0">Mautner L</data>
      <data key="d1">person</data>
      <data key="d2">Mautner L is an author who worked on rapid detection methods for SARS-CoV-2 using RT-LAMP.&lt;SEP&gt;Mautner L is an author researching rapid detection methods for SARS-CoV-2 using RT-LAMP.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Baillie CK">
      <data key="d0">Baillie CK</data>
      <data key="d1">person</data>
      <data key="d2">Baillie CK is a co-author with Mautner L on the research regarding rapid detection of SARS-CoV-2.&lt;SEP&gt;Baillie CK is a co-author of a study focusing on rapid point-of-care detection of SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Herold HM">
      <data key="d0">Herold HM</data>
      <data key="d1">person</data>
      <data key="d2">Herold HM is another co-author with Mautner L and Baillie CK on SARS-CoV-2 detection methods.&lt;SEP&gt;Herold HM is involved in the research of rapid SARS-CoV-2 detection methods.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Broughton JP">
      <data key="d0">Broughton JP</data>
      <data key="d1">person</data>
      <data key="d2">Broughton JP is an author of a study on CRISPR-Cas12-based detection methods for SARS-CoV-2.&lt;SEP&gt;Broughton JP is an author studying CRISPR-Cas12-based detection of SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Deng X">
      <data key="d0">Deng X</data>
      <data key="d1">person</data>
      <data key="d2">Deng X is a co-author with Broughton JP in the research on CRISPR-Cas12 detection of SARS-CoV-2.&lt;SEP&gt;Deng X is a co-author examining the CRISPR-Cas12 detection method for SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Yu G">
      <data key="d0">Yu G</data>
      <data key="d1">person</data>
      <data key="d2">Yu G is another co-author with Broughton JP and Deng X focusing on SARS-CoV-2 detection methods.&lt;SEP&gt;Yu G is involved in research on the use of CRISPR technology for SARS-CoV-2 detection.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Puvar AP">
      <data key="d0">Puvar AP</data>
      <data key="d1">person</data>
      <data key="d2">Puvar AP is an author discussing a PCR-based method for detecting the Omicron variant of SARS-CoV-2.&lt;SEP&gt;Puvar AP is an author developing a simple PCR-based method for detecting the Omicron variant.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Chaudhari AM">
      <data key="d0">Chaudhari AM</data>
      <data key="d1">person</data>
      <data key="d2">Chaudhari AM is a co-author with Puvar AP on a PCR-based detection method for SARS-CoV-2 variants.&lt;SEP&gt;Chaudhari AM is a co-author on a study focusing on PCR methods for variant detection.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Travadi T">
      <data key="d0">Travadi T</data>
      <data key="d1">person</data>
      <data key="d2">Travadi T is another co-author alongside Puvar AP and Chaudhari AM on the Omicron detection method study.&lt;SEP&gt;Travadi T is a co-author involved in developing quick PCR detection methods for SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Zelyas N">
      <data key="d0">Zelyas N</data>
      <data key="d1">person</data>
      <data key="d2">Zelyas N is the author of a study discussing rapid detection and surveillance strategies for the SARS-CoV-2 B.1.1.7 variant.&lt;SEP&gt;Zelyas N is an author analyzing the precision response to the SARS-CoV-2 B.1.1.7 variant.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Pabbaraju K">
      <data key="d0">Pabbaraju K</data>
      <data key="d1">person</data>
      <data key="d2">Pabbaraju K is a co-author with Zelyas N on the study regarding the B.1.1.7 variant of concern.&lt;SEP&gt;Pabbaraju K focuses on combining novel PCR assays and genome sequencing for variant detection.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Croxen MA">
      <data key="d0">Croxen MA</data>
      <data key="d1">person</data>
      <data key="d2">Croxen MA is another co-author with Zelyas N and Pabbaraju K on rapid detection methods for SARS-CoV-2 variants.&lt;SEP&gt;Croxen MA is a co-author on a study emphasizing rapid variant detection in surveillance.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791257</data>
      <data key="d6" />
    </node>
    <node id="Giovacchini N">
      <data key="d0">Giovacchini N</data>
      <data key="d1">person</data>
      <data key="d2">Giovacchini N is an author working on rapid screening methods for SARS-CoV-2 variants.&lt;SEP&gt;Giovacchini N is an author performing rapid screening for the SARS-CoV-2 variant VOC-alpha.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Coppi M">
      <data key="d0">Coppi M</data>
      <data key="d1">person</data>
      <data key="d2">Coppi M is a co-author with Giovacchini N on rapid screening for SARS-CoV-2 variants.&lt;SEP&gt;Coppi M co-authored a study on rapid screening methods for SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="WHO">
      <data key="d0">WHO</data>
      <data key="d1">organization</data>
      <data key="d2">The World Health Organization (WHO) is a specialized agency of the United Nations that plays a pivotal role in international public health. It is responsible for providing guidance on a range of health issues, notably the classification and tracking of SARS-CoV-2 variants, the virus responsible for COVID-19. The WHO not only oversees global health responses to the pandemic but also sets public health guidelines aimed at mitigating its impact.

In addition to monitoring the variants of SARS-CoV-2, the WHO is involved in collecting and disseminating information about potential vaccines. This includes providing a draft landscape of candidate vaccines, like the AZD1222 vaccine, which the WHO has approved for use in multiple countries. The organizations efforts assure that health policies are informed by the best available science and evidence related to vaccination and disease management. 

Overall, the World Health Organization is crucial in coordinating global efforts to improve public health and manage health crises, exemplified by its leadership during the ongoing COVID-19 pandemic.</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Aiezza N">
      <data key="d0">Aiezza N</data>
      <data key="d1">person</data>
      <data key="d2">Aiezza N is another co-author with Giovacchini N and Coppi M focusing on screening methods for SARS-CoV-2 variants.&lt;SEP&gt;Aiezza N is involved in research on screening SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="La Rosa G">
      <data key="d0">La Rosa G</data>
      <data key="d1">person</data>
      <data key="d2">La Rosa G is an author involved in research related to SARS-CoV-2 variants and rapid screening methods.&lt;SEP&gt;La Rosa G is an author researching rapid screening techniques for SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Mancini P">
      <data key="d0">Mancini P</data>
      <data key="d1">person</data>
      <data key="d2">Mancini P is an author contributing to the research on diagnostic methods for SARS-CoV-2 variants of concern.&lt;SEP&gt;Mancini P co-authored a study focusing on nested RT-PCR assays for SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Bonanno Ferraro G">
      <data key="d0">Bonanno Ferraro G</data>
      <data key="d1">person</data>
      <data key="d2">Bonanno Ferraro G is an author who co-authored a study on rapid screening for SARS-CoV-2 variants.&lt;SEP&gt;Bonanno Ferraro G is a co-author investigating nested RT-PCR assays for SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Kashir J">
      <data key="d0">Kashir J</data>
      <data key="d1">person</data>
      <data key="d2">Kashir J is an author who researched loop-mediated isothermal amplification assays for COVID-19 diagnostics.&lt;SEP&gt;Kashir J is an author focusing on loop-mediated isothermal amplification (LAMP) assays for COVID-19 diagnostics.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Yaqinuddin A">
      <data key="d0">Yaqinuddin A</data>
      <data key="d1">person</data>
      <data key="d2">Yaqinuddin A is a co-author involved in the development of diagnostic methods for COVID-19.&lt;SEP&gt;Yaqinuddin A is a co-author exploring LAMP assays as a rapid diagnostic for COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Int J Mol Med">
      <data key="d0">Int J Mol Med</data>
      <data key="d1">journal</data>
      <data key="d2">The International Journal of Molecular Medicine is a journal where the review on COVID-19 diagnostic methods was published in 2021.&lt;SEP&gt;The International Journal of Molecular Medicine publishes research studies, including those on innovative COVID-19 diagnostic methods.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="APL Bioeng">
      <data key="d0">APL Bioeng</data>
      <data key="d1">journal</data>
      <data key="d2">APL Bioengineering is a journal where the evaluation of current diagnostic methods for COVID-19 was published.&lt;SEP&gt;APL Bioengineering is a journal that features research on current diagnostic methods for COVID-19.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Lancet Infect Dis">
      <data key="d0">Lancet Infect Dis</data>
      <data key="d1">journal</data>
      <data key="d2">The Lancet Infectious Diseases is the journal that published the systematic review on SARS-CoV-2 testing methods in 2021.&lt;SEP&gt;Lancet Infect Dis is a medical journal that published various studies on vaccine safety and immunogenicity.&lt;SEP&gt;The Lancet Infectious Diseases is a journal that published a systematic review on SARS-CoV-2 RT-PCR testing approaches.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="J Clin Microbiol">
      <data key="d0">J Clin Microbiol</data>
      <data key="d1">journal</data>
      <data key="d2">J Clin Microbiol is a journal that published a study on a fast PCR melting-temperature assay for SARS-CoV-2 variants.&lt;SEP&gt;The Journal of Clinical Microbiology is where the study on the SARS-CoV-2 E gene variant was published in 2021.&lt;SEP&gt;The Journal of Clinical Microbiology published findings on the SARS-CoV-2 E gene variant and viral detection methods.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Virol J">
      <data key="d0">Virol J</data>
      <data key="d1">journal</data>
      <data key="d2">Virology Journal published the research on rapid point-of-care detection of SARS-CoV-2 using RT-LAMP in 2020.&lt;SEP&gt;Virology Journal includes studies on rapid point-of-care detection methods for SARS-CoV-2 using RT-LAMP.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Nat Biotechnol">
      <data key="d0">Nat Biotechnol</data>
      <data key="d1">journal</data>
      <data key="d2">Nature Biotechnology is where the research on CRISPR-Cas12-based detection of SARS-CoV-2 was published in 2020.&lt;SEP&gt;Nature Biotechnology published research about CRISPR-Cas12-based detection methods for SARS-CoV-2.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Microbiol Spectr">
      <data key="d0">Microbiol Spectr</data>
      <data key="d1">journal</data>
      <data key="d2">Microbiology Spectrum is the journal that published the research on the response to the B.1.1.7 variant in 2021.&lt;SEP&gt;Microbiology Spectrum published studies addressing responses to SARS-CoV-2 variants using novel PCR assays.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Int J Infect Dis">
      <data key="d0">Int J Infect Dis</data>
      <data key="d1">journal</data>
      <data key="d2">Int J Infect Dis is a journal that published an article on rapid screening methods for SARS-CoV-2 variants.&lt;SEP&gt;The International Journal of Infectious Diseases published the rapid screening study for SARS-CoV-2 variants in 2021.&lt;SEP&gt;The International Journal of Infectious Diseases published rapid screening methods for SARS-CoV-2 variants.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Water Res">
      <data key="d0">Water Res</data>
      <data key="d1">journal</data>
      <data key="d2">Water Research published results on rapid screening for SARS-CoV-2 variants in clinical and environmental samples.</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Acute Respiratory Distress Syndromes">
      <data key="d0">Acute Respiratory Distress Syndromes</data>
      <data key="d1">medicalcondition</data>
      <data key="d2">Acute Respiratory Distress Syndromes (ARDS) are severe lung conditions that SARS-CoV-2 may lead to during infection.&lt;SEP&gt;Acute Respiratory Distress Syndromes (ARDS) can occur as a severe complication from infections caused by the SARS-CoV-2 virus.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Variants of Interest">
      <data key="d0">Variants of Interest</data>
      <data key="d1">concept</data>
      <data key="d2">Variants of Interest (VOIs) are classified by the WHO based on specific mutations that may affect transmissibility and disease severity.&lt;SEP&gt;Variants of Interest (VOIs) are SARS-CoV-2 variants that have mutations leading to receptor binding changes and other concerning epidemiological traits.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Variants of Concern">
      <data key="d0">Variants of Concern</data>
      <data key="d1">concept</data>
      <data key="d2">Variants of Concern (VOCs) are classified variants that show evidence of increased transmissibility and reduced efficacy of neutralization by antibodies.&lt;SEP&gt;Variants of Concern (VOCs) are more serious SARS-CoV-2 variants with significant evidence of increased transmissibility and severity.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Virulence">
      <data key="d0">Virulence</data>
      <data key="d1">concept</data>
      <data key="d2">Virulence refers to the degree of pathogenicity and the ability of a virus to cause disease.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Greek Alphabet">
      <data key="d0">Greek Alphabet</data>
      <data key="d1">concept</data>
      <data key="d2">The Greek Alphabet is proposed by the WHO for the standardized naming of new SARS-CoV-2 variants to facilitate tracking.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791258</data>
      <data key="d6" />
    </node>
    <node id="Diagnostic Methods">
      <data key="d0">Diagnostic Methods</data>
      <data key="d1">method</data>
      <data key="d2">Diagnostic methods for SARS-CoV-2 infections include molecular testing, antigen testing, and serological testing.&lt;SEP&gt;Diagnostic methods for SARS-CoV-2 refer to the techniques used to detect the virus, including molecular testing, antigen testing, and serological testing.</data>
      <data key="d3">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="BBIBP-CorV Vaccine">
      <data key="d0">BBIBP-CorV Vaccine</data>
      <data key="d1">product</data>
      <data key="d2">BBIBP-CorV Vaccine refers specifically to the Sinopharm BIBP COVID-19 vaccine developed for immunization against COVID-19, emphasizing its role as a vaccine.&lt;SEP&gt;BBIBP-CorV is an inactivated SARS-CoV-2 vaccine evaluated for safety and immunogenicity in clinical trials.</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="UAE Ministry of Health">
      <data key="d0">UAE Ministry of Health</data>
      <data key="d1">organization</data>
      <data key="d2">The UAE Ministry of Health announced the 86 percent efficacy of a COVID-19 vaccine on December 9, 2020.&lt;SEP&gt;The UAE Ministry of Health announced vaccine efficacy and is involved in the health response to COVID-19.</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Algeria">
      <data key="d0">Algeria</data>
      <data key="d1">location</data>
      <data key="d2">Algeria is a country that received a donation of 200,000 doses of the anti-COVID-19 vaccine from China.&lt;SEP&gt;Algeria is a country that received a donation of COVID-19 vaccines from China.&lt;SEP&gt;Algeria received a donation of 200,000 doses of the anti-COVID-19 vaccine from China.</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Morocco">
      <data key="d0">Morocco</data>
      <data key="d1">location</data>
      <data key="d2">Morocco is a country that received half a million doses of the Sinopharm COVID-19 vaccine.&lt;SEP&gt;Morocco received doses of the Sinopharm COVID-19 vaccine as part of its vaccination efforts.&lt;SEP&gt;Morocco received half a million doses of the Sinopharm COVID-19 vaccine.</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Global COVID-19 Vaccine Summary">
      <data key="d0">Global COVID-19 Vaccine Summary</data>
      <data key="d1">content</data>
      <data key="d2">The Global COVID-19 Vaccine Summary is a report detailing side effects and other related information about COVID-19 vaccines.</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="ChAdOx1 nCoV-19 Vaccine">
      <data key="d0">ChAdOx1 nCoV-19 Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">ChAdOx1 nCoV-19 vaccine is a vaccine developed to combat SARS-CoV-2, with research on its safety and immunogenicity documented in various studies.&lt;SEP&gt;The ChAdOx1 nCoV-19 vaccine is designed to counter SARS-CoV-2 and has undergone preliminary phase 1/2 trial evaluations regarding safety and immunogenicity.&lt;SEP&gt;The ChAdOx1 nCoV-19 vaccine is designed to provide protection against SARS-CoV-2 and has been studied for its safety and immunogenicity.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Oxford/AstraZeneca Vaccine">
      <data key="d0">Oxford/AstraZeneca Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">Oxford/AstraZeneca vaccine (AZD1222) is a specific COVID-19 vaccine developed by AstraZeneca, with various studies published on its safety and efficacy.&lt;SEP&gt;The Oxford/AstraZeneca vaccine, referred to as AZD1222, was developed for COVID-19 and has been analyzed for safety and efficacy in various trials.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccine Tracker">
      <data key="d0">COVID-19 Vaccine Tracker</data>
      <data key="d1">data</data>
      <data key="d2">COVID-19 vaccine tracker provides up-to-date information on COVID-19 vaccinations, including details on the Oxford/AstraZeneca vaccine.&lt;SEP&gt;The COVID-19 Vaccine Tracker is a resource that tracks the progress and information regarding COVID-19 vaccines, including Oxford/AstraZeneca.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Phase 1/2 Trial">
      <data key="d0">Phase 1/2 Trial</data>
      <data key="d1">method</data>
      <data key="d2">The Phase 1/2 trial refers to the early stages of clinical trials assessing the ChAdOx1 nCoV-19 vaccine for safety and immunogenicity.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Blood Clots">
      <data key="d0">Blood Clots</data>
      <data key="d1">concept</data>
      <data key="d2">Blood clots are a health concern highlighted in discussions regarding the safety of the Oxford/AstraZeneca vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Thromboembolism">
      <data key="d0">Thromboembolism</data>
      <data key="d1">concept</data>
      <data key="d2">Thromboembolism is a possible side effect associated with the use of the Oxford/AstraZeneca COVID-19 vaccine.&lt;SEP&gt;Thromboembolism refers to the formation of a blood clot in a blood vessel, which can lead to serious health issues and is discussed in the context of vaccine side effects.&lt;SEP&gt;Thromboembolism refers to the formation of a thrombus (clot) within a blood vessel, which has raised concerns regarding the Oxford-AstraZeneca vaccine amidst reports of side effects.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="BMJ">
      <data key="d0">BMJ</data>
      <data key="d1">organization</data>
      <data key="d2">BMJ is a journal that published articles regarding the side effects and data surrounding the Oxford/AstraZeneca vaccine.&lt;SEP&gt;BMJ (British Medical Journal) is a medical journal publishing studies and research in the medical field.&lt;SEP&gt;The BMJ (British Medical Journal) is a medical journal that reports on research and news in the field of health and medicine.&lt;SEP&gt;BMJ is a peer-reviewed medical journal that published findings from a study on arterial events related to the Oxford-AstraZeneca vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Folegatti PM">
      <data key="d0">Folegatti PM</data>
      <data key="d1">person</data>
      <data key="d2">Folegatti PM is an author involved in several studies regarding the safety and immunogenicity of COVID-19 vaccines.&lt;SEP&gt;Folegatti PM is a researcher involved in multiple studies evaluating the safety and immunogenicity of vaccines, including ChAdOx1 nCoV-19.&lt;SEP&gt;Folegatti PM is a researcher who conducted a study on the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Ewer KJ">
      <data key="d0">Ewer KJ</data>
      <data key="d1">person</data>
      <data key="d2">Ewer KJ is a researcher who co-authored studies on the ChAdOx1 nCoV-19 vaccine and its efficacy.&lt;SEP&gt;Ewer KJ is a researcher involved in studies evaluating viral vectors as vaccine platforms, examining their immunogenicity and overall impact.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Aley PK">
      <data key="d0">Aley PK</data>
      <data key="d1">person</data>
      <data key="d2">Aley PK is a contributor to the research on the ChAdOx1 nCoV-19 vaccine, focusing on its safety and immunogenicity.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Bellamy D">
      <data key="d0">Bellamy D</data>
      <data key="d1">person</data>
      <data key="d2">Bellamy D is a researcher who participated in studies regarding the recombinant simian adenovirus vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Roberts R">
      <data key="d0">Roberts R</data>
      <data key="d1">person</data>
      <data key="d2">Roberts R is involved in research on the safety and effectiveness of the ChAdOx2 vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Guo J">
      <data key="d0">Guo J</data>
      <data key="d1">person</data>
      <data key="d2">Guo J is a researcher focused on the development of novel vaccine vectors, including chimpanzee adenoviral vectors.&lt;SEP&gt;Guo J is a researcher involved in the development of novel vaccine vectors, specifically chimpanzee adenoviral vectors as discussed in the literature.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Mondal M">
      <data key="d0">Mondal M</data>
      <data key="d1">person</data>
      <data key="d2">Mondal M is a researcher who collaborated on the development of chimpanzee adenoviral vaccine vectors.&lt;SEP&gt;Mondal M is a researcher collaborating on the development of novel vaccine vectors and has contributed to studies regarding vaccine technologies.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Zhou D">
      <data key="d0">Zhou D</data>
      <data key="d1">person</data>
      <data key="d2">Zhou D is a scientist who has worked on novel vaccine vectors research.&lt;SEP&gt;Zhou D is a researcher who has worked on the development of novel vaccine vectors, particularly focusing on chimpanzee adenoviral vectors.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Lambe T">
      <data key="d0">Lambe T</data>
      <data key="d1">person</data>
      <data key="d2">Lambe T is involved in research on viral vectors as vaccine platforms and their immunogenicity.&lt;SEP&gt;Lambe T is a member of the research team studying viral vectors, contributing to the evaluation of their safety and efficacy for vaccines.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Rollier CS">
      <data key="d0">Rollier CS</data>
      <data key="d1">person</data>
      <data key="d2">Rollier CS is a researcher focusing on viral vectors used in vaccine development.&lt;SEP&gt;Rollier CS is a researcher focused on the impact of viral vectors as vaccine platforms, known for their immunogenic response.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Pottegrd A">
      <data key="d0">Pottegrd A</data>
      <data key="d1">person</data>
      <data key="d2">Pottegrd A is a researcher involved in studying the effects of vaccination using the Oxford-AstraZeneca vaccine.&lt;SEP&gt;Pottegrd A is a researcher studying the effects of vaccination with the Oxford-AstraZeneca vaccine.&lt;SEP&gt;Pottegrd A is a researcher who conducted a population-based cohort study on arterial events linked to vaccination with the Oxford-AstraZeneca vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Lund LC">
      <data key="d0">Lund LC</data>
      <data key="d1">person</data>
      <data key="d2">Lund LC is a researcher who has analyzed arterial events and thromboembolic phenomena after vaccination.&lt;SEP&gt;Lund LC is a researcher collaborating on studies investigating the effects of the Oxford-AstraZeneca vaccine, including complications such as venous thromboembolism.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="Karlstad ">
      <data key="d0">Karlstad </data>
      <data key="d1">person</data>
      <data key="d2">Karlstad  is a researcher involved in evaluating the safety of the Oxford-AstraZeneca vaccine.&lt;SEP&gt;Karlstad  is a researcher who participated in examining arterial events and their connection to vaccines, including the Oxford-AstraZeneca vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="stergaard SD">
      <data key="d0">stergaard SD</data>
      <data key="d1">person</data>
      <data key="d2">stergaard SD is a researcher who studied the relationship between thromboembolism and the Oxford-AstraZeneca vaccine.</data>
      <data key="d3">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791259</data>
      <data key="d6" />
    </node>
    <node id="BBIBP-CorV">
      <data key="d0">BBIBP-CorV</data>
      <data key="d1">artifact</data>
      <data key="d2">BBIBP-CorV is a Sinopharm vaccine that is one of two inactivated virus COVID-19 vaccines developed.&lt;SEP&gt;BBIBP-CorV is a vaccine that demonstrated 78.1% effectiveness against symptomatic COVID-19 cases and 100% effectiveness against severe cases.&lt;SEP&gt;BBIBP-CorV is an inactivated virus COVID-19 vaccine developed by Sinopharm, designed to induce high levels of neutralizing antibodies in various mammalian species.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="AZD1222">
      <data key="d0">AZD1222</data>
      <data key="d1">artifact</data>
      <data key="d2">AZD1222, also known as Oxford-AstraZeneca, is a recombinant adenovirus-based vaccine for SARS-CoV-2, using a simian chimpanzee adenovirus vector.&lt;SEP&gt;The AZD1222 vaccine is mentioned as a point of comparison in efficacy against COVID-19.&lt;SEP&gt;AZD1222 is another COVID-19 vaccine linked to the presence of neutralizing antibodies among patients with immuno-compromised conditions.&lt;SEP&gt;AZD1222 is another COVID-19 vaccine used for comparison with BBIBP-CorV regarding vaccine effectiveness and protective measures.&lt;SEP&gt;AZD1222 is another vaccine administered to patients to help produce neutralizing antibodies against COVID-19 variants.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="United Arab Emirates (UAE)">
      <data key="d0">United Arab Emirates (UAE)</data>
      <data key="d1">location</data>
      <data key="d2">The United Arab Emirates is a region where peer-reviewed data on the BBIBP-CorV vaccine was obtained.&lt;SEP&gt;The United Arab Emirates is one of the countries where effectiveness data for the BBIBP-CorV vaccine was reported.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Bahrain">
      <data key="d0">Bahrain</data>
      <data key="d1">location</data>
      <data key="d2">Bahrain is also a location where data on the BBIBP-CorV vaccine was reported.&lt;SEP&gt;Bahrain reported that the BBIBP-CorV vaccine is effective against COVID-19, with varying rates of efficacy.&lt;SEP&gt;Bahrain is another location that provided initial effectiveness data for the BBIBP-CorV vaccine.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccine">
      <data key="d0">COVID-19 Vaccine</data>
      <data key="d1">artifact</data>
      <data key="d2">The COVID-19 Vaccine is a general term for vaccines developed to protect against COVID-19, including Vero Cell and BBIBP-CorV versions.&lt;SEP&gt;COVID-19 Vaccine refers to vaccines developed to prevent COVID-19, including various types like mRNA vaccines.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Phase I Trials">
      <data key="d0">Phase I Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase I trials are clinical studies that tested the BBIBP-CorV vaccine on 192 adults to assess its safety and tolerance.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Phase II Trials">
      <data key="d0">Phase II Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase II trials involved 448 adults and evaluated the efficacy of the BBIBP-CorV vaccine in generating antibodies.</data>
      <data key="d3">chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Translational Cancer Research Facility">
      <data key="d0">Translational Cancer Research Facility</data>
      <data key="d1">organization</data>
      <data key="d2">The Translational Cancer Research Facility is affiliated with the National Center for Cancer Care and Research in Doha, Qatar.&lt;SEP&gt;The Translational Cancer Research Facility is associated with the National Center for Cancer Care and Research, focusing on cancer research and treatment strategies.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83&lt;SEP&gt;chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Betacoronavirus">
      <data key="d0">Betacoronavirus</data>
      <data key="d1">concept</data>
      <data key="d2">Betacoronavirus is a genus of viruses that includes SARS-CoV-2 and has been associated with various zoonotic outbreaks.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Coronaviridae">
      <data key="d0">Coronaviridae</data>
      <data key="d1">family</data>
      <data key="d2">Coronaviridae is the virus family to which SARS-CoV-2 belongs, characterized by pathogens responsible for respiratory infections.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="National Center for Cancer Care and Research">
      <data key="d0">National Center for Cancer Care and Research</data>
      <data key="d1">organization</data>
      <data key="d2">The National Center for Cancer Care and Research works in collaboration with various contributors on COVID-19-related studies.&lt;SEP&gt;The National Center for Cancer Care and Research is an organization that encompasses the Translational Cancer Research Facility and focuses on cancer treatment and research.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Amino Acid Mutations">
      <data key="d0">Amino Acid Mutations</data>
      <data key="d1">concept</data>
      <data key="d2">Amino acid mutations refer to changes in the amino acid sequences within proteins, which may impact the function of the SARS-CoV-2 virus.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="RBD Region">
      <data key="d0">RBD Region</data>
      <data key="d1">concept</data>
      <data key="d2">The RBD (receptor-binding domain) region is a specific part of the spike protein of the SARS-CoV-2 virus crucial for its attachment to human cells.</data>
      <data key="d3">chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="UK">
      <data key="d0">UK</data>
      <data key="d1">location</data>
      <data key="d2">The UK is a country that made a decision to prioritize a 12-week interval between doses of a vaccine.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="European Medicines Agency">
      <data key="d0">European Medicines Agency</data>
      <data key="d1">organization</data>
      <data key="d2">The European Medicines Agency (EMA) oversees the evaluation and surveillance of medicines, including vaccine safety.&lt;SEP&gt;The European Medicines Agency (EMA) is responsible for assessing the safety of vaccines like AZD1222 and reported the incidence of thromboembolic events in vaccinated individuals.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Gam-COVID-Vac">
      <data key="d0">Gam-COVID-Vac</data>
      <data key="d1">artifact</data>
      <data key="d2">Gam-COVID-Vac, also known as Sputnik V, is a heterologous adenoviral vector-based vaccine against SARS-CoV-2.&lt;SEP&gt;Gam-COVID-Vac is a vaccine that was mentioned as being able to neutralize different strains of SARS-CoV-2.&lt;SEP&gt;Gam-COVID-Vac, also known as Sputnik V, is a heterologous adenoviral vector-based vaccine against SARS-CoV-2 using two vector components.&lt;SEP&gt;Gam-COVID-Vac is a vaccine that has shown efficacy in neutralizing different SARS-CoV-2 variants in trials.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f&lt;SEP&gt;chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="rAd26">
      <data key="d0">rAd26</data>
      <data key="d1">artifact</data>
      <data key="d2">rAd26 is one of the recombinant adenoviruses used in the Gam-COVID-Vac vaccine formulation.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="rAd5">
      <data key="d0">rAd5</data>
      <data key="d1">artifact</data>
      <data key="d2">rAd5 is the second recombinant adenovirus component used in the Gam-COVID-Vac vaccine.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Thrombocytopenia">
      <data key="d0">Thrombocytopenia</data>
      <data key="d1">concept</data>
      <data key="d2">Thrombocytopenia is a medical condition that has been linked to the use of the AZD1222 vaccine, associated with bleeding episodes.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Phase 1/2 Clinical Trials">
      <data key="d0">Phase 1/2 Clinical Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase 1/2 clinical trials evaluate the safety and immune response of two formulations of the SARS-CoV-2 vaccine.&lt;SEP&gt;Phase 1/2 clinical trials were conducted to assess the safety and immunogenicity of the Gam-COVID-Vac vaccine on healthy adult volunteers.</data>
      <data key="d3">chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="RT-PCR Assays">
      <data key="d0">RT-PCR Assays</data>
      <data key="d1">method</data>
      <data key="d2">RT-PCR assays are a method used for rapid screening of SARS-CoV-2 variants by targeting key mutations of the spike protein.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="Water Research">
      <data key="d0">Water Research</data>
      <data key="d1">journal</data>
      <data key="d2">Water Research is a journal that published a study on detecting SARS-CoV-2 variants in environmental samples.&lt;SEP&gt;Water Research is a scientific journal where a study on SARS-CoV-2 variants and screening methods was published.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791260</data>
      <data key="d6" />
    </node>
    <node id="LAMP Assays">
      <data key="d0">LAMP Assays</data>
      <data key="d1">method</data>
      <data key="d2">LAMP (Loop-mediated Isothermal Amplification) assays serve as a rapid diagnostic tool for COVID-19.&lt;SEP&gt;LAMP assays are a rapid diagnostic method for COVID-19 discussed in the text.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Gao D">
      <data key="d0">Gao D</data>
      <data key="d1">person</data>
      <data key="d2">Gao D is a researcher contributing to the development of rapid CRISPR-Cas13-based diagnostics.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Zhu X">
      <data key="d0">Zhu X</data>
      <data key="d1">person</data>
      <data key="d2">Zhu X is an author who worked alongside Gao D on CRISPR-Cas13 diagnostics for rapid detection.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Lu B">
      <data key="d0">Lu B</data>
      <data key="d1">person</data>
      <data key="d2">Lu B is a researcher involved in the application of sensitive diagnostics for COVID-19.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Microarray Hybridization Assay">
      <data key="d0">Microarray Hybridization Assay</data>
      <data key="d1">method</data>
      <data key="d2">Microarray hybridization assays allow for comprehensive detection and identification of animal and human coronaviruses.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Banada P">
      <data key="d0">Banada P</data>
      <data key="d1">person</data>
      <data key="d2">Banada P is an author focused on developing simple assays for SARS-CoV-2 variant screening.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Green R">
      <data key="d0">Green R</data>
      <data key="d1">person</data>
      <data key="d2">Green R is a co-author involved in research aimed at rapid screening for circulating SARS-CoV-2 variants.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Banik S">
      <data key="d0">Banik S</data>
      <data key="d1">person</data>
      <data key="d2">Banik S is a researcher contributing to assays for SARS-CoV-2 variant detection.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Diagnostics">
      <data key="d0">Diagnostics</data>
      <data key="d1">journal</data>
      <data key="d2">Diagnostics pertain to the methods developed to detect SARS-CoV-2 infections and the challenges posed by emerging variants.&lt;SEP&gt;Diagnostics is a journal that features research on SARS-CoV-2 protein detection methods.&lt;SEP&gt;Diagnostics is a medical journal where several relevant studies and discussions on COVID-19 diagnostics were published.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="ELISA Test">
      <data key="d0">ELISA Test</data>
      <data key="d1">method</data>
      <data key="d2">The ELISA (Enzyme-Linked Immunosorbent Assay) test is employed to detect SARS-CoV-2 proteins.&lt;SEP&gt;The ELISA test is used for detecting SARS-CoV-2 proteins and is mentioned as a method for diagnostics.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Automated Western Immunoblotting">
      <data key="d0">Automated Western Immunoblotting</data>
      <data key="d1">method</data>
      <data key="d2">Automated Western immunoblotting is a technique used for detecting anti-SARS-CoV-2 serum antibodies in samples.&lt;SEP&gt;Automated Western immunoblotting is a technique for detecting anti-SARS-CoV-2 serum antibodies.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Eur J Clin Microbiol Infect Dis">
      <data key="d0">Eur J Clin Microbiol Infect Dis</data>
      <data key="d1">journal</data>
      <data key="d2">Eur J Clin Microbiol Infect Dis is a journal that published a study on automated Western immunoblotting for anti-SARS-CoV-2 antibodies.&lt;SEP&gt;Eur J Clin Microbiol Infect Dis is a journal that published research on the detection of antibodies related to SARS-CoV-2.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7&lt;SEP&gt;chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Robinson J">
      <data key="d0">Robinson J</data>
      <data key="d1">person</data>
      <data key="d2">Robinson J is an author discussing COVID-19 therapy trials and relevant treatment options.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Drug Treatment Options">
      <data key="d0">Drug Treatment Options</data>
      <data key="d1">concept</data>
      <data key="d2">Drug treatment options for COVID-19 are discussed, detailing various therapies available against SARS-CoV-2.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="ACTT-2 Study Group">
      <data key="d0">ACTT-2 Study Group</data>
      <data key="d1">organization</data>
      <data key="d2">The ACTT-2 Study Group is a research team involved in the study of treatments for hospitalized adults with COVID-19, specifically focusing on baricitinib and remdesivir.</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Sinopharm COVID-19 Vaccine">
      <data key="d0">Sinopharm COVID-19 Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The Sinopharm COVID-19 vaccine is another vaccine type that is mentioned in the context of vaccine distribution in Morocco.&lt;SEP&gt;The Sinopharm COVID-19 vaccine is an anti-COVID-19 vaccine supplied to various countries.&lt;SEP&gt;Sinopharm COVID-19 Vaccine is an anti-COVID-19 vaccine provided in large quantities to various countries.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Serbia">
      <data key="d0">Serbia</data>
      <data key="d1">location</data>
      <data key="d2">Serbia is a country that received a million doses of the Sinopharm COVID-19 vaccine from China.&lt;SEP&gt;Serbia received a million doses of the Sinopharm COVID-19 vaccine from China.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccination">
      <data key="d0">COVID-19 Vaccination</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 vaccination refers to the process of administering vaccines to protect against the COVID-19 virus.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Transplant Recipients">
      <data key="d0">Transplant Recipients</data>
      <data key="d1">group</data>
      <data key="d2">Transplant recipients are patients who have received organ transplants and are subjects in studies regarding COVID-19 vaccination effectiveness.&lt;SEP&gt;Transplant recipients are individuals who have received organ transplants and are studied for vaccine efficacy.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Clinical Effectiveness Study">
      <data key="d0">Clinical Effectiveness Study</data>
      <data key="d1">concept</data>
      <data key="d2">The Clinical Effectiveness Study investigates the effectiveness of COVID-19 vaccination in solid organ transplant recipients.&lt;SEP&gt;The Clinical Effectiveness Study refers to research examining the efficacy of COVID-19 vaccinations in specific populations, such as organ transplant recipients.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791261</data>
      <data key="d6" />
    </node>
    <node id="Breakthrough Infections">
      <data key="d0">Breakthrough Infections</data>
      <data key="d1">concept</data>
      <data key="d2">Breakthrough infections are instances where vaccinated individuals contract SARS-CoV-2 after vaccination.</data>
      <data key="d3">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Lopinavir">
      <data key="d0">Lopinavir</data>
      <data key="d1">drug</data>
      <data key="d2">Lopinavir is an anti-HIV drug that targets RNA viruses, evaluated for potential therapeutic use against COVID-19.&lt;SEP&gt;Lopinavir is an anti-HIV drug that was evaluated for its effectiveness against COVID-19 symptoms.&lt;SEP&gt;Lopinavir is a protease inhibitor that has been discredited in the context of SARS-CoV-2 treatment strategies.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Ritonavir">
      <data key="d0">Ritonavir</data>
      <data key="d1">drug</data>
      <data key="d2">Ritonavir is an anti-HIV drug commonly used with Lopinavir, which also aimed to improve COVID-19 patient symptoms.&lt;SEP&gt;Ritonavir is an anti-HIV drug used in conjunction with Lopinavir to treat patients with SARS.&lt;SEP&gt;Ritonavir is a drug that is paired with Lopinavir and has shown limited effectiveness against SARS-CoV-2 infections.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Chloroquine">
      <data key="d0">Chloroquine</data>
      <data key="d1">drug</data>
      <data key="d2">Chloroquine is an anti-malarial drug that has shown some effectiveness against SARS-CoV-2 infections but has also shown mixed results in trials.&lt;SEP&gt;Chloroquine is an anti-malarial drug that has shown some effectiveness against SARS-CoV-2 infections.&lt;SEP&gt;Chloroquine is an anti-malarial drug that has been studied for its effectiveness against SARS-CoV-2 infections but is not conclusively proven for this purpose.&lt;SEP&gt;Chloroquine is an antiviral medication studied for its effect on animal viruses and its potential reuse for infections in the 21st century.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Sarilumab">
      <data key="d0">Sarilumab</data>
      <data key="d1">drug</data>
      <data key="d2">Sarilumab is a monoclonal antibody that has been repurposed for use against COVID-19 and shows potential benefits in reducing mortality in hospitalized patients.&lt;SEP&gt;Sarilumab is a drug that enhanced survival rates and reduced mortality in hospitalized Covid-19 patients as per the trial findings.&lt;SEP&gt;Sarilumab is a monoclonal antibody similar to Tocilizumab, also repurposed for the treatment of severe COVID-19 infections.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="REMAP-CAP">
      <data key="d0">REMAP-CAP</data>
      <data key="d1">study</data>
      <data key="d2">Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired pneumonia (REMAP-CAP) is a clinical trial that demonstrated improved survival rates with Tocilizumab and Sarilumab in COVID-19 patients.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Cytokine Storm">
      <data key="d0">Cytokine Storm</data>
      <data key="d1">concept</data>
      <data key="d2">Cytokine Storm is a severe inflammatory response that can occur in critical COVID-19 infections, which Tocilizumab is designed to treat.</data>
      <data key="d3">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Oxford-AstraZeneca COVID-19 Vaccine">
      <data key="d0">Oxford-AstraZeneca COVID-19 Vaccine</data>
      <data key="d1">vaccine</data>
      <data key="d2">The Oxford-AstraZeneca COVID-19 vaccine is a vaccination developed to mitigate the effects of COVID-19.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Denmark">
      <data key="d0">Denmark</data>
      <data key="d1">location</data>
      <data key="d2">Denmark is a country in Northern Europe involved in the study of adverse events linked to the Oxford-AstraZeneca vaccine.&lt;SEP&gt;Denmark is a country in Northern Europe where a study regarding the Oxford-AstraZeneca vaccine was conducted.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Norway">
      <data key="d0">Norway</data>
      <data key="d1">location</data>
      <data key="d2">Norway is a country in Northern Europe that participated in research regarding the Oxford-AstraZeneca vaccine and its effects.&lt;SEP&gt;Norway is a country in Northern Europe that participated in the study of the Oxford-AstraZeneca vaccine.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Logunov DY">
      <data key="d0">Logunov DY</data>
      <data key="d1">person</data>
      <data key="d2">Logunov DY is a researcher involved in the study of the rAd26 and rAd5 vector-based COVID-19 vaccine's safety and immunogenicity.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Russia">
      <data key="d0">Russia</data>
      <data key="d1">location</data>
      <data key="d2">Russia is a country where studies regarding the safety and efficacy of the COVID-19 vaccine were conducted.&lt;SEP&gt;Russia is a country where a study involving a heterologous prime-boost COVID-19 vaccine was conducted.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Anywaine Z">
      <data key="d0">Anywaine Z</data>
      <data key="d1">person</data>
      <data key="d2">Anywaine Z is a researcher involved in the phase 1 randomized clinical trial of the Ebola vaccines.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Uganda">
      <data key="d0">Uganda</data>
      <data key="d1">location</data>
      <data key="d2">Uganda is a country where clinical trials for Ebola vaccines were conducted.&lt;SEP&gt;Uganda is a country in East Africa where a 2-dose heterologous vaccination study was carried out.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Tanzania">
      <data key="d0">Tanzania</data>
      <data key="d1">location</data>
      <data key="d2">Tanzania is a country that participated alongside Uganda in research on Ebola vaccine safety and immunogenicity.&lt;SEP&gt;Tanzania is a country in East Africa involved in the 2-dose heterologous vaccination study.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Williams K">
      <data key="d0">Williams K</data>
      <data key="d1">person</data>
      <data key="d2">Williams K is a researcher associated with the safety and immunogenicity study of a respiratory syncytial virus vaccine.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Barouch DH">
      <data key="d0">Barouch DH</data>
      <data key="d1">person</data>
      <data key="d2">Barouch DH is a researcher involved in evaluating a mosaic HIV-1 vaccine in a clinical trial.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="HIV-1 Vaccine">
      <data key="d0">HIV-1 Vaccine</data>
      <data key="d1">vaccine</data>
      <data key="d2">The HIV-1 vaccine is being evaluated for its effectiveness in preventing HIV infection.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Adenovirus Vector">
      <data key="d0">Adenovirus Vector</data>
      <data key="d1">method</data>
      <data key="d2">Adenovirus vector technology is used for gene therapy, vaccination, and cancer therapy in various studies.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Phase 1/2 Studies">
      <data key="d0">Phase 1/2 Studies</data>
      <data key="d1">event</data>
      <data key="d2">Phase 1/2 studies are clinical trials aimed at evaluating the safety and immunogenicity of vaccines, specifically referenced for the rAd26 and rAd5 vector-based COVID-19 vaccine.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791262</data>
      <data key="d6" />
    </node>
    <node id="Heterologous Prime-Boost Vaccination">
      <data key="d0">Heterologous Prime-Boost Vaccination</data>
      <data key="d1">method</data>
      <data key="d2">Heterologous prime-boost vaccination is a vaccination approach involving different vaccines administered in a specific sequence to enhance immune response.</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="UAE">
      <data key="d0">UAE</data>
      <data key="d1">location</data>
      <data key="d2">The UAE previously announced interim results showing that a COVID-19 vaccine provided 86% efficacy.</data>
      <data key="d3">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Argentina">
      <data key="d0">Argentina</data>
      <data key="d1">location</data>
      <data key="d2">Argentina was the site of a randomized double-blind placebo-controlled phase III clinical trial for a COVID-19 vaccine.&lt;SEP&gt;Argentina conducted randomized, double-blind, placebo-controlled trials for the BBIBP-CorV vaccine and reported lower effectiveness compared to mRNA vaccines.</data>
      <data key="d3">chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Solid Organ Transplant Recipients (SOTRs)">
      <data key="d0">Solid Organ Transplant Recipients (SOTRs)</data>
      <data key="d1">group</data>
      <data key="d2">Solid organ transplant recipients are a vulnerable population related to the efficacy of COVID-19 vaccines.&lt;SEP&gt;Solid organ transplant recipients (SOTRs) are patients who may exhibit high susceptibility to breakthrough COVID-19 infections post-vaccination.</data>
      <data key="d3">chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Computational Approaches">
      <data key="d0">Computational Approaches</data>
      <data key="d1">method</data>
      <data key="d2">Computational approaches are used to predict the impact of SARS-CoV-2 variants on vaccine effectiveness.&lt;SEP&gt;Computational approaches like epitope prediction are used to model and predict the impact of SARS-CoV-2 variants on vaccine efficacy.</data>
      <data key="d3">chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Epitope Prediction">
      <data key="d0">Epitope Prediction</data>
      <data key="d1">method</data>
      <data key="d2">Epitope prediction is a computational method that identifies structural vaccine targets affected by virus mutations.</data>
      <data key="d3">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Transmissibility">
      <data key="d0">Transmissibility</data>
      <data key="d1">concept</data>
      <data key="d2">Transmissibility refers to the ability of a virus, such as SARS-CoV-2, to spread from one individual to another.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Severity">
      <data key="d0">Severity</data>
      <data key="d1">concept</data>
      <data key="d2">Severity refers to the gravity of illness caused by SARS-CoV-2 variants, impacting treatment and outcomes.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Antibody Treatments">
      <data key="d0">Antibody Treatments</data>
      <data key="d1">concept</data>
      <data key="d2">Antibody treatments are therapies used against SARS-CoV-2 that may vary in effectiveness based on the virus variant.&lt;SEP&gt;Antibody treatments involve using monoclonal antibodies to counteract COVID-19 infections, particularly effective against variants.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Molecular Testing">
      <data key="d0">Molecular Testing</data>
      <data key="d1">method</data>
      <data key="d2">Molecular testing is a diagnostic method that targets specific viral nucleic acids to detect SARS-CoV-2 infections.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Antigen Testing">
      <data key="d0">Antigen Testing</data>
      <data key="d1">method</data>
      <data key="d2">Antigen testing is a type of diagnostic method that detects proteins from the SARS-CoV-2 virus.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Serological Testing">
      <data key="d0">Serological Testing</data>
      <data key="d1">method</data>
      <data key="d2">Serological testing is a diagnostic method that identifies anti-SARS-CoV-2 antibodies in individuals, indicating past infection or immunity.</data>
      <data key="d3">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="rAd26-S">
      <data key="d0">rAd26-S</data>
      <data key="d1">vaccine</data>
      <data key="d2">rAd26-S is a vaccine administered through a single intramuscular dose in clinical trials as part of the vaccination process.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="rAd5-S">
      <data key="d0">rAd5-S</data>
      <data key="d1">vaccine</data>
      <data key="d2">rAd5-S is a vaccine given in conjunction with rAd26-S during the vaccination regimen.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Participants">
      <data key="d0">Participants</data>
      <data key="d1">person</data>
      <data key="d2">Participants in the vaccine trials are healthy adult volunteers aged between 18 and 60 years.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 1 Trials">
      <data key="d0">Phase 1 Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase 1 trials involve a single dose administration of rAd26-S or rAd5-S to gauge safety and tolerability.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 2 Trials">
      <data key="d0">Phase 2 Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase 2 trials follow Phase 1 and involve a two-dose regimen of rAd26-S and rAd5-S to further assess efficacy.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 3 Trials">
      <data key="d0">Phase 3 Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase 3 trials include a larger group of nearly 22,000 adult participants to evaluate the vaccine's efficacy.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 1">
      <data key="d0">Phase 1</data>
      <data key="d1">event</data>
      <data key="d2">Phase 1 refers to the initial stage of clinical trials where a single dose of the vaccine is administered to participants for safety evaluation.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 2">
      <data key="d0">Phase 2</data>
      <data key="d1">event</data>
      <data key="d2">Phase 2 follows Phase 1 and involves administering additional doses to assess efficacy in a larger group of participants.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Phase 3">
      <data key="d0">Phase 3</data>
      <data key="d1">event</data>
      <data key="d2">Phase 3 represents the final stage of clinical trials, aimed at providing comprehensive data on the vaccine's effectiveness and safety in a large population.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791263</data>
      <data key="d6" />
    </node>
    <node id="Higher IgG Titre">
      <data key="d0">Higher IgG Titre</data>
      <data key="d1">data</data>
      <data key="d2">The higher IgG titre indicates a stronger immune response from the frozen formulation compared to the lyophilized one.</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Patterson TF">
      <data key="d0">Patterson TF</data>
      <data key="d1">person</data>
      <data key="d2">Patterson TF is a researcher mentioned in studies related to COVID-19 treatments.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="ACTT-2 Study">
      <data key="d0">ACTT-2 Study</data>
      <data key="d1">study</data>
      <data key="d2">The ACTT-2 Study is a clinical trial that investigates the effectiveness of Baricitinib combined with remdesivir for hospitalized COVID-19 patients.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Magro G">
      <data key="d0">Magro G</data>
      <data key="d1">person</data>
      <data key="d2">Magro G is a researcher who conducted a review on available drugs and therapies against SARS-CoV-2.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Virus Research">
      <data key="d0">Virus Research</data>
      <data key="d1">journal</data>
      <data key="d2">Virus Research is a scientific journal where research regarding COVID-19 drugs and therapies is published.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Chu CM">
      <data key="d0">Chu CM</data>
      <data key="d1">person</data>
      <data key="d2">Chu CM is a researcher who studied the role of Lopinavir/Ritonavir in treating SARS.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Thorax">
      <data key="d0">Thorax</data>
      <data key="d1">journal</data>
      <data key="d2">Thorax is a medical journal that publishes research findings, including studies on treatments for respiratory diseases like SARS.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Inglot AD">
      <data key="d0">Inglot AD</data>
      <data key="d1">person</data>
      <data key="d2">Inglot AD is a researcher comparing antiviral activities of non-steroidal anti-inflammatory drugs.</data>
      <data key="d3">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="J Phys Chem Lett">
      <data key="d0">J Phys Chem Lett</data>
      <data key="d1">content</data>
      <data key="d2">J Phys Chem Lett is a scientific journal that published research on dynamics simulations for epitope prediction related to SARS-CoV-2.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Colonic Cells">
      <data key="d0">Colonic Cells</data>
      <data key="d1">cellularstructure</data>
      <data key="d2">Colonic cells are human cells that were shown to be persistently infected by SARS-CoV in research.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Pathogenesis">
      <data key="d0">Pathogenesis</data>
      <data key="d1">concept</data>
      <data key="d2">Pathogenesis refers to the process by which SARS-CoV and other coronaviruses cause disease in humans.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Angiotensin-Converting Enzyme 2 (ACE2)">
      <data key="d0">Angiotensin-Converting Enzyme 2 (ACE2)</data>
      <data key="d1">protein</data>
      <data key="d2">ACE2 is a receptor that SARS-CoV-2 uses to infect host cells, particularly noted in the context of its tissue distribution.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Neurological Manifestations">
      <data key="d0">Neurological Manifestations</data>
      <data key="d1">concept</data>
      <data key="d2">Neurological manifestations refer to the neurological symptoms observed in patients hospitalized with COVID-19.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="MIG">
      <data key="d0">MIG</data>
      <data key="d1">protein</data>
      <data key="d2">MIG is a chemokine mentioned in the context of its potential role in the pathogenesis of SARS-CoV infection.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Severe Acute Respiratory Syndrome (SARS)">
      <data key="d0">Severe Acute Respiratory Syndrome (SARS)</data>
      <data key="d1">concept</data>
      <data key="d2">Severe Acute Respiratory Syndrome (SARS) is an infectious disease caused by the SARS-CoV virus, known for significant clinical manifestations and implications.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Human Coronavirus 229E">
      <data key="d0">Human Coronavirus 229E</data>
      <data key="d1">creature</data>
      <data key="d2">Human Coronavirus 229E is a strain of coronavirus associated with respiratory infections and is mentioned in the context of neurotropism studies.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Human Coronavirus OC43">
      <data key="d0">Human Coronavirus OC43</data>
      <data key="d1">creature</data>
      <data key="d2">Human Coronavirus OC43 is a strain of coronavirus that has been studied for its axonal transport and propagation in neurons.</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Community-Acquired Pneumonia">
      <data key="d0">Community-Acquired Pneumonia</data>
      <data key="d1">concept</data>
      <data key="d2">Community-Acquired Pneumonia refers to pneumonia acquired outside a hospital setting and is the subject of the discussed trial.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Remap-Cap">
      <data key="d0">Remap-Cap</data>
      <data key="d1">event</data>
      <data key="d2">Remap-Cap is a trial that investigated the efficacy of various treatments for hospitalized Covid-19 patients.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="NHS Guidance">
      <data key="d0">NHS Guidance</data>
      <data key="d1">content</data>
      <data key="d2">NHS Guidance advocates for the use of Tocilizumab and Sarilumab in treating hospitalized Covid-19 patients in ICUs.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Casirivimab">
      <data key="d0">Casirivimab</data>
      <data key="d1">drug</data>
      <data key="d2">Casirivimab is part of a monoclonal antibody cocktail for treating Covid-19 and is noted for binding to the SARS-CoV-2 spike protein.&lt;SEP&gt;Casirivimab is a monoclonal antibody that forms part of the REGEN-COV cocktail, targeting SARS-CoV-2 to reduce hospitalization and mortality rates in COVID-19 patients.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Imdevimab">
      <data key="d0">Imdevimab</data>
      <data key="d1">drug</data>
      <data key="d2">Imdevimab is combined with Casirivimab to create a monoclonal antibody cocktail named REGEN-COV for Covid-19 treatment.&lt;SEP&gt;Imdevimab is a monoclonal antibody that, alongside Casirivimab, forms the REGEN-COV cocktail, which is beneficial for treating COVID-19.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="NSP12">
      <data key="d0">NSP12</data>
      <data key="d1">protein</data>
      <data key="d2">NSP12 is a protein in SARS-CoV-2 that possesses RdRp activity and is targeted by antiviral drugs like Remdesivir.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Spike Protein">
      <data key="d0">SARS-CoV-2 Spike Protein</data>
      <data key="d1">protein</data>
      <data key="d2">The SARS-CoV-2 spike protein is a target for monoclonal antibodies and is significant in determining the virus's ability to escape immune responses.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="Efficacy of SARS-CoV-2 Antiviral Drugs">
      <data key="d0">Efficacy of SARS-CoV-2 Antiviral Drugs</data>
      <data key="d1">concept</data>
      <data key="d2">The efficacy of SARS-CoV-2 antiviral drugs refers to their effectiveness against different variants of the virus.</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791264</data>
      <data key="d6" />
    </node>
    <node id="rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine">
      <data key="d0">rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine</data>
      <data key="d1">method</data>
      <data key="d2">The rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine is designed for use in a randomized controlled phase-3 trial in Russia, focusing on safety and efficacy.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Sputnik V Vaccine">
      <data key="d0">Sputnik V Vaccine</data>
      <data key="d1">method</data>
      <data key="d2">The Sputnik V vaccine is a COVID-19 vaccine that has shown neutralizing activity against variants of SARS-CoV-2.&lt;SEP&gt;Sputnik V Vaccine is a COVID-19 vaccine developed in Russia, mentioned in studies assessing its neutralizing activity against SARS-CoV-2.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="mRNA-Based Therapeutics">
      <data key="d0">mRNA-Based Therapeutics</data>
      <data key="d1">concept</data>
      <data key="d2">mRNA-based therapeutics represent a new class of drugs that utilize mRNA technology for treatment and vaccination purposes.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Zika Virus">
      <data key="d0">Zika Virus</data>
      <data key="d1">virus</data>
      <data key="d2">The Zika virus is a mosquito-borne virus for which protection has been demonstrated through mRNA vaccination.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="mRNA Rabies Vaccine">
      <data key="d0">mRNA Rabies Vaccine</data>
      <data key="d1">method</data>
      <data key="d2">The mRNA rabies vaccine is an innovative vaccine that demonstrated safety and immunogenicity in healthy adults during phase-1 clinical trials.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Influenza A Virus">
      <data key="d0">Influenza A Virus</data>
      <data key="d1">virus</data>
      <data key="d2">Influenza A virus is a common virus that causes influenza, against which specific mRNA vaccines have protective efficacy.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="mRNA-1273 SARS-CoV-2 Vaccine">
      <data key="d0">mRNA-1273 SARS-CoV-2 Vaccine</data>
      <data key="d1">method</data>
      <data key="d2">The mRNA-1273 vaccine is specifically designed against SARS-CoV-2 and studied for its efficacy and safety.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="BNT162b2 mRNA COVID-19 Vaccine">
      <data key="d0">BNT162b2 mRNA COVID-19 Vaccine</data>
      <data key="d1">method</data>
      <data key="d2">The BNT162b2 mRNA vaccine has been studied for safety and efficacy in preventing COVID-19.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="BioNTech">
      <data key="d0">BioNTech</data>
      <data key="d1">organization</data>
      <data key="d2">BioNTech is a biotechnology company that developed the BNT162b2 mRNA COVID-19 vaccine in collaboration with Pfizer.&lt;SEP&gt;BioNTech is a biotechnology company that has developed the BNT162b2 mRNA COVID-19 vaccine in collaboration with Pfizer.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Pfizer">
      <data key="d0">Pfizer</data>
      <data key="d1">organization</data>
      <data key="d2">Pfizer is a pharmaceutical company that collaborated with BioNTech to develop and analyze the BNT162b2 vaccine.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Moderna">
      <data key="d0">Moderna</data>
      <data key="d1">organization</data>
      <data key="d2">Moderna is a biotechnology firm that developed the mRNA-1273 vaccine against COVID-19.&lt;SEP&gt;Moderna is a biotechnology company known for its development of mRNA-based COVID-19 vaccines.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963&lt;SEP&gt;chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Clinical Trial">
      <data key="d0">Clinical Trial</data>
      <data key="d1">event</data>
      <data key="d2">The Clinical Trial is a phase-3 trial conducted in Russia to analyze the safety and efficacy of the rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine.</data>
      <data key="d3">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Central Nervous System (CNS)">
      <data key="d0">Central Nervous System (CNS)</data>
      <data key="d1">anatomicalstructure</data>
      <data key="d2">The CNS is part of the body that may be invaded by SARS-CoV-2, showing potential neuro-invasive properties.</data>
      <data key="d3">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="CNS Infection">
      <data key="d0">CNS Infection</data>
      <data key="d1">concept</data>
      <data key="d2">CNS Infection refers to the possibility of SARS-CoV-2 invading the central nervous system, leading to neurological symptoms.</data>
      <data key="d3">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Public Health Emergency">
      <data key="d0">Public Health Emergency</data>
      <data key="d1">concept</data>
      <data key="d2">Public Health Emergency related to COVID-19 underscores the urgency and seriousness of the pandemic's impact worldwide.</data>
      <data key="d3">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Human Endothelial Cells">
      <data key="d0">Human Endothelial Cells</data>
      <data key="d1">celltype</data>
      <data key="d2">Human Endothelial Cells express ACE2 in vivo but failed to be infected by SARS-CoV, highlighting the complexity of viral infection dynamics.</data>
      <data key="d3">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Hepatocytes">
      <data key="d0">Hepatocytes</data>
      <data key="d1">celltype</data>
      <data key="d2">Hepatocytes are liver cells found to be infected by SARS-CoV despite having comparatively undetectable levels of ACE2.</data>
      <data key="d3">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Neutralisation">
      <data key="d0">Neutralisation</data>
      <data key="d1">concept</data>
      <data key="d2">Neutralisation refers to the process by which antibodies render a virus harmless, a crucial aspect in the context of COVID-19 vaccination.</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="L452R">
      <data key="d0">L452R</data>
      <data key="d1">mutation</data>
      <data key="d2">L452R is a mutation of the spike protein of SARS-CoV-2 that is noted for its impact on treatment resistance.</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Neutralization">
      <data key="d0">Neutralization</data>
      <data key="d1">concept</data>
      <data key="d2">Neutralization is defined as the process by which antibodies inhibit the infectious capacity of a virus.</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Lipid Nanoparticles">
      <data key="d0">Lipid Nanoparticles</data>
      <data key="d1">naturalobject</data>
      <data key="d2">Lipid nanoparticles are utilized in the delivery of mRNA vaccines, providing a protective carrier for the mRNA.&lt;SEP&gt;Lipid nanoparticles (LNPs) are biocompatible carriers used to encapsulate and stabilize mRNA for vaccines.</data>
      <data key="d3">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Phase III Clinical Trials">
      <data key="d0">Phase III Clinical Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase III clinical trials are research studies to test the effectiveness and safety of vaccines in large populations.</data>
      <data key="d3">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Moderna Biotechnologies Inc.">
      <data key="d0">Moderna Biotechnologies Inc.</data>
      <data key="d1">organization</data>
      <data key="d2">Moderna Biotechnologies Inc. is a biotechnology company that developed the mRNA-1273 vaccine for COVID-19.</data>
      <data key="d3">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Polack et al.">
      <data key="d0">Polack et al.</data>
      <data key="d1">person</data>
      <data key="d2">Polack et al. refers to a group of researchers who demonstrated the efficacy of the BNT162b2 vaccine in individuals aged 16 and older.</data>
      <data key="d3">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791265</data>
      <data key="d6" />
    </node>
    <node id="Thompson et al.">
      <data key="d0">Thompson et al.</data>
      <data key="d1">person</data>
      <data key="d2">Thompson et al. refers to researchers who showed that full immunization with mRNA vaccines provides significant efficacy against COVID-19.</data>
      <data key="d3">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Interleukin-6">
      <data key="d0">Interleukin-6</data>
      <data key="d1">concept</data>
      <data key="d2">Interleukin-6 is a cytokine involved in inflammation and immune responses, relevant in critically ill patients with COVID-19.</data>
      <data key="d3">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="India">
      <data key="d0">India</data>
      <data key="d1">location</data>
      <data key="d2">India is the country where the COVINTOC trial took place, focusing on COVID-19-associated cytokine release syndrome.</data>
      <data key="d3">chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Clin Drug Investig">
      <data key="d0">Clin Drug Investig</data>
      <data key="d1">organization</data>
      <data key="d2">Clin Drug Investig is a publication that discusses the rational use of tocilizumab in the treatment of COVID-19 pneumonia.</data>
      <data key="d3">chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Antiviral Res">
      <data key="d0">Antiviral Res</data>
      <data key="d1">organization</data>
      <data key="d2">Antiviral Res is a journal that published findings on the genetic conservation of SARS-CoV-2 RNA replication complex.</data>
      <data key="d3">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="138 Hospitalized Patients">
      <data key="d0">138 Hospitalized Patients</data>
      <data key="d1">data</data>
      <data key="d2">The 138 hospitalized patients refer to individuals studied in Wuhan for clinical characteristics related to COVID-19.</data>
      <data key="d3">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Covid-19 Vaccines">
      <data key="d0">Covid-19 Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Covid-19 vaccines are essential for prevention and protection against coronavirus infection and are discussed for their development and efficacy.</data>
      <data key="d3">chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Moderna COVID-19 Vaccine">
      <data key="d0">Moderna COVID-19 Vaccine</data>
      <data key="d1">content</data>
      <data key="d2">The Moderna COVID-19 Vaccine is a vaccine candidate that met its primary efficacy endpoint in the COVE study.</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Health Care Personnel">
      <data key="d0">Health Care Personnel</data>
      <data key="d1">group</data>
      <data key="d2">Health care personnel are individuals involved in the medical field who have been studied for vaccine effectiveness.</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="B.1.617.2 (Delta) Variant">
      <data key="d0">B.1.617.2 (Delta) Variant</data>
      <data key="d1">variant</data>
      <data key="d2">The B.1.617.2 (Delta) variant is a strain of SARS-CoV-2 that was studied for the effectiveness of COVID-19 vaccines.</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="MMWR Morb Mortal Wkly Rep">
      <data key="d0">MMWR Morb Mortal Wkly Rep</data>
      <data key="d1">publication</data>
      <data key="d2">MMWR Morb Mortal Wkly Rep is a publication featuring studies on vaccine effectiveness for COVID-19 among frontline workers.</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Nature">
      <data key="d0">Nature</data>
      <data key="d1">publication</data>
      <data key="d2">Nature is a scientific journal that published findings regarding the BNT162b2 vaccine's ability to induce antibodies and T cells.</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Q. Fernandes">
      <data key="d0">Q. Fernandes</data>
      <data key="d1">person</data>
      <data key="d2">Q. Fernandes is one of the authors who wrote the initial draft of the manuscript.</data>
      <data key="d3">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Open Access Funding">
      <data key="d0">Open Access Funding</data>
      <data key="d1">concept</data>
      <data key="d2">Open Access funding is provided by the Qatar National Library to support publication efforts.</data>
      <data key="d3">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Manuscript">
      <data key="d0">Manuscript</data>
      <data key="d1">content</data>
      <data key="d2">The manuscript discusses the transmissibility of a virus, advancements in treatment, and collaboration among authors for its preparation.</data>
      <data key="d3">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791266</data>
      <data key="d6" />
    </node>
    <node id="Virus">
      <data key="d0">Virus</data>
      <data key="d1">concept</data>
      <data key="d2">The virus in question is rapidly evolving, posing a threat to global health with emerging strains.</data>
      <data key="d3">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Therapeutic Strategies">
      <data key="d0">Therapeutic Strategies</data>
      <data key="d1">method</data>
      <data key="d2">Therapeutic strategies are approaches aimed at improving treatment outcomes based on ongoing research regarding the virus.</data>
      <data key="d3">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Viral Envelope">
      <data key="d0">Viral Envelope</data>
      <data key="d1">naturalobject</data>
      <data key="d2">The viral Envelope is a structure of the SARS-CoV-2 virus that is part of the detection targets in PCR technology.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Nucleocapsid">
      <data key="d0">Nucleocapsid</data>
      <data key="d1">naturalobject</data>
      <data key="d2">The Nucleocapsid is another component of the SARS-CoV-2 virus used for detecting specific viral RNA.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="ORF1ab Regions">
      <data key="d0">ORF1ab Regions</data>
      <data key="d1">naturalobject</data>
      <data key="d2">The ORF1ab regions are segments of the viral genome involved in replication and are detected through specific assays.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="E154K">
      <data key="d0">E154K</data>
      <data key="d1">mutation</data>
      <data key="d2">E154K is a specific mutation of the SARS-CoV-2 virus referenced in post-vaccination sera studies.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="G142D">
      <data key="d0">G142D</data>
      <data key="d1">mutation</data>
      <data key="d2">G142D is a mutation of SARS-CoV-2 that has been studied in relation to antibody treatments.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="P681R">
      <data key="d0">P681R</data>
      <data key="d1">mutation</data>
      <data key="d2">P681R is a mutation of the SARS-CoV-2 virus discussed in the context of neutralization studies.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="T76I">
      <data key="d0">T76I</data>
      <data key="d1">mutation</data>
      <data key="d2">T76I is a mutation of SARS-CoV-2 mentioned in the context of transmissibility.</data>
      <data key="d3">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Spike">
      <data key="d0">SARS-CoV-2 Spike</data>
      <data key="d1">protein</data>
      <data key="d2">SARS-CoV-2 spike is a viral protein targeted by neutralizing antibodies generated in response to vaccination.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Sinovac Biotech Ltd">
      <data key="d0">Sinovac Biotech Ltd</data>
      <data key="d1">organization</data>
      <data key="d2">Sinovac Biotech Ltd is the company that developed the COVID-19 Vaccine (Vero Cell), focusing on vaccine production and clinical trials.&lt;SEP&gt;Sinovac Biotech Ltd is a pharmaceutical company developing an inactivated SARS-CoV-2 vaccine.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Whole Virus Vaccines">
      <data key="d0">Whole Virus Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Whole virus vaccines are vaccines produced using inactivated whole pathogens for immunity generation against various viral diseases.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Influenza">
      <data key="d0">Influenza</data>
      <data key="d1">disease</data>
      <data key="d2">Influenza is a viral infection for which whole virus vaccines have historically been used for prevention and treatment.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Poliomyelitis">
      <data key="d0">Poliomyelitis</data>
      <data key="d1">disease</data>
      <data key="d2">Poliomyelitis is a viral disease preventable by vaccines, including whole virus vaccines.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Human Papillomavirus Infections">
      <data key="d0">Human Papillomavirus Infections</data>
      <data key="d1">disease</data>
      <data key="d2">Human Papillomavirus infections are viral infections that can be prevented by the use of whole viral inactivation vaccines.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="CD4 T Cells">
      <data key="d0">CD4 T Cells</data>
      <data key="d1">celltype</data>
      <data key="d2">CD4 T cells are a type of immune cell whose expression was upregulated in response to mRNA vaccination.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="CD8 T Cells">
      <data key="d0">CD8 T Cells</data>
      <data key="d1">celltype</data>
      <data key="d2">CD8 T cells are another type of immune cell, which were detected at low levels after the mRNA vaccination.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Neutralizing Antibodies">
      <data key="d0">Neutralizing Antibodies</data>
      <data key="d1">protein</data>
      <data key="d2">Neutralizing antibodies are specific antibodies that defend against pathogens, measured during clinical trials to assess vaccine effectiveness.&lt;SEP&gt;Neutralizing antibodies specifically target viruses to prevent infection, generated in response to mRNA vaccination.&lt;SEP&gt;Neutralizing antibodies are immune responses developed by individuals, including vulnerable populations, upon vaccination against SARS-CoV-2.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-a218174a04fc9428ffade976a83e2c22&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Memory T Cells">
      <data key="d0">Memory T Cells</data>
      <data key="d1">celltype</data>
      <data key="d2">Memory T cells are a type of immune cell that helps maintain immunity after vaccination against viruses like SARS-CoV-2.&lt;SEP&gt;Memory T cells are immune cells that can provide long-term immunity, showing strong response post-booster dose of vaccines.</data>
      <data key="d3">chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="V-2 Mutagenesis">
      <data key="d0">V-2 Mutagenesis</data>
      <data key="d1">method</data>
      <data key="d2">V-2 mutagenesis refers to a technique involving the use of an RNA template for mutagenesis.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="RNA Template">
      <data key="d0">RNA Template</data>
      <data key="d1">concept</data>
      <data key="d2">The RNA template is a component used in V-2 mutagenesis for guiding the mutational process.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Kabinger F">
      <data key="d0">Kabinger F</data>
      <data key="d1">person</data>
      <data key="d2">Kabinger F is an author who contributed to research on the mechanism of molnupiravir-induced mutagenesis.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Stiller C">
      <data key="d0">Stiller C</data>
      <data key="d1">person</data>
      <data key="d2">Stiller C is a co-author involved in the study of molnupiravir's effects on SARS-CoV-2.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Schmitzova J">
      <data key="d0">Schmitzova J</data>
      <data key="d1">person</data>
      <data key="d2">Schmitzova J is a co-author of the research discussing the mutagenesis mechanisms of molnupiravir.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791267</data>
      <data key="d6" />
    </node>
    <node id="Sheahan TP">
      <data key="d0">Sheahan TP</data>
      <data key="d1">person</data>
      <data key="d2">Sheahan TP is a researcher focused on antiviral therapies against SARS-CoV-2.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Sims AC">
      <data key="d0">Sims AC</data>
      <data key="d1">person</data>
      <data key="d2">Sims AC is a researcher who worked on the impact of an antiviral in human airway epithelial cell cultures.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Zhou S">
      <data key="d0">Zhou S</data>
      <data key="d1">person</data>
      <data key="d2">Zhou S is a co-author involved in the study of antiviral effects on coronaviruses.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Wang Z">
      <data key="d0">Wang Z</data>
      <data key="d1">person</data>
      <data key="d2">Wang Z is a researcher who highlighted the therapeutic potential of Paxlovid in managing COVID-19.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Yang L">
      <data key="d0">Yang L</data>
      <data key="d1">person</data>
      <data key="d2">Yang L is a researcher discussing COVID-19 treatments during the Omicron variant's prevalence.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Tian JH">
      <data key="d0">Tian JH</data>
      <data key="d1">person</data>
      <data key="d2">Tian JH is a researcher involved in the study of NVX-CoV2373's vaccine candidate and its effectiveness.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Spike Glycoprotein Vaccine Candidate NVX-CoV2373">
      <data key="d0">Spike Glycoprotein Vaccine Candidate NVX-CoV2373</data>
      <data key="d1">vaccine</data>
      <data key="d2">NVX-CoV2373 is a vaccine candidate aimed at inducing an immune response against SARS-CoV-2.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Baboon">
      <data key="d0">Baboon</data>
      <data key="d1">creature</data>
      <data key="d2">Baboons were used in research to study the immunogenicity of the NVX-CoV2373 vaccine.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Albert G">
      <data key="d0">Albert G</data>
      <data key="d1">person</data>
      <data key="d2">Albert G is a co-researcher involved in the Phase 1/2 trial of the SARS-CoV-2 vaccine.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Cho I">
      <data key="d0">Cho I</data>
      <data key="d1">person</data>
      <data key="d2">Cho I is a researcher involved in the trials of the recombinant spike protein vaccine for SARS-CoV-2.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="M Set">
      <data key="d0">M Set</data>
      <data key="d1">person</data>
      <data key="d2">M Set is a co-author in the investigation of the NVX-CoV2373 vaccine trial results.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Matrix-M Adjuvant">
      <data key="d0">Matrix-M Adjuvant</data>
      <data key="d1">adjuvant</data>
      <data key="d2">Matrix-M adjuvant is used to enhance immune response in vaccine formulations.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="PLoS One">
      <data key="d0">PLoS One</data>
      <data key="d1">content</data>
      <data key="d2">PLoS One is a scientific journal where research related to Matrix-M adjuvant was published.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="NVX-CoV2373 Vaccine">
      <data key="d0">NVX-CoV2373 Vaccine</data>
      <data key="d1">vaccine</data>
      <data key="d2">The NVX-CoV2373 vaccine is aimed at providing immunity against SARS-CoV-2.</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Comorbidities">
      <data key="d0">Comorbidities</data>
      <data key="d1">concept</data>
      <data key="d2">Comorbidities refer to additional health conditions in participants studied for vaccine efficacy.</data>
      <data key="d3">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="CD4 T Cell Response">
      <data key="d0">CD4 T Cell Response</data>
      <data key="d1">immuneresponse</data>
      <data key="d2">The CD4 T cell response is a significant immune response induced by the NVX-CoV2373 vaccine.</data>
      <data key="d3">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Antibody Dependent Cellular Cytotoxicity">
      <data key="d0">Antibody Dependent Cellular Cytotoxicity</data>
      <data key="d1">immuneresponse</data>
      <data key="d2">Antibody Dependent Cellular Cytotoxicity is a mechanism by which immune effector cells eliminate infected cells post-vaccination.</data>
      <data key="d3">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="CD8 T Cell Response">
      <data key="d0">CD8 T Cell Response</data>
      <data key="d1">immuneresponse</data>
      <data key="d2">The CD8 T cell response is an immune response noted to be induced by vaccine, important for combating infections like SARS-CoV-2.</data>
      <data key="d3">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Protein Vaccine">
      <data key="d0">Protein Vaccine</data>
      <data key="d1">concept</data>
      <data key="d2">A protein vaccine is a type of vaccine that uses total or subunit parts of proteins to induce an immune response.</data>
      <data key="d3">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Vaccine">
      <data key="d0">Vaccine</data>
      <data key="d1">concept</data>
      <data key="d2">The term 'vaccine' refers to biological preparations used to provide immunity against specific diseases.</data>
      <data key="d3">chunk-f849139a3171d7c3bad48d83b0e56bf7&lt;SEP&gt;chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Safety">
      <data key="d0">Safety</data>
      <data key="d1">concept</data>
      <data key="d2">Safety refers to the condition of being protected from harm or risk, particularly in the context of vaccine administration and efficacy monitoring.</data>
      <data key="d3">chunk-f849139a3171d7c3bad48d83b0e56bf7&lt;SEP&gt;chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Science">
      <data key="d0">Science</data>
      <data key="d1">organization</data>
      <data key="d2">Science is a well-known scientific journal that published insights on SARS-CoV-2 sequences in 2021.</data>
      <data key="d3">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="Next-Generation Gene Sequencing">
      <data key="d0">Next-Generation Gene Sequencing</data>
      <data key="d1">method</data>
      <data key="d2">Next-Generation Gene Sequencing is a method used for the detection of viral presence and epidemiology understanding of SARS-CoV-2.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791268</data>
      <data key="d6" />
    </node>
    <node id="PCR Melting Temperature Assays">
      <data key="d0">PCR Melting Temperature Assays</data>
      <data key="d1">method</data>
      <data key="d2">PCR melting temperature assays are techniques used for detecting SARS-CoV-2 and are comparable to genome sequencing.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Sangers Sequencing">
      <data key="d0">Sangers Sequencing</data>
      <data key="d1">method</data>
      <data key="d2">Sangers Sequencing is an alternate sequencing platform capable of identifying all SARS-CoV-2 variants of concern (VOCs).</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Anti-SARS-CoV-2 Antibody-Based Detection">
      <data key="d0">Anti-SARS-CoV-2 Antibody-Based Detection</data>
      <data key="d1">method</data>
      <data key="d2">Anti-SARS-CoV-2 antibody-based detection techniques are used to identify antibodies related to SARS-CoV-2 infections.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Immuno-Assignments">
      <data key="d0">Immuno-Assignments</data>
      <data key="d1">method</data>
      <data key="d2">Immuno-Assignments refer to various antigen-based immunoassays that are reliable methods for detecting SARS-CoV-2 infections.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Antigen">
      <data key="d0">SARS-CoV-2 Antigen</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 Antigen refers to specific proteins, namely S and N proteins, associated with the SARS-CoV-2 virus and targeted by various detection methods.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Immunofluorescent Assays">
      <data key="d0">Immunofluorescent Assays</data>
      <data key="d1">method</data>
      <data key="d2">Immunofluorescent Assays are a type of antigen-based immunoassay used for the detection of SARS-CoV-2 infections.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Immunochromatographic Assays">
      <data key="d0">Immunochromatographic Assays</data>
      <data key="d1">method</data>
      <data key="d2">Immunochromatographic Assays are antigen-based tests employed to detect SARS-CoV-2 infections.&lt;SEP&gt;Immunochromatographic assays are testing methods used for the detection of antibodies specific to SARS-CoV-2.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Chemiluminescent Immunoassays">
      <data key="d0">Chemiluminescent Immunoassays</data>
      <data key="d1">method</data>
      <data key="d2">Chemiluminescent Immunoassays are another form of antigen detection employed to identify SARS-CoV-2 infections.</data>
      <data key="d3">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Vaccine (Vero Cell)">
      <data key="d0">COVID-19 Vaccine (Vero Cell)</data>
      <data key="d1">artifact</data>
      <data key="d2">COVID-19 Vaccine (Vero Cell) is an inactivated SARS-CoV-2 vaccine developed by Sinovac Biotech Ltd, utilizing adjuvant characteristics and a two-dose regimen for administration.&lt;SEP&gt;The COVID-19 Vaccine (Vero Cell) is an inactivated vaccine with very few reported cases of hypersensitivity, including severe allergic reactions.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 (CN2 strain)">
      <data key="d0">SARS-CoV-2 (CN2 strain)</data>
      <data key="d1">virus</data>
      <data key="d2">SARS-CoV-2 (CN2 strain) is the virus that the COVID-19 Vaccine (Vero Cell) is designed to combat through vaccination.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Aluminium Hydroxide">
      <data key="d0">Aluminium Hydroxide</data>
      <data key="d1">chemical</data>
      <data key="d2">Aluminium Hydroxide is an adjuvant used in the COVID-19 Vaccine (Vero Cell) formulation to enhance immune response.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Rhesus Macaca Mulatta">
      <data key="d0">Rhesus Macaca Mulatta</data>
      <data key="d1">creature</data>
      <data key="d2">Rhesus Macaca Mulatta, or rhesus macaque, is a type of monkey used in safety evaluations for the COVID-19 Vaccine (Vero Cell).</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Two-Dose Regimen">
      <data key="d0">Two-Dose Regimen</data>
      <data key="d1">concept</data>
      <data key="d2">Two-Dose Regimen is the administration method for the COVID-19 Vaccine (Vero Cell), involving doses at day 0 and day 28.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Phase II Clinical Trials">
      <data key="d0">Phase II Clinical Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase II Clinical Trials involve an extended testing of the COVID-19 Vaccine (Vero Cell) Inactivated with 600 participants to assess efficacy and safety.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Hypersensitivity">
      <data key="d0">Hypersensitivity</data>
      <data key="d1">medicalcondition</data>
      <data key="d2">Hypersensitivity refers to a condition with extreme reactions to vaccines, which is minimally reported in the case of the COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Two-Dose Immunization Schedule">
      <data key="d0">Two-Dose Immunization Schedule</data>
      <data key="d1">concept</data>
      <data key="d2">Two-Dose Immunization Schedule refers to the method of administering the COVID-19 Vaccine (Vero Cell) in two doses, focusing on optimal timing for efficacy.</data>
      <data key="d3">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Queenie Fernandes">
      <data key="d0">Queenie Fernandes</data>
      <data key="d1">person</data>
      <data key="d2">Queenie Fernandes is a contributor to the review article on emerging COVID-19 variants and diagnosis, therapeutics, and vaccines.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Varghese Philipose Inchakalody">
      <data key="d0">Varghese Philipose Inchakalody</data>
      <data key="d1">person</data>
      <data key="d2">Varghese Philipose Inchakalody is a contributor to the review article on COVID-19 variants and their impact.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Qatar University">
      <data key="d0">Qatar University</data>
      <data key="d1">organization</data>
      <data key="d2">Qatar University is an academic institution contributing to the research discussed in the review article on COVID-19.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Hamad General Hospital">
      <data key="d0">Hamad General Hospital</data>
      <data key="d1">organization</data>
      <data key="d2">Hamad General Hospital is part of Hamad Medical Corporation, focusing on allergy and immunology in relation to COVID-19.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83&lt;SEP&gt;chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Doha">
      <data key="d0">Doha</data>
      <data key="d1">location</data>
      <data key="d2">Doha is the capital city of Qatar and the location involved in the research and healthcare initiatives discussed in the article.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791269</data>
      <data key="d6" />
    </node>
    <node id="Therapeutics">
      <data key="d0">Therapeutics</data>
      <data key="d1">concept</data>
      <data key="d2">Therapeutics refer to the treatment protocols and drugs developed for COVID-19 and its variants.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Vaccines">
      <data key="d0">Vaccines</data>
      <data key="d1">concept</data>
      <data key="d2">Vaccines are immunological preparations developed to provide protection against COVID-19 and its variants.&lt;SEP&gt;Vaccines provide immunization against SARS-CoV-2 and its variants, showing varying efficacy rates among different populations.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Immunological Impact">
      <data key="d0">Immunological Impact</data>
      <data key="d1">concept</data>
      <data key="d2">Immunological impact refers to the body's immune response resulting from vaccination and therapeutic interventions against COVID-19.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Allergy and Immunology Section">
      <data key="d0">Allergy and Immunology Section</data>
      <data key="d1">organization</data>
      <data key="d2">The Allergy and Immunology Section is part of Hamad General Hospital, focusing on COVID-19 related research and treatment.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Intensive Care Unit">
      <data key="d0">Intensive Care Unit</data>
      <data key="d1">organization</data>
      <data key="d2">The Intensive Care Unit is a department within Hamad General Hospital involved in critical care related to COVID-19 patients.</data>
      <data key="d3">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Emergency Use Authorization">
      <data key="d0">Emergency Use Authorization</data>
      <data key="d1">concept</data>
      <data key="d2">Emergency Use Authorization is a regulatory mechanism that allows the use of medical products during public health emergencies, relevant in the context of the COVID-19 vaccine deployment.</data>
      <data key="d3">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Thrombosis">
      <data key="d0">Thrombosis</data>
      <data key="d1">concept</data>
      <data key="d2">Thrombosis refers to the formation of blood clots in blood vessels, mentioned as a side effect linked to the AZD1222 vaccine.</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Neutrophils">
      <data key="d0">Neutrophils</data>
      <data key="d1">cell</data>
      <data key="d2">Neutrophils are a type of immune cell that play a role in recognizing and eliminating infected cells as part of the immune response.</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Eosinophils">
      <data key="d0">Eosinophils</data>
      <data key="d1">cell</data>
      <data key="d2">Eosinophils are immune cells that can recognize infected cells and participate in cytotoxic processes during the immune response.</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Macrophages">
      <data key="d0">Macrophages</data>
      <data key="d1">cell</data>
      <data key="d2">Macrophages are immune cells that play a critical role in identifying and destroying infected cells.</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="NK Cells">
      <data key="d0">NK Cells</data>
      <data key="d1">cell</data>
      <data key="d2">NK (Natural Killer) cells are part of the immune system and are involved in recognizing and eliminating infected cells.</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Al Kaabi N">
      <data key="d0">Al Kaabi N</data>
      <data key="d1">person</data>
      <data key="d2">Al Kaabi N is a researcher involved in a randomized clinical trial assessing the effectiveness of inactivated SARS-CoV-2 vaccines.</data>
      <data key="d3">chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Phase-III Trial Results">
      <data key="d0">Phase-III Trial Results</data>
      <data key="d1">data</data>
      <data key="d2">Phase-III trial results pertain to the testing and evaluation of the Sinovac vaccine in China, describing its effectiveness and safety.</data>
      <data key="d3">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Reports of Suspected Adverse Reaction">
      <data key="d0">Reports of Suspected Adverse Reaction</data>
      <data key="d1">data</data>
      <data key="d2">Reports of suspected adverse reactions provide information on the safety of COVID-19 vaccines, detailing incidents from March to April 2021.</data>
      <data key="d3">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Randomised Clinical Trials">
      <data key="d0">Randomised Clinical Trials</data>
      <data key="d1">method</data>
      <data key="d2">Randomised clinical trials are research methods used to evaluate the efficacy of COVID-19 vaccines, including inactivated SARS-CoV-2 vaccines.</data>
      <data key="d3">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 VOC-alpha">
      <data key="d0">SARS-CoV-2 VOC-alpha</data>
      <data key="d1">concept</data>
      <data key="d2">SARS-CoV-2 VOC-alpha, also known as the alpha variant (202012/01, TM B.1.1.7), is a variant of concern identified in COVID-19 cases.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Allplex SARS-CoV-2/FluA/FluB/ RSV Assay">
      <data key="d0">Allplex SARS-CoV-2/FluA/FluB/ RSV Assay</data>
      <data key="d1">method</data>
      <data key="d2">The Allplex SARS-CoV-2/FluA/FluB/ RSV assay is a diagnostic test used for rapid screening of the SARS-CoV-2 virus and its variants.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Nested RT-PCR Assays">
      <data key="d0">Nested RT-PCR Assays</data>
      <data key="d1">method</data>
      <data key="d2">Nested RT-PCR assays are employed to detect SARS-CoV-2 variants in both clinical and environmental samples.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="CRISPR-Cas13-based Diagnosis">
      <data key="d0">CRISPR-Cas13-based Diagnosis</data>
      <data key="d1">method</data>
      <data key="d2">CRISPR-Cas13-based diagnosis involves a rapid testing method utilizing CRISPR technology for identifying infectious agents.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Hybridization Assay">
      <data key="d0">Hybridization Assay</data>
      <data key="d1">method</data>
      <data key="d2">The micro-array hybridization assay is used for the detection and identification of coronaviruses, including human respiratory coronavirus-229E.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Reverse Transcriptase PCR Melting-Temperature Assay">
      <data key="d0">Reverse Transcriptase PCR Melting-Temperature Assay</data>
      <data key="d1">method</data>
      <data key="d2">A simple reverse transcriptase PCR melting-temperature assay is utilized for the rapid screening of SARS-CoV-2 variants.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Sanger-based Approach">
      <data key="d0">Sanger-based Approach</data>
      <data key="d1">method</data>
      <data key="d2">The sanger-based approach facilitates scaling up the screening of SARS-CoV-2 variants of interest and concern.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 Therapy Trials">
      <data key="d0">COVID-19 Therapy Trials</data>
      <data key="d1">concept</data>
      <data key="d2">COVID-19 therapy trials involve research and clinical testing of treatment options for COVID-19.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="2019-new Coronavirus">
      <data key="d0">2019-new Coronavirus</data>
      <data key="d1">concept</data>
      <data key="d2">The 2019-new coronavirus (2019-nCoV) refers to the virus responsible for the COVID-19 pandemic, prompting various treatment studies.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791270</data>
      <data key="d6" />
    </node>
    <node id="Intervirology">
      <data key="d0">Intervirology</data>
      <data key="d1">publication</data>
      <data key="d2">Intervirology is a journal that published an article on the detection of animal and human coronaviruses.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Infect Genet Evol">
      <data key="d0">Infect Genet Evol</data>
      <data key="d1">publication</data>
      <data key="d2">Infect Genet Evol is a journal that published a study on a Sanger-based approach for screening SARS-CoV-2 variants.</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Antibodies">
      <data key="d0">Antibodies</data>
      <data key="d1">data</data>
      <data key="d2">Antibodies are immune proteins generated against the SARS-CoV-2 viral antigens, specifically targeting the S and N proteins.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Chemiluminescence Assays">
      <data key="d0">Chemiluminescence Assays</data>
      <data key="d1">method</data>
      <data key="d2">Chemiluminescence assays are another diagnostic technique used in the detection of antibodies to SARS-CoV-2.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="ELISA">
      <data key="d0">ELISA</data>
      <data key="d1">method</data>
      <data key="d2">ELISA (Enzyme-Linked Immunosorbent Assay) is a method employed to detect antibodies generated in response to the SARS-CoV-2 antigen.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Immunoglobulin M (IgM)">
      <data key="d0">Immunoglobulin M (IgM)</data>
      <data key="d1">data</data>
      <data key="d2">Immunoglobulin M (IgM) is one type of antibody measured to indicate an immune response to SARS-CoV-2 infection.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Immunoglobulin G (IgG)">
      <data key="d0">Immunoglobulin G (IgG)</data>
      <data key="d1">data</data>
      <data key="d2">Immunoglobulin G (IgG) is another type of antibody that is measured along with IgM to assess the immune response to SARS-CoV-2.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Humoral Immune Responses">
      <data key="d0">Humoral Immune Responses</data>
      <data key="d1">concept</data>
      <data key="d2">Humoral immune responses refer to the component of the immune response that involves the production of antibodies against pathogens.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Rapid Capillary-Based Platforms">
      <data key="d0">Rapid Capillary-Based Platforms</data>
      <data key="d1">method</data>
      <data key="d2">Rapid capillary-based platforms are automated systems used to detect the immune response against SARS-CoV-2 viral antigens.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Variants of Concern (VOCs)">
      <data key="d0">Variants of Concern (VOCs)</data>
      <data key="d1">concept</data>
      <data key="d2">Variants of Concern (VOCs) are different strains of viruses that are monitored for changes in prevalence and virulence.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Remdesivir Triphosphate">
      <data key="d0">Remdesivir Triphosphate</data>
      <data key="d1">drug</data>
      <data key="d2">Remdesivir triphosphate is the active form of Remdesivir that resembles RNA of the coronavirus and integrates into viral RNA strands to inhibit replication.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Janus-Kinase STAT Signalling Inhibitor">
      <data key="d0">Janus-Kinase STAT Signalling Inhibitor</data>
      <data key="d1">concept</data>
      <data key="d2">The Janus-Kinase STAT signalling inhibitor refers to a class of drugs, like Baricitinib, that modulate immune response by targeting specific signaling pathways.</data>
      <data key="d3">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Phase III Trials">
      <data key="d0">Phase III Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase III trials are clinical trials planned for the BBIBP-CorV vaccine to assess long-term safety and efficacy.</data>
      <data key="d3">chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="SOTRs (Solid Organ Transplant Recipients)">
      <data key="d0">SOTRs (Solid Organ Transplant Recipients)</data>
      <data key="d1">person</data>
      <data key="d2">SOTRs refers to individuals who have undergone solid organ transplants and are included in immune response studies for vaccines.</data>
      <data key="d3">chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Oxford-AstraZeneca">
      <data key="d0">Oxford-AstraZeneca</data>
      <data key="d1">organization</data>
      <data key="d2">Oxford-AstraZeneca is a pharmaceutical company involved in the development of COVID-19 vaccines, including the ChAdOx1-S vaccine studied in Denmark and Norway.</data>
      <data key="d3">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Ebola Vaccines">
      <data key="d0">Ebola Vaccines</data>
      <data key="d1">product</data>
      <data key="d2">Ebola vaccines, such as Ad26.ZEBOV and MVA-BN-Filo, were part of a vaccination regimen studied for safety and immunogenicity.</data>
      <data key="d3">chunk-d300ad0251280be6e2b2d713e9ee6b72&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Respiratory Syncytial Virus Vaccine">
      <data key="d0">Respiratory Syncytial Virus Vaccine</data>
      <data key="d1">product</data>
      <data key="d2">The Respiratory Syncytial Virus Vaccine is a vaccine being studied for safety and immunogenicity using an adenovirus 26 vector.</data>
      <data key="d3">chunk-d300ad0251280be6e2b2d713e9ee6b72&lt;SEP&gt;chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Adenovirus Vectors">
      <data key="d0">Adenovirus Vectors</data>
      <data key="d1">concept</data>
      <data key="d2">Adenovirus vectors are viral constructs used for gene therapy, vaccination, and cancer treatment, highlighted in various studies.</data>
      <data key="d3">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="rAd26 and rAd5">
      <data key="d0">rAd26 and rAd5</data>
      <data key="d1">concept</data>
      <data key="d2">rAd26 and rAd5 are adenovirus vectors used in a COVID-19 vaccination study focusing on safety and immunogenicity.</data>
      <data key="d3">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Vaccine">
      <data key="d0">SARS-CoV-2 Vaccine</data>
      <data key="d1">concept</data>
      <data key="d2">The SARS-CoV-2 vaccine is constructed from two vector components, rAd26 and rAd5, to elicit an immune response against the virus.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Recombinant Adenovirus Type 26">
      <data key="d0">Recombinant Adenovirus Type 26</data>
      <data key="d1">concept</data>
      <data key="d2">Recombinant Adenovirus Type 26, abbreviated as rAd26, is one of the viral vectors used in the development of the SARS-CoV-2 vaccine.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Recombinant Adenovirus Type 5">
      <data key="d0">Recombinant Adenovirus Type 5</data>
      <data key="d1">concept</data>
      <data key="d2">Recombinant Adenovirus Type 5, abbreviated as rAd5, is the second viral vector used in the SARS-CoV-2 vaccine formulation.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Phase 3 Clinical Trials">
      <data key="d0">Phase 3 Clinical Trials</data>
      <data key="d1">event</data>
      <data key="d2">Phase 3 clinical trials involve a larger participant group to evaluate the efficacy and safety of the vaccine.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="IgG Titre">
      <data key="d0">IgG Titre</data>
      <data key="d1">data</data>
      <data key="d2">IgG titre refers to the measurement of antibodies in the serum, indicating the immune response following vaccination.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791271</data>
      <data key="d6" />
    </node>
    <node id="Frozen Formulation">
      <data key="d0">Frozen Formulation</data>
      <data key="d1">concept</data>
      <data key="d2">The frozen formulation of the SARS-CoV-2 vaccine shows a higher immune response compared to the lyophilized formulation in clinical trials.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Lyophilized Formulation">
      <data key="d0">Lyophilized Formulation</data>
      <data key="d1">concept</data>
      <data key="d2">The lyophilized formulation of the SARS-CoV-2 vaccine is one of the two formulations tested in clinical trials, though it shows lower effectiveness than the frozen formulation.</data>
      <data key="d3">chunk-a218174a04fc9428ffade976a83e2c22&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Vaccine mRNA-1273">
      <data key="d0">Vaccine mRNA-1273</data>
      <data key="d1">product</data>
      <data key="d2">The vaccine mRNA-1273 is a specific COVID-19 vaccine investigated for its safety and immune response in transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Aslam S">
      <data key="d0">Aslam S</data>
      <data key="d1">person</data>
      <data key="d2">Aslam S is a researcher involved in a study on the clinical effectiveness of COVID-19 vaccinations in solid organ transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Adler E">
      <data key="d0">Adler E</data>
      <data key="d1">person</data>
      <data key="d2">Adler E is a researcher participating in the investigation of COVID-19 vaccination effectiveness among transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Mekeel K">
      <data key="d0">Mekeel K</data>
      <data key="d1">person</data>
      <data key="d2">Mekeel K is a researcher contributing to the study of vaccine effectiveness in solid organ transplant patients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Qin CX">
      <data key="d0">Qin CX</data>
      <data key="d1">person</data>
      <data key="d2">Qin CX is a researcher investigating the risk of breakthrough SARS-CoV-2 infections in adult transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Moore LW">
      <data key="d0">Moore LW</data>
      <data key="d1">person</data>
      <data key="d2">Moore LW is a researcher studying the risk of breakthrough infections in transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Immunogenicity Study">
      <data key="d0">Immunogenicity Study</data>
      <data key="d1">event</data>
      <data key="d2">The Immunogenicity Study examines the immune response generated by a single dose of the SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients.</data>
      <data key="d3">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="REMAP-CAP Trial">
      <data key="d0">REMAP-CAP Trial</data>
      <data key="d1">study</data>
      <data key="d2">REMAP-CAP Trial is a clinical trial evaluating the effectiveness of various treatments, showing beneficial outcomes for Tocilizumab and Sarilumab in hospitalized COVID-19 patients.</data>
      <data key="d3">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="RNA-Dependent RNA Polymerase (RdRP)">
      <data key="d0">RNA-Dependent RNA Polymerase (RdRP)</data>
      <data key="d1">protein</data>
      <data key="d2">RNA-Dependent RNA Polymerase (RdRP) is a viral protein target for antiviral drugs, including remdesivir, involved in viral RNA synthesis.</data>
      <data key="d3">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Emerging Variants of Concern (VOCs)">
      <data key="d0">Emerging Variants of Concern (VOCs)</data>
      <data key="d1">concept</data>
      <data key="d2">Emerging variants of concern (VOCs) are new strains of SARS-CoV-2 that have mutations affecting their transmissibility and vaccine escape potential.</data>
      <data key="d3">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="CAPTURE Study">
      <data key="d0">CAPTURE Study</data>
      <data key="d1">study</data>
      <data key="d2">The CAPTURE study reported the presence of neutralizing antibodies in cancer patients after immunization with COVID-19 vaccines.</data>
      <data key="d3">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Immuno-Compromised Individuals">
      <data key="d0">Immuno-Compromised Individuals</data>
      <data key="d1">population</data>
      <data key="d2">Immuno-compromised individuals include those with conditions such as cancer and organ transplant recipients who may react differently to vaccination.</data>
      <data key="d3">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Breakthrough Disease">
      <data key="d0">Breakthrough Disease</data>
      <data key="d1">concept</data>
      <data key="d2">Breakthrough disease refers to COVID-19 infections occurring in vaccinated individuals, especially among vulnerable populations.</data>
      <data key="d3">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="DV">
      <data key="d0">DV</data>
      <data key="d1">person</data>
      <data key="d2">DV is an author associated with a study on the safety and efficacy of a COVID-19 vaccine.</data>
      <data key="d3">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Sputnik V">
      <data key="d0">Sputnik V</data>
      <data key="d1">vaccine</data>
      <data key="d2">Sputnik V is a COVID-19 vaccine developed in Russia, known for its neutralizing activity against SARS-CoV-2 variants.</data>
      <data key="d3">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="mRNA Vaccine">
      <data key="d0">mRNA Vaccine</data>
      <data key="d1">concept</data>
      <data key="d2">mRNA Vaccine refers to a new class of vaccines using messenger RNA to generate an immune response.</data>
      <data key="d3">chunk-442deee46860f108f0c5389563ea0e97&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Zika Virus Vaccine">
      <data key="d0">Zika Virus Vaccine</data>
      <data key="d1">vaccine</data>
      <data key="d2">The Zika Virus Vaccine provides protection through nucleoside-modified mRNA vaccination.</data>
      <data key="d3">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="C4591001 Clinical Trial Group">
      <data key="d0">C4591001 Clinical Trial Group</data>
      <data key="d1">organization</data>
      <data key="d2">The C4591001 Clinical Trial Group is involved in clinical trials assessing the safety and efficacy of COVID-19 vaccines.</data>
      <data key="d3">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791272</data>
      <data key="d6" />
    </node>
    <node id="Triveri A">
      <data key="d0">Triveri A</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Triveri A is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791275</data>
      <data key="d6" />
    </node>
    <node id="Ding Y">
      <data key="d0">Ding Y</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Ding Y is an author who contributed to the clinical pathology report related to Severe Acute Respiratory Syndrome caused by SARS-CoV.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791276</data>
      <data key="d6" />
    </node>
    <node id="Gu J">
      <data key="d0">Gu J</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Gu J is an author who researched multiple organ infections and pathogenesis associated with Severe Acute Respiratory Syndrome (SARS).</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791276</data>
      <data key="d6" />
    </node>
    <node id="SARS">
      <data key="d0">SARS</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Gu J is an author who researched multiple organ infections and pathogenesis associated with Severe Acute Respiratory Syndrome (SARS).</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791276</data>
      <data key="d6" />
    </node>
    <node id="Serapian SA">
      <data key="d0">Serapian SA</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Serapian SA is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791276</data>
      <data key="d6" />
    </node>
    <node id="Marchetti F">
      <data key="d0">Marchetti F</data>
      <data key="d3">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d2">Marchetti F is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791277</data>
      <data key="d6" />
    </node>
    <node id="LAMP">
      <data key="d0">LAMP</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d2">LAMP is considered a reliable and efficient alternative for SARS-CoV-2 detection.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791279</data>
      <data key="d6" />
    </node>
    <node id="CRISPR">
      <data key="d0">CRISPR</data>
      <data key="d3">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d2">CRISPR technology provides a novel method for targeting specific genes of the SARS-CoV-2 virus in diagnostics.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791279</data>
      <data key="d6" />
    </node>
    <node id="J Biol Chem">
      <data key="d0">J Biol Chem</data>
      <data key="d3">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d2">Gordon CJ contributed to research published in J Biol Chem regarding the mutagenesis of SARS-CoV-2.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791285</data>
      <data key="d6" />
    </node>
    <node id="Novel Coronavirus">
      <data key="d0">Novel Coronavirus</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d2">Zhu N contributed to the research on a novel coronavirus from patients with pneumonia in China.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791290</data>
      <data key="d6" />
    </node>
    <node id="Coronavirus Disease 2019">
      <data key="d0">Coronavirus Disease 2019</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d2">Guan WJ contributed to the research on clinical characteristics of coronavirus disease 2019 in China.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791291</data>
      <data key="d6" />
    </node>
    <node id="Genomic Characterization">
      <data key="d0">Genomic Characterization</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d2">Chan JF contributed to the research on genomic characterization of the novel human-pathogenic coronavirus.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791291</data>
      <data key="d6" />
    </node>
    <node id="Cultivation of Viruses">
      <data key="d0">Cultivation of Viruses</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d2">Tyrrell DA contributed to the research on the cultivation of viruses from patients with colds.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791291</data>
      <data key="d6" />
    </node>
    <node id="Coronaviruses">
      <data key="d0">Coronaviruses</data>
      <data key="d3">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d2">Perlman S contributed to the research on coronaviruses over the decades.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791291</data>
      <data key="d6" />
    </node>
    <node id="Athletics Championship">
      <data key="d0">Athletics Championship</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d2">Noah Carter's participation in the World Athletics Championship is marked by his record-breaking performance.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791294</data>
      <data key="d6" />
    </node>
    <node id="Noah Carter">
      <data key="d0">Noah Carter</data>
      <data key="d3">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d2">Noah Carter's participation in the World Athletics Championship is marked by his record-breaking performance.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791294</data>
      <data key="d6" />
    </node>
    <node id="Current Diagnostic Methods">
      <data key="d0">Current Diagnostic Methods</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d2">Falzone L contributed to the review of current methods for diagnosing COVID-19 infection.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791301</data>
      <data key="d6" />
    </node>
    <node id="Rapid Detection Methods">
      <data key="d0">Rapid Detection Methods</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d2">Mautner L is developing rapid detection methods for SARS-CoV-2 using RT-LAMP.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791301</data>
      <data key="d6" />
    </node>
    <node id="CRISPR-Cas12 Detection">
      <data key="d0">CRISPR-Cas12 Detection</data>
      <data key="d3">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d2">Broughton JP is studying CRISPR-Cas12-based detection for SARS-CoV-2.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791301</data>
      <data key="d6" />
    </node>
    <node id="Sinopharm Vaccine">
      <data key="d0">Sinopharm Vaccine</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d2">Morocco received half a million doses of the Sinopharm COVID-19 vaccine for its vaccination campaign.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791302</data>
      <data key="d6" />
    </node>
    <node id="Xia S">
      <data key="d0">Xia S</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d2">Xia S contributed to the research regarding the BBIBP-CorV vaccine as part of a study on safety and immunogenicity outcomes.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791303</data>
      <data key="d6" />
    </node>
    <node id="Duan K">
      <data key="d0">Duan K</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d2">Duan K contributed to the research regarding the BBIBP-CorV vaccine regarding safety and immunogenicity outcomes.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791304</data>
      <data key="d6" />
    </node>
    <node id="Zhang Y">
      <data key="d0">Zhang Y</data>
      <data key="d3">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d2">Zhang Y contributed to the research of the BBIBP-CorV vaccine focusing on safety and immunogenicity outcomes.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791304</data>
      <data key="d6" />
    </node>
    <node id="CRISPR-Cas13-based diagnostics">
      <data key="d0">CRISPR-Cas13-based diagnostics</data>
      <data key="d3">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d2">Gao D contributed to the sensitive CRISPR-Cas13-based diagnostics for detecting SARS-CoV-2.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791306</data>
      <data key="d6" />
    </node>
    <node id="rAd26 and rAd5 Vector-Based COVID-19 Vaccine">
      <data key="d0">rAd26 and rAd5 Vector-Based COVID-19 Vaccine</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d2">Logunov DY studied the safety and immunogenicity of the rAd26 and rAd5 vector-based COVID-19 vaccine in Russia.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791309</data>
      <data key="d6" />
    </node>
    <node id="Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines">
      <data key="d0">Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines</data>
      <data key="d3">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d2">Heterologous prime-boost vaccination methodology was evaluated for the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines in clinical trials.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791309</data>
      <data key="d6" />
    </node>
    <node id="No Severe Adverse Reactions">
      <data key="d0">No Severe Adverse Reactions</data>
      <data key="d3">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d2">Results from Phase 1 Trials indicated no severe adverse reactions among participants post-vaccination.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791311</data>
      <data key="d6" />
    </node>
    <node id="Neurotropism">
      <data key="d0">Neurotropism</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d2">Research highlights the neurotropic properties of Human Coronavirus 229E, impacting neurological health.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791312</data>
      <data key="d6" />
    </node>
    <node id="Neurons">
      <data key="d0">Neurons</data>
      <data key="d3">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d2">Human Coronavirus OC43 has been shown to propagate from neuron to neuron via axonal transport mechanisms.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791312</data>
      <data key="d6" />
    </node>
    <node id="Remark-Cap">
      <data key="d0">Remark-Cap</data>
      <data key="d3">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d2">NHS Guidance recommends Tocilizumab and Sarilumab for treating Covid-19 in hospitalized patients.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791313</data>
      <data key="d6" />
    </node>
    <node id="United Kingdom/Nigeria">
      <data key="d0">United Kingdom/Nigeria</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d2">B.1.525 is classified as a variant of interest (VOI) originating from the United Kingdom and Nigeria.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791314</data>
      <data key="d6" />
    </node>
    <node id="United States">
      <data key="d0">United States</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d2">B.1.526 is classified as a variant of interest (VOI) originating from the United States.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791314</data>
      <data key="d6" />
    </node>
    <node id="Peru">
      <data key="d0">Peru</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d2">C.37 is classified as a variant of interest (VOI) originating from Peru.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791315</data>
      <data key="d6" />
    </node>
    <node id="Colombia">
      <data key="d0">Colombia</data>
      <data key="d3">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d2">B.1.621 is classified as a variant of interest (VOI) originating from Colombia.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791315</data>
      <data key="d6" />
    </node>
    <node id="Pfizer-BioNTech COVID-19 Vaccine">
      <data key="d0">Pfizer-BioNTech COVID-19 Vaccine</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d2">The FDA authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use to combat the pandemic.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791318</data>
      <data key="d6" />
    </node>
    <node id="COVID-19 vaccines">
      <data key="d0">COVID-19 vaccines</data>
      <data key="d3">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d2">The purpose of the COVID-19 vaccines, including BNT162b2 and mRNA-1273, is to prevent infection by the SARS-CoV-2 virus.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791318</data>
      <data key="d6" />
    </node>
    <node id="NevX-CoV2373 Vaccine">
      <data key="d0">NevX-CoV2373 Vaccine</data>
      <data key="d3">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d2">The NVX-CoV2373 vaccine assessed immunogenicity in baboons as part of research.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791326</data>
      <data key="d6" />
    </node>
    <node id="Influenza Vaccine Effectiveness Network">
      <data key="d0">Influenza Vaccine Effectiveness Network</data>
      <data key="d3">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d2">Noah Carter is involved in studies assessing the effectiveness of vaccines within the network.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791327</data>
      <data key="d6" />
    </node>
    <node id="Revenko H">
      <data key="d0">Revenko H</data>
      <data key="d3">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d2">Revenko H's work focuses on assessing immunity related to vaccines in the context of health research.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791328</data>
      <data key="d6" />
    </node>
    <node id="Development of Novel Vaccine Vectors">
      <data key="d0">Development of Novel Vaccine Vectors</data>
      <data key="d3">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d2">Guo J's research focuses on developing novel vaccine vectors, particularly in conjunction with other listed researchers.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791333</data>
      <data key="d6" />
    </node>
    <node id="Viral Vectors as Vaccine Platforms">
      <data key="d0">Viral Vectors as Vaccine Platforms</data>
      <data key="d3">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d2">Ewer KJ conducts research investigating the role of viral vectors in vaccines, focusing on their immunogenicity and effectiveness.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791333</data>
      <data key="d6" />
    </node>
    <node id="Oxford-AstraZeneca Vaccine">
      <data key="d0">Oxford-AstraZeneca Vaccine</data>
      <data key="d3">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d2">Pottegrd A's research investigates safety concerns associated with the Oxford-AstraZeneca vaccine, particularly arterial events.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791333</data>
      <data key="d6" />
    </node>
    <node id="Infected Cells">
      <data key="d0">Infected Cells</data>
      <data key="d3">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d2">Neutrophils recognize and eliminate infected cells as part of the immune response.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791333</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Proteins">
      <data key="d0">SARS-CoV-2 Proteins</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">The ELISA test is developed to detect specific proteins associated with SARS-CoV-2 infection.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791334</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Antibodies">
      <data key="d0">SARS-CoV-2 Antibodies</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">Automated Western immunoblotting is utilized in the detection of anti-SARS-CoV-2 antibodies.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791334</data>
      <data key="d6" />
    </node>
    <node id="Rapid Screening for SARS-CoV-2 Variants">
      <data key="d0">Rapid Screening for SARS-CoV-2 Variants</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">The Int J Infect Dis published research detailing methods for rapid screening of SARS-CoV-2 variants.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791334</data>
      <data key="d6" />
    </node>
    <node id="Detection of Coronaviruses">
      <data key="d0">Detection of Coronaviruses</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">Intervirology published findings on detecting various coronaviruses.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791335</data>
      <data key="d6" />
    </node>
    <node id="PCR Melting-Temperature Assay">
      <data key="d0">PCR Melting-Temperature Assay</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">The J Clin Microbiol published research on a rapid PCR melting-temperature assay for screening SARS-CoV-2 variants.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791335</data>
      <data key="d6" />
    </node>
    <node id="Sanger-based Screening">
      <data key="d0">Sanger-based Screening</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">Infect Genet Evol published a study on a Sanger-based approach for screening SARS-CoV-2 variants.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791335</data>
      <data key="d6" />
    </node>
    <node id="SARS-CoV-2 Protein Detection">
      <data key="d0">SARS-CoV-2 Protein Detection</data>
      <data key="d3">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d2">Diagnostics featured research on the detection methods for SARS-CoV-2 proteins.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791335</data>
      <data key="d6" />
    </node>
    <node id="new variants">
      <data key="d0">new variants</data>
      <data key="d3">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d2">The emergence of new SARS-CoV-2 variants necessitates ongoing evaluation of treatment efficacy and adaptations in therapy.</data>
      <data key="d1">UNKNOWN</data>
      <data key="d4">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d5">1761791338</data>
      <data key="d6" />
    </node>
    <edge source="SARS-CoV-2 Polymerase" target="Remdesivir">
      <data key="d7">1.0</data>
      <data key="d8">Research has been conducted on how remdesivir stalls the SARS-CoV-2 polymerase during viral replication.</data>
      <data key="d9">antiviral research,mechanism analysis</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Kalil AC" target="Baricitinib">
      <data key="d7">1.0</data>
      <data key="d8">Kalil AC is associated with the study on baricitinib in conjunction with remdesivir for COVID-19.</data>
      <data key="d9">COVID-19 treatment,research collaboration</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Kalil AC" target="ACTT-2 Study Group Members">
      <data key="d7">1.0</data>
      <data key="d8">Kalil AC leads the ACTT-2 Study Group, which researches treatments for COVID-19.</data>
      <data key="d9">collaborative research,leadership</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Kalil AC" target="ACTT-2 Study Group">
      <data key="d7">1.0</data>
      <data key="d8">Kalil AC is a member of the ACTT-2 Study Group that investigated baricitinib plus remdesivir for treatment in hospitalized adults with COVID-19.</data>
      <data key="d9">COVID-19 treatment,research contribution</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Kalil AC" target="ACTT-2 Study">
      <data key="d7">1.0</data>
      <data key="d8">Kalil AC is involved in the ACTT-2 Study, which tests the combination of Baricitinib and remdesivir for COVID-19 treatment.</data>
      <data key="d9">clinical trials,research involvement</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Baricitinib" target="Remdesivir">
      <data key="d7">3.0</data>
      <data key="d8">Baricitinib is used in combination with Remdesivir to enhance recovery rates in COVID-19 pneumonia cases.&lt;SEP&gt;Baricitinib is shown to work better in combination with Remdesivir to reduce recovery time in COVID-19 patients.&lt;SEP&gt;Baricitinib is being studied in combination with Remdesivir for treating hospitalized COVID-19 patients.</data>
      <data key="d9">COVID-19 treatment,combination therapy,recovery,treatment effectiveness</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Baricitinib" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">Baricitinib acts as a modifier to reduce recovery time in hospitalized COVID-19 patients.</data>
      <data key="d9">recovery assistance,treatment</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">Research findings related to COVID-19 treatments have been published in N Engl J Med.</data>
      <data key="d9">disease research,publication</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="Brown MJ">
      <data key="d7">1.0</data>
      <data key="d8">Brown MJ contributed to research published in N Engl J Med regarding COVID-19 treatments.</data>
      <data key="d9">publication contribution,research dissemination</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="Alazawi W">
      <data key="d7">1.0</data>
      <data key="d8">Alazawi W contributed to the publication of research on interleukin-6 receptor antagonists in N Engl J Med.</data>
      <data key="d9">publication contribution,research dissemination</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="Kanoni S">
      <data key="d7">1.0</data>
      <data key="d8">Kanoni S is an author whose work was published in N Engl J Med regarding COVID-19.</data>
      <data key="d9">publication contribution,research dissemination</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="Phan LT">
      <data key="d7">1.0</data>
      <data key="d8">Phan LT is a co-author of the study published in N Engl J Med concerning novel coronavirus transmission in Vietnam.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="N Engl J Med" target="Cao B">
      <data key="d7">1.0</data>
      <data key="d8">Cao B's study on Lopinavir-Ritonavir for severe COVID-19 was published in the New England Journal of Medicine.</data>
      <data key="d9">COVID-19 trial,research publication</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="Lopinavir-Ritonavir" target="Cao B">
      <data key="d7">1.0</data>
      <data key="d8">Cao B participated in the trial assessing the effectiveness of Lopinavir-Ritonavir for severe COVID-19 patients.</data>
      <data key="d9">antiviral study,trial participation</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Lopinavir-Ritonavir" target="Wang Y">
      <data key="d7">1.0</data>
      <data key="d8">Wang Y was involved in the research trial regarding Lopinavir-Ritonavir for the treatment of COVID-19.</data>
      <data key="d9">antiviral research,trial involvement</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Lopinavir-Ritonavir" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">Lopinavir-Ritonavir has been evaluated for its effectiveness against COVID-19 in adults.</data>
      <data key="d9">antiviral efficacy,treatment study</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791274</data>
      <data key="d13" />
    </edge>
    <edge source="Hydroxychloroquine" target="BCN-PEP-CoV2 Research Group">
      <data key="d7">2.0</data>
      <data key="d8">The BCN-PEP-CoV2 Research Group conducted trials assessing hydroxychloroquine for the prevention of COVID-19.&lt;SEP&gt;The BCN-PEP-CoV2 Research Group conducts research on hydroxychloroquine for the prevention of COVID-19.</data>
      <data key="d9">COVID-19 prevention,research initiative,research involvement</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="Hydroxychloroquine" target="COVID-19">
      <data key="d7">2.0</data>
      <data key="d8">Hydroxychloroquine therapy was ineffective in preventing SARS-CoV-2 infection.&lt;SEP&gt;Hydroxychloroquine was studied for its potential to prevent COVID-19 in individuals.</data>
      <data key="d9">antiviral,preventive study,prophylactic failure,viral infection</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="Hydroxychloroquine" target="Chloroquine">
      <data key="d7">1.0</data>
      <data key="d8">Chloroquine is related to Hydroxychloroquine in the context of antiviral studies and treatment strategies.</data>
      <data key="d9">antiviral study,drug relationship</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Hydroxychloroquine" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">Hydroxychloroquine was evaluated for its potential to prevent SARS-CoV-2 infections after exposure.&lt;SEP&gt;Hydroxychloroquine was tested as a post-exposure therapy for SARS-CoV-2 but proved ineffective.</data>
      <data key="d9">efficacy evaluation,evaluation,post-exposure prevention,therapeutic research</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="ACTT-2 Study Group Members" target="Mehta AK">
      <data key="d7">1.0</data>
      <data key="d8">Mehta AK is part of the ACTT-2 Study Group, contributing to research on COVID-19 treatment options.</data>
      <data key="d9">COVID-19 studies,research collaboration</data>
      <data key="d10">chunk-0f080134bfa565ca2ca485938ce85ec1</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791274</data>
      <data key="d13" />
    </edge>
    <edge source="Mehta AK" target="ACTT-2 Study">
      <data key="d7">1.0</data>
      <data key="d8">Mehta AK participates in the ACTT-2 Study investigating COVID-19 treatments.</data>
      <data key="d9">clinical trials,research involvement</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="OVID-Vac" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">OVID-Vac is indicated to potentially protect against SARS-CoV-2 variants.</data>
      <data key="d9">vaccine efficacy,viral protection</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791273</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines are effective at inducing immune responses against SARS-CoV-2 infections.</data>
      <data key="d9">vaccination,viral response</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791274</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="Rabies">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines have demonstrated the ability to induce immune reactions against Rabies.</data>
      <data key="d9">immune response,vaccine efficacy</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="Zika">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines have been shown to induce immune reactions against Zika.</data>
      <data key="d9">immune response,vaccine efficacy</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="Influenza A">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines are effective in inducing immune reactions against Influenza A infections.</data>
      <data key="d9">immune response,vaccine efficacy</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="mRNA-Based Therapeutics">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines are classified under the innovative category of mRNA-based therapeutics.</data>
      <data key="d9">innovation,therapeutic classification</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="Zika Virus">
      <data key="d7">1.0</data>
      <data key="d8">Protection against the Zika virus has been shown through the application of mRNA vaccines.</data>
      <data key="d9">therapeutic application,vaccination protection</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines are developed as a response to the COVID-19 pandemic to induce immune responses against the virus.</data>
      <data key="d9">pandemic response,vaccine technology</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="CD4 T Cells">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines upregulate CD4 T cell expression as part of the immune response.</data>
      <data key="d9">cell activation,immune response</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA Vaccines" target="CD8 T Cells">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines lead to a low level of CD8 T cell detection in response to vaccination.</data>
      <data key="d9">cell activation,immune response</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">BNT162b2 is approved by the FDA for emergency use to prevent COVID-19.</data>
      <data key="d9">disease prevention,vaccine approval</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="mRNA-1273">
      <data key="d7">1.0</data>
      <data key="d8">BNT162b2 and mRNA-1273 vaccines are both mRNA-based and have been shown to be effective against COVID-19.</data>
      <data key="d9">effectiveness,vaccine comparison</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="FDA">
      <data key="d7">3.0</data>
      <data key="d8">The FDA approved BNT162b2 for emergency use during the COVID-19 pandemic.&lt;SEP&gt;BNT162b2 was approved by the FDA for emergency use as a prevention against COVID-19.&lt;SEP&gt;The FDA authorized the use of the BNT162b2 COVID-19 vaccine for emergency use in adolescents.</data>
      <data key="d9">authorization,emergency use,regulatory approval,vaccine approval,vaccine use</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="SIREN Study">
      <data key="d7">1.0</data>
      <data key="d8">The SIREN Study assesses the effectiveness of the BNT162b2 vaccine among health care workers in England.</data>
      <data key="d9">healthcare coverage,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Thompson MG">
      <data key="d7">1.0</data>
      <data key="d8">Thompson MG contributed to the research on the effectiveness of the BNT162b2 COVID-19 vaccine.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Burgess JL">
      <data key="d7">1.0</data>
      <data key="d8">Burgess JL was involved in studies assessing the effectiveness of the BNT162b2 COVID-19 vaccine.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Naleway AL">
      <data key="d7">1.0</data>
      <data key="d8">Naleway AL contributed to the research related to BNT162b2 vaccine effectiveness.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Hall VJ">
      <data key="d7">1.0</data>
      <data key="d8">Hall VJ was an author in a study assessing the effectiveness of the BNT162b2 vaccine.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Foulkes S">
      <data key="d7">1.0</data>
      <data key="d8">Foulkes S contributed to studies on the effectiveness of the BNT162b2 COVID-19 vaccine.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Saei A">
      <data key="d7">1.0</data>
      <data key="d8">Saei A is noted for contributions in research related to the effectiveness of the BNT162b2 vaccine.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Lopez Bernal J">
      <data key="d7">1.0</data>
      <data key="d8">Lopez Bernal J was involved in research on the effectiveness of BNT162b2.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Andrews N">
      <data key="d7">1.0</data>
      <data key="d8">Andrews N contributed to studies assessing the BNT162b2 vaccine's effectiveness.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Solid Organ Transplant Recipients (SOTRs)">
      <data key="d7">1.0</data>
      <data key="d8">SOTRs were reported to have developed neutralizing antibodies after being vaccinated with BNT162b2.</data>
      <data key="d9">immunology,vaccine response</data>
      <data key="d10">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">BNT162b2 demonstrates significant efficacy against preventing SARS-CoV-2 infection.</data>
      <data key="d9">vaccine efficacy,virus prevention</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Phase III Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase III Clinical Trials showed over 90% efficacy for BNT162b2 in individuals with no prior infection.</data>
      <data key="d9">clinical testing,vaccine efficacy</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="B.1.1.7">
      <data key="d7">1.0</data>
      <data key="d8">The effectiveness of BNT162b2 against the B.1.1.7 variant was reduced to 87.9%.</data>
      <data key="d9">efficacy reduction,variant impact</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="B.1.617.2">
      <data key="d7">1.0</data>
      <data key="d8">The effectiveness of BNT162b2 was reduced against the emerging B.1.617.2 COVID-19 variant.</data>
      <data key="d9">efficacy concern,variant impact</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Polack et al.">
      <data key="d7">1.0</data>
      <data key="d8">Polack et al. demonstrated that the BNT162b2 vaccine conferred 95% protection against COVID-19.</data>
      <data key="d9">research findings,vaccine efficacy</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="SARS-CoV-2 Spike">
      <data key="d7">1.0</data>
      <data key="d8">BNT162b2 induces neutralizing antibodies specifically targeting the SARS-CoV-2 spike protein.</data>
      <data key="d9">immune response,vaccine efficacy</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Neutralizing Antibodies">
      <data key="d7">2.0</data>
      <data key="d8">BNT162b2 induces the production of neutralizing antibodies targeting SARS-CoV-2.&lt;SEP&gt;The BNT162b2 vaccine has been reported to induce neutralizing antibodies in patients after immunization.</data>
      <data key="d9">immune response,vaccine,vaccine efficacy</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9&lt;SEP&gt;chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2" target="Memory T Cells">
      <data key="d7">1.0</data>
      <data key="d8">BNT162b2 has been shown to elicit a strong memory T cell response following vaccination.</data>
      <data key="d9">long-term immunity,vaccine response</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="COVE Study Group">
      <data key="d7">2.0</data>
      <data key="d8">The COVE Study Group reported the efficacy of the mRNA-1273 vaccine in preventing COVID-19 illness.&lt;SEP&gt;The COVE Study Group reported no safety concerns associated with mRNA-1273 based on research findings.</data>
      <data key="d9">clinical results,study reporting,vaccine efficacy,vaccine safety</data>
      <data key="d10">chunk-fc104ffbeb7ccb0418a3795f253b7df8&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791274</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="COVE Study">
      <data key="d7">1.0</data>
      <data key="d8">The findings from the COVE Study include data on the mRNA-1273 vaccine's effectiveness.</data>
      <data key="d9">clinical findings,vaccine evaluation</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="FDA">
      <data key="d7">2.0</data>
      <data key="d8">The FDA approved mRNA-1273 for emergency use as a preventive measure against SARS-CoV-2 infections.&lt;SEP&gt;mRNA-1273 was approved by the FDA for emergency use as a prevention against COVID-19.</data>
      <data key="d9">emergency use,regulatory approval,vaccine approval</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="Phase III Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase III Clinical Trials reported 94.1% efficacy for mRNA-1273 in preventing COVID-19 illness.</data>
      <data key="d9">clinical testing,vaccine efficacy</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="B.1.351">
      <data key="d7">1.0</data>
      <data key="d8">Further studies are needed to determine mRNA-1273's effectiveness against the B.1.351 variant.</data>
      <data key="d9">vaccine effectiveness,variant impact</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="Thompson et al.">
      <data key="d7">1.0</data>
      <data key="d8">Thompson et al. indicated that mRNA-1273 provides 90% effectiveness against COVID-19 after full immunization.</data>
      <data key="d9">research findings,vaccine efficacy</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">mRNA-1273 presents high efficacy in preventing SARS-CoV-2 infection based on trial results.</data>
      <data key="d9">vaccine efficacy,virus prevention</data>
      <data key="d10">chunk-bcf2fae51213896d1bf2c29dfc9f1a2d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">mRNA-1273 was shown to induce an immune response in participants during COVID-19 clinical trials.</data>
      <data key="d9">immune response,vaccine development</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Angiotensin-Converting Enzyme 2" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 utilizes Angiotensin-Converting Enzyme 2 as a receptor to enter and infect host cells.</data>
      <data key="d9">pathogen interaction,receptor binding</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="Wuhan" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">The outbreak of SARS-CoV-2 originated in Wuhan, China.&lt;SEP&gt;Wuhan is the city where the outbreak of the SARS-CoV-2 virus began, marking it as the epicenter of the COVID-19 pandemic.</data>
      <data key="d9">epicenter,location,outbreak origin</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="Wuhan" target="Hubei Province">
      <data key="d7">2.0</data>
      <data key="d8">Wuhan is the capital city of Hubei Province, where the COVID-19 outbreak began.&lt;SEP&gt;Wuhan is the capital city of Hubei Province, where the pneumonia outbreak linked to the novel coronavirus began.</data>
      <data key="d9">capital city,geographical relation,location association,outbreak origin</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="Wuhan" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">Wuhan is the city where significant studies on hospitalized patients with COVID-19 are conducted.</data>
      <data key="d9">patient study,research context</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Severe Acute Respiratory Syndrome" target="SARS-CoV">
      <data key="d7">1.0</data>
      <data key="d8">Severe Acute Respiratory Syndrome is caused by the SARS-CoV virus, which has similarities with SARS-CoV-2 in terms of infection mechanisms.</data>
      <data key="d9">causal relationship,viral infection</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791275</data>
      <data key="d13" />
    </edge>
    <edge source="Severe Acute Respiratory Syndrome" target="Gorbalenya AE">
      <data key="d7">1.0</data>
      <data key="d8">Gorbalenya AE contributed to the research on severe acute respiratory syndrome-related coronavirus.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="Neuroinvasive Potential" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">The neuroinvasive potential of SARS-CoV-2 may explain the neurological manifestations observed in some COVID-19 patients.</data>
      <data key="d9">neurological aspects,symptom correlation</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791277</data>
      <data key="d13" />
    </edge>
    <edge source="J Chem Inf Model" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">J Chem Inf Model described how mutations in the spike protein of SARS-CoV-2 affect antibody response.</data>
      <data key="d9">antibody response,scientific publication</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="J Med Virol" target="SARS-CoV">
      <data key="d7">1.0</data>
      <data key="d8">J Med Virol has documented studies related to the clinical implications of SARS-CoV infection.</data>
      <data key="d9">clinical research,viral impact</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="J Med Virol" target="CRISPR-Cas13-based Diagnosis">
      <data key="d7">1.0</data>
      <data key="d8">J Med Virol featured research on using CRISPR-Cas13 for diagnosing SARS-CoV-2.</data>
      <data key="d9">innovative diagnostics,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7 Variant" target="Remdesivir">
      <data key="d7">2.0</data>
      <data key="d8">Remdesivir's efficacy was evaluated against the B.1.1.7 variant concerning mutations in the RNA polymerase.&lt;SEP&gt;Remdesivir targets the RNA-Dependent RNA Polymerase (RdRP) sequence that remains conserved despite mutations in the B.1.1.7 variant.</data>
      <data key="d9">antiviral target,efficacy assessment,treatment effectiveness,variant impact</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7 Variant" target="NSP12">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.1.7 variant showed low genetic variation in the NSP12 protein compared to early variants.</data>
      <data key="d9">mutation analysis,protein conservation</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7 Variant" target="BNT162b2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The effectiveness of the BNT162b2 vaccine against the B.1.1.7 variant was analyzed by researchers.</data>
      <data key="d9">vaccine assessment,variant effectiveness</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7 Variant" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.1.7 variant is part of the SARS-CoV-2 family and is being analyzed for quick detection and response strategies.</data>
      <data key="d9">virus variant</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.351 Variant" target="Remdesivir">
      <data key="d7">2.0</data>
      <data key="d8">Remdesivir's effectiveness was tested against the B.1.351 variant and its mutations in the polymerase.&lt;SEP&gt;Remdesivir is also effective against the B.1.351 variant due to the conservation of the RdRP sequence.</data>
      <data key="d9">antiviral target,efficacy assessment,treatment effectiveness,variant impact</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.351 Variant" target="NSP12">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.351 variant exhibited mutations in the spike protein but conserved NSP12 functionality.</data>
      <data key="d9">mutation analysis,protein conservation</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.351 Variant" target="BNT162b2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The BNT162b2 vaccine's effectiveness against the B.1.351 variant was also studied.</data>
      <data key="d9">vaccine assessment,variant effectiveness</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="SARS-CoV-2 Variants">
      <data key="d7">2.0</data>
      <data key="d8">SARS-CoV-2 variants may challenge the effectiveness of Molnupiravir as an antiviral treatment.&lt;SEP&gt;Molnupiravir functions by misdirecting the viral polymerase during replication among SARS-CoV-2 variants.</data>
      <data key="d9">drug action,treatment challenges,vaccine resistance,viral replication</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="SARS-CoV-2">
      <data key="d7">3.0</data>
      <data key="d8">Molnupiravir targets the viral polymerase of SARS-CoV-2 during replication.&lt;SEP&gt;Molnupiravir promotes mutagenesis of SARS-CoV-2, impacting its evolution.&lt;SEP&gt;Molnupiravir induces mutagenesis in SARS-CoV-2, making it a significant therapeutic candidate.</data>
      <data key="d9">antiviral mechanism,antiviral treatment,therapeutic application,viral mutagenesis,viral mutation,viral replication</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791296</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="Gordon CJ">
      <data key="d7">1.0</data>
      <data key="d8">Gordon CJ is a notable author of studies regarding Molnupiravir and SARS-CoV-2 mutations.</data>
      <data key="d9">research contribution,study author</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="J Biological Chemistry">
      <data key="d7">1.0</data>
      <data key="d8">Research on Molnupiravir's effects on SARS-CoV-2 was published in the J Biological Chemistry.</data>
      <data key="d9">article publication,research findings</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="Nature Structural &amp; Molecular Biology">
      <data key="d7">1.0</data>
      <data key="d8">The mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis was discussed in Nature Structural &amp; Molecular Biology.</data>
      <data key="d9">mechanism elucidation,research article</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="RNA-Dependent RNA Polymerase">
      <data key="d7">1.0</data>
      <data key="d8">Molnupiravir functions by targeting RNA-Dependent RNA Polymerase during viral replication.</data>
      <data key="d9">antiviral mechanism,target interaction</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Molnupiravir" target="Kabinger F">
      <data key="d7">1.0</data>
      <data key="d8">Kabinger F contributed to understanding how molnupiravir induces mutagenesis in SARS-CoV-2.</data>
      <data key="d9">mechanism study,research contribution</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Paxlovid" target="SARS-CoV-2 Variants">
      <data key="d7">1.0</data>
      <data key="d8">Paxlovid is reported to remain effective against currently known SARS-CoV-2 variants.</data>
      <data key="d9">efficacy,viral resistance</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791277</data>
      <data key="d13" />
    </edge>
    <edge source="Paxlovid" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">Paxlovid is approved for use against SARS-CoV-2 variants, including the omicron variant.&lt;SEP&gt;Paxlovid is aimed at treating COVID-19 caused by SARS-CoV-2 during the Omicron variant spread.</data>
      <data key="d9">COVID-19 treatment,FDA approval,antiviral efficacy,viral treatment</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="Paxlovid" target="Sheahan TP">
      <data key="d7">1.0</data>
      <data key="d8">Sheahan TP investigated the effects of Paxlovid on SARS-CoV-2 infected cultures.</data>
      <data key="d9">antiviral study,research focus</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccines" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">COVID-19 vaccines are crucial for preventing infection with the SARS-CoV-2 virus.</data>
      <data key="d9">prevention,vaccination</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791277</data>
      <data key="d13" />
    </edge>
    <edge source="RNA-Dependent RNA Polymerase" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">RNA-Dependent RNA Polymerase is essential for the replication of the SARS-CoV-2 virus.&lt;SEP&gt;SARS-CoV-2 utilizes RNA-Dependent RNA Polymerase for its replication, which is a critical target for antiviral treatments.</data>
      <data key="d9">enzyme function,target interaction,viral mechanism,viral replication</data>
      <data key="d10">chunk-51f69829efd648a30ff1473dea354390&lt;SEP&gt;chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="RNA-Dependent RNA Polymerase" target="Remdesivir">
      <data key="d7">1.0</data>
      <data key="d8">Remdesivir targets RNA-Dependent RNA Polymerase in the SARS-CoV-2 treatment process.</data>
      <data key="d9">antiviral mechanism,target interaction</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Omicron Variant" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">The Omicron variant represents a specific version of SARS-CoV-2 that requires targeted detection methods.&lt;SEP&gt;SARS-CoV-2 includes the Omicron variant as one of its notable mutations requiring detection methods.</data>
      <data key="d9">detection necessity,viral mutation,virus variant</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800&lt;SEP&gt;chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="Omicron Variant" target="PCR Primers">
      <data key="d7">1.0</data>
      <data key="d8">PCR primers are developed specifically for the rapid detection of the Omicron variant's mutations.</data>
      <data key="d9">detection method,specific targeting</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="Omicron Variant" target="Real-Time PCR Technology">
      <data key="d7">1.0</data>
      <data key="d8">The Omicron variant includes key mutations targeted by real-time PCR technology for rapid detection.</data>
      <data key="d9">detection method,variant evolution</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="PCR Primers" target="VOCs">
      <data key="d7">1.0</data>
      <data key="d8">PCR primers are developed for detecting various VOCs, including specific mutations in the spike protein.</data>
      <data key="d9">detection relevance,specific targeting</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791277</data>
      <data key="d13" />
    </edge>
    <edge source="Multi-Target Assays" target="SARS-CoV-2 Variants">
      <data key="d7">1.0</data>
      <data key="d8">Multi-Target Assays aim to improve the detection of viral mutations among SARS-CoV-2 variants.</data>
      <data key="d9">detection improvement,viral mutation</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="Genome Sequencing" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">Genome sequencing remains the gold standard for detecting and identifying strains of SARS-CoV-2.</data>
      <data key="d9">detection standard,viral identification</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="Loop-Mediated Isothermal Amplification (LAMP)" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">LAMP provides a rapid alternative method for the diagnosis of SARS-CoV-2.</data>
      <data key="d9">diagnostic alternative,viral detection</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">CRISPR assays are a sensitive technology targeting genes of SARS-CoV-2 for detection purposes.</data>
      <data key="d9">detection technology,sensitivity</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="Microarray-Based Technology" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">Microarray-based technology is used for detecting SARS-CoV-2 by quantifying hybridized viral RNA.</data>
      <data key="d9">RNA quantification,viral detection</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791330</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="PCR-Based Tests">
      <data key="d7">1.0</data>
      <data key="d8">PCR-based tests are designed to identify and differentiate between SARS-CoV-2 variants.</data>
      <data key="d9">diagnostic efficiency,strain identification</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="WHO">
      <data key="d7">2.0</data>
      <data key="d8">The World Health Organization provides guidelines for tracking SARS-CoV-2 variants.&lt;SEP&gt;WHO is responsible for tracking SARS-CoV-2 variants.</data>
      <data key="d9">assignment,health organization,public health guidance,virus tracking</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="CDC">
      <data key="d7">2.0</data>
      <data key="d8">The Centers for Disease Control and Prevention offers classifications and definitions for SARS-CoV-2 variants.&lt;SEP&gt;CDC is responsible for defining SARS-CoV-2 variant classifications.</data>
      <data key="d9">assignment,health organization,public health classification,virus tracking</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e&lt;SEP&gt;chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Immunogenicity">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 variants can affect the immunogenicity of the COVID-19 vaccines and their effectiveness.</data>
      <data key="d9">immune response,variant impact</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Diagnostic Methods">
      <data key="d7">1.0</data>
      <data key="d8">The emergence of SARS-CoV-2 variants has created challenges for the effectiveness of existing diagnostic methods.</data>
      <data key="d9">detection challenge,virus characteristic</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Molecular Testing">
      <data key="d7">1.0</data>
      <data key="d8">The detection of SARS-CoV-2 variants often relies on molecular testing techniques, which must adapt to variant changes.</data>
      <data key="d9">detection challenges,testing method</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Antigen Testing">
      <data key="d7">1.0</data>
      <data key="d8">Antigen testing is affected by the presence of different SARS-CoV-2 variants, influencing its reliability.</data>
      <data key="d9">testing method,variant detection</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Serological Testing">
      <data key="d7">1.0</data>
      <data key="d8">Serological testing may reflect varying responses against different SARS-CoV-2 variants in individuals.</data>
      <data key="d9">immune response,testing method</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Remdesivir">
      <data key="d7">1.0</data>
      <data key="d8">The presence of SARS-CoV-2 variants raises concerns about the effectiveness of Remdesivir against the virus.</data>
      <data key="d9">antiviral effectiveness,evolving threats</data>
      <data key="d10">chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Variants" target="Reverse Transcriptase PCR Melting-Temperature Assay">
      <data key="d7">1.0</data>
      <data key="d8">The reverse transcriptase melting-temperature assay is effective in rapidly screening for circulating SARS-CoV-2 variants.</data>
      <data key="d9">screening method,variant detection</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="Ding Y">
      <data key="d7">1.0</data>
      <data key="d8">Ding Y is an author who contributed to the clinical pathology report related to Severe Acute Respiratory Syndrome caused by SARS-CoV.</data>
      <data key="d9">research contribution,study authorship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="ACE2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV requires ACE2 to enter host cells, demonstrating the importance of this receptor in viral infection.</data>
      <data key="d9">infection mechanism,viral entry</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="SARS-CoV-2">
      <data key="d7">3.0</data>
      <data key="d8">SARS-CoV-2 and SARS-CoV are related viruses within the same coronavirus family, sharing similar characteristics and outbreak histories.&lt;SEP&gt;SARS-CoV and SARS-CoV-2 are both known to enter and infect host cells, indicating their relatedness in terms of viral properties.&lt;SEP&gt;SARS-CoV-2 is compared to SARS-CoV as both are zoonotic coronaviruses causing respiratory illnesses.</data>
      <data key="d9">comparative analysis,infectious disease,related virus,viral comparison,viral lineage,virus history</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="Colonic Cells">
      <data key="d7">1.0</data>
      <data key="d8">Research showed that SARS-CoV can persistently infect colonic cells, demonstrating its ability to affect various cell types.</data>
      <data key="d9">infection study,virus behavior</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="China">
      <data key="d7">1.0</data>
      <data key="d8">China has been a significant location for conducting research and case studies on SARS and coronaviruses.</data>
      <data key="d9">clinical observation,research location</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="MIG">
      <data key="d7">1.0</data>
      <data key="d8">The chemokine MIG may play a role in the immune response and pathogenesis of SARS-CoV infections.</data>
      <data key="d9">immune response,pathogenesis</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="Severe Acute Respiratory Syndrome (SARS)">
      <data key="d7">1.0</data>
      <data key="d8">SARS is caused by the SARS-CoV virus, leading to significant health implications and clinical concerns.</data>
      <data key="d9">disease relationship,viral cause</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV" target="Central Nervous System (CNS)">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV is known to enter the CNS, demonstrating its neuro-invasive capabilities.</data>
      <data key="d9">neuro-invasion,viral infection</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="MERS-CoV" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">SARS-CoV-2 and MERS-CoV are both zoonotic coronaviruses known to cause respiratory syndromes in humans.&lt;SEP&gt;SARS-CoV-2 can be analyzed alongside MERS-CoV to gain insights into the behavior of coronaviruses.</data>
      <data key="d9">comparative analysis,related virus,viral lineage,virus history</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="MERS-CoV" target="Central Nervous System (CNS)">
      <data key="d7">1.0</data>
      <data key="d8">MERS-CoV can also enter the CNS, indicating potential neuro-invasive properties similar to those of SARS-CoV-2.</data>
      <data key="d9">neuro-invasion,viral infection</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="ACE2" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 enters host cells through the ACE2 receptor, highlighting its role in viral infection.</data>
      <data key="d9">receptor interaction,viral infection</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Pandemic" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 is the causative agent of the COVID-19 pandemic, leading to serious global health concerns.</data>
      <data key="d9">global crisis,public health impact</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Pandemic" target="Healthcare Workers">
      <data key="d7">1.0</data>
      <data key="d8">Healthcare workers face significant risks of infection from the COVID-19 pandemic due to high transmission rates in medical settings.</data>
      <data key="d9">infection risk,transmission</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Pandemic" target="Neurologic Symptoms">
      <data key="d7">1.0</data>
      <data key="d8">Neurologic symptoms such as headaches and nausea have been reported in COVID-19 patients, highlighting health implications of the pandemic.</data>
      <data key="d9">health implications,symptom identification</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Pandemic" target="Acute Cerebrovascular Disease">
      <data key="d7">1.0</data>
      <data key="d8">Acute cerebrovascular disease is one of the serious neurologic manifestations observed in severe cases of COVID-19.</data>
      <data key="d9">clinical manifestation,severe condition</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Pandemic" target="FDA">
      <data key="d7">1.0</data>
      <data key="d8">The COVID-19 pandemic prompted the FDA to authorize COVID-19 vaccines for emergency use to address the health crisis.</data>
      <data key="d9">public health response,vaccine authorization</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="Central Nervous System" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 has shown the potential to invade the Central Nervous System, paralleling prior behaviors of related coronaviruses.</data>
      <data key="d9">neuro-invasion,respiratory illness</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791280</data>
      <data key="d13" />
    </edge>
    <edge source="Healthcare Workers" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">Healthcare Workers are at risk of SARS-CoV-2 infection, especially in settings where human-to-human transmission is common.</data>
      <data key="d9">infection risk,transmission</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="Qatar National Library" target="Authors of the Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">The authors of the manuscript acknowledge the Qatar National Library for its support in the publication process.</data>
      <data key="d9">manuscript development,publication support</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791278</data>
      <data key="d13" />
    </edge>
    <edge source="Qatar National Library" target="Funding">
      <data key="d7">1.0</data>
      <data key="d8">The funding for the publication was provided by the Qatar National Library.</data>
      <data key="d9">financial support,publication</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="Qatar National Library" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">The Qatar National Library supports the publication of the manuscript through funding.</data>
      <data key="d9">funding,support</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="Medullary Neurons" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 has the potential to invade medullary neurons, potentially leading to neurological damage.</data>
      <data key="d9">neuro-invasion,potential damage</data>
      <data key="d10">chunk-0a60b0692db3daf8de021fda40a42927</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="Neurologic Symptoms" target="COVID-19">
      <data key="d7">1.0</data>
      <data key="d8">Neurologic Symptoms such as headaches and impaired consciousness are manifestations of COVID-19.</data>
      <data key="d9">clinical manifestation,disease symptoms</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7" target="Spike Protein Substitutions">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.1.7 variant exhibits specific spike protein substitutions impacting transmissibility.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791279</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7" target="NVX-CoV2373">
      <data key="d7">1.0</data>
      <data key="d8">NVX-CoV2373 has shown strong efficacy against the B.1.1.7 variant of SARS-CoV-2.</data>
      <data key="d9">efficacy testing,variant response</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.7" target="Transmissibility">
      <data key="d7">1.0</data>
      <data key="d8">Transmissibility of the B.1.1.7 variant is noted to be 50% higher than earlier strains.</data>
      <data key="d9">variant impact,virus characteristics</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.351" target="Spike Protein Substitutions">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.351 variant also features significant spike protein substitutions affecting severity.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791280</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.351" target="Severity">
      <data key="d7">1.0</data>
      <data key="d8">The severity associated with the B.1.351 variant has implications for treatment strategies.</data>
      <data key="d9">health outcome,variant impact</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="P.1" target="Spike Protein Substitutions">
      <data key="d7">1.0</data>
      <data key="d8">P.1 variant has its own key spike protein substitutions pertinent to its characteristics.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791280</data>
      <data key="d13" />
    </edge>
    <edge source="P.1" target="Transmissibility">
      <data key="d7">1.0</data>
      <data key="d8">The P.1 variant shows significant transmissibility traits affecting its spread.</data>
      <data key="d9">variant impact,virus characteristics</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="COVID-19">
      <data key="d7">3.0</data>
      <data key="d8">Remdesivir is used as an antiviral treatment for managing COVID-19 symptoms in patients with pneumonia.&lt;SEP&gt;Remdesivir is approved for treating COVID-19 patients, particularly those with pneumonia.&lt;SEP&gt;Remdesivir is recognized for its ability to manage viral loads in patients suffering from COVID-19.</data>
      <data key="d9">antiviral,treatment,viral load control</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781&lt;SEP&gt;chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="FDA">
      <data key="d7">1.0</data>
      <data key="d8">Remdesivir gained FDA approval for the treatment of patients with COVID-19 pneumonia.</data>
      <data key="d9">approval,regulatory process</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="Efficacy of SARS-CoV-2 Antiviral Drugs">
      <data key="d7">1.0</data>
      <data key="d8">The efficacy of SARS-CoV-2 antiviral drugs like Remdesivir is assessed against various new variants of the virus.</data>
      <data key="d9">drug evaluation,treatment effectiveness</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">Remdesivir is reported to face resistance from certain variants of SARS-CoV-2.&lt;SEP&gt;SARS-CoV-2 has minimal resistance to Remdesivir, indicating its effectiveness as a treatment option.</data>
      <data key="d9">antiviral therapy,antiviral treatment,resistance,viral resistance</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="2019-new Coronavirus">
      <data key="d7">1.0</data>
      <data key="d8">Remdesivir is studied as a treatment option for patients infected with the 2019-new coronavirus.</data>
      <data key="d9">antiviral research,drug treatment</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="Remdesivir" target="RNA-Dependent RNA Polymerase (RdRP)">
      <data key="d7">1.0</data>
      <data key="d8">Remdesivir targets RNA-Dependent RNA Polymerase (RdRP) to inhibit SARS-CoV-2 replication.</data>
      <data key="d9">antiviral mechanism,target interaction</data>
      <data key="d10">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.617.2" target="Spike Protein Substitutions">
      <data key="d7">1.0</data>
      <data key="d8">B.1.617.2 variant includes noteworthy spike protein mutations influencing transmissibility.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791280</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.529" target="Spike Protein Substitutions">
      <data key="d7">1.0</data>
      <data key="d8">B.1.1.529 variant features key spike protein substitutions that may influence immune responses.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.1.529" target="Antibody Treatments">
      <data key="d7">1.0</data>
      <data key="d8">The effectiveness of antibody treatments against the B.1.1.529 variant may vary due to its mutations.</data>
      <data key="d9">treatment effectiveness,variant impact</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="Spike Protein Substitutions" target="B.1.525">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.525 variant exhibits spike protein substitutions that influence transmissibility.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="Spike Protein Substitutions" target="B.1.526">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.526 variant features specific spike protein substitutions related to its characteristics.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="Spike Protein Substitutions" target="B.1.617.1">
      <data key="d7">1.0</data>
      <data key="d8">The B.1.617.1 variant contains significant spike protein substitutions affecting immune response.</data>
      <data key="d9">mutation overview,variant impact</data>
      <data key="d10">chunk-011e180e8a15a1d31d1e61e1c124eb17</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="E484K" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">E484K is a mutation found in SARS-CoV-2 that affects vaccine and post-infection antibody responses.&lt;SEP&gt;The E484K mutation represents an evolutionary adaptation of SARS-CoV-2 that may affect vaccine efficacy.</data>
      <data key="d9">antibody response,evolutionary adaptation,mutation characteristic,mutation impact</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="N501Y" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">N501Y is a mutation in SARS-CoV-2 that plays a role in the virus's susceptibility to infection.</data>
      <data key="d9">COVID-19,mutation characteristic</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="N501Y" target="D614G">
      <data key="d7">1.0</data>
      <data key="d8">N501Y and D614G are mutations of SARS-CoV-2 that are compared for their implications on susceptibility to infection.</data>
      <data key="d9">infection susceptibility,mutation comparison</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="D614G" target="SARS-CoV-2">
      <data key="d7">2.0</data>
      <data key="d8">D614G is a recognized mutation in SARS-CoV-2 affecting its behavior and response to treatments.&lt;SEP&gt;The D614G mutation is a spike protein variant that contributes to the characteristics of SARS-CoV-2.</data>
      <data key="d9">COVID-19,mutation characteristic,mutation impact,virus characteristics</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8&lt;SEP&gt;chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="D614G" target="P681H">
      <data key="d7">1.0</data>
      <data key="d8">P681H and D614G are both discussed regarding their impacts on the effectiveness of tests for SARS-CoV-2.</data>
      <data key="d9">test performance,virus mutation</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.525" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">B.1.525 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791282</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.525" target="United Kingdom/Nigeria">
      <data key="d7">1.0</data>
      <data key="d8">B.1.525 is classified as a variant of interest (VOI) originating from the United Kingdom and Nigeria.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.526" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">B.1.526 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.526" target="United States">
      <data key="d7">1.0</data>
      <data key="d8">B.1.526 is classified as a variant of interest (VOI) originating from the United States.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.617.1" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">B.1.617.1 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.617.1" target="India">
      <data key="d7">1.0</data>
      <data key="d8">B.1.617.1 is classified as a variant of interest (VOI) originating from India.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="COVE Study" target="Moderna COVID-19 Vaccine Candidate">
      <data key="d7">1.0</data>
      <data key="d8">The COVE Study evaluated the efficacy of the Moderna COVID-19 vaccine candidate.</data>
      <data key="d9">clinical trial,vaccine evaluation</data>
      <data key="d10">chunk-a74440dec970c1b665115bec7710e2c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791281</data>
      <data key="d13" />
    </edge>
    <edge source="COVE Study" target="Moderna COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The Moderna COVID-19 Vaccine was evaluated in the COVE Study, which assessed its efficacy.</data>
      <data key="d9">clinical trial,vaccine evaluation</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="C.37" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">C.37 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="C.37" target="Peru">
      <data key="d7">1.0</data>
      <data key="d8">C.37 is classified as a variant of interest (VOI) originating from Peru.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.621" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">B.1.621 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="B.1.621" target="Colombia">
      <data key="d7">1.0</data>
      <data key="d8">B.1.621 is classified as a variant of interest (VOI) originating from Colombia.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="P.3" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">P.3 is classified as a Variant of Interest related to SARS-CoV-2.</data>
      <data key="d9">COVID-19,variant classification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="P.3" target="Philippines">
      <data key="d7">1.0</data>
      <data key="d8">P.3 is classified as a variant of interest (VOI) originating from the Philippines.</data>
      <data key="d9">origin,variant classification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="Nucleic Acid-Based Detection" target="Nasopharyngeal Swab">
      <data key="d7">1.0</data>
      <data key="d8">Nasopharyngeal swab samples are the most reliable for nucleic acid-based detection of SARS-CoV-2 infection.</data>
      <data key="d9">detection method,sample reliability</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791283</data>
      <data key="d13" />
    </edge>
    <edge source="Nucleic Acid-Based Detection" target="Real-Time PCR Technology">
      <data key="d7">1.0</data>
      <data key="d8">Real-time PCR technology is used for nucleic acid-based detection of SARS-CoV-2.</data>
      <data key="d9">detection method,viral identification</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791284</data>
      <data key="d13" />
    </edge>
    <edge source="Nucleic Acid-Based Detection" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">Nucleic acid-based detection is used for identifying SARS-CoV-2 infections.</data>
      <data key="d9">detection method,virus identification</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="Nasopharyngeal Swab" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">Nasopharyngeal swabs are one of the most reliable sources for detecting SARS-CoV-2 due to their high sensitivity.</data>
      <data key="d9">detection method,sample source</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791315</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="SARS-CoV-2">
      <data key="d7">5.0</data>
      <data key="d8">SARS-CoV-2 is the virus responsible for causing the disease COVID-19.&lt;SEP&gt;COVID-19 is caused by the SARS-CoV-2 virus, necessitating vaccine development.&lt;SEP&gt;SARS-CoV-2 is responsible for causing the disease COVID-19, leading to a wide range of clinical symptoms.&lt;SEP&gt;COVID-19 is caused by the SARS-CoV-2 virus.&lt;SEP&gt;COVID-19 is caused by the SARS-CoV-2 virus highlighted in several studies.</data>
      <data key="d9">causal relationship,causation,disease,disease causation,viral infection,viral outbreak,virus,virus-disease relationship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e&lt;SEP&gt;chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2&lt;SEP&gt;chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="mRNA-1273 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The mRNA-1273 vaccine's effectiveness against COVID-19 variants is under study to determine its immunogenic potential.</data>
      <data key="d9">immune response,research</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="BNT162b2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The BNT162b2 vaccine is reported to provide strong protection against COVID-19, reflecting its effectiveness amid circulating variants.</data>
      <data key="d9">immune response,vaccine effectiveness</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="World Health Organization">
      <data key="d7">2.0</data>
      <data key="d8">The World Health Organization officially named the viral illness caused by SARS-CoV-2 as COVID-19.&lt;SEP&gt;The World Health Organization formally named the viral illness COVID-19.</data>
      <data key="d9">disease naming,health organization action,naming authority,public health response</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="FDA">
      <data key="d7">2.0</data>
      <data key="d8">The FDA monitors and reports suspected adverse reactions to COVID-19 vaccines.&lt;SEP&gt;The FDA oversees COVID-19 vaccine regulations and reports on adverse reactions.</data>
      <data key="d9">health reporting,regulatory oversight,safety monitoring,vaccine response</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="UAE Ministry of Health">
      <data key="d7">2.0</data>
      <data key="d8">The UAE Ministry of Health publicly announced the efficacy of a COVID-19 vaccine, indicating its role in combating the pandemic.&lt;SEP&gt;The UAE Ministry of Health is involved in the COVID-19 health response by reporting vaccine efficacy.</data>
      <data key="d9">health response,public health,vaccine efficacy announcement,vaccine reporting</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Lopinavir">
      <data key="d7">3.0</data>
      <data key="d8">Lopinavir has been evaluated for its potential therapeutic benefits against COVID-19.&lt;SEP&gt;Lopinavir was evaluated for its therapeutic potential against COVID-19 symptoms.&lt;SEP&gt;Lopinavir was evaluated for COVID-19 treatment and found ineffective, leading to its discrediting.</data>
      <data key="d9">antiviral,discrediting,evaluation,therapeutic potential,therapeutic research</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Ritonavir">
      <data key="d7">2.0</data>
      <data key="d8">Ritonavir has been assessed for possible improvements in symptoms of COVID-19 patients.&lt;SEP&gt;Ritonavir was assessed alongside Lopinavir and showed limited effectiveness in COVID-19 treatment.</data>
      <data key="d9">antiviral,discrediting,therapeutic potential,therapeutic research</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Chloroquine">
      <data key="d7">1.0</data>
      <data key="d8">Chloroquine's effectiveness against COVID-19 has been analyzed in several studies.</data>
      <data key="d9">antiviral,therapeutic evaluation</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Tocilizumab">
      <data key="d7">2.0</data>
      <data key="d8">Tocilizumab is used as an immunotherapy drug for treating severe COVID-19 symptoms related to cytokine storms.&lt;SEP&gt;Tocilizumab was repurposed for treating COVID-19 to manage the cytokine storm in severe cases.</data>
      <data key="d9">cytokine storm,immunotherapy,repurposed treatment</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Sarilumab">
      <data key="d7">2.0</data>
      <data key="d8">Sarilumab is repurposed for use against COVID-19, showing benefits for severe patients.&lt;SEP&gt;Sarilumab was similarly repurposed as an anti-inflammatory treatment for severe COVID-19 infections.</data>
      <data key="d9">cytokine storm,immunotherapy,repurposed treatment</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Neurological Manifestations">
      <data key="d7">1.0</data>
      <data key="d8">Neurological manifestations have been observed in hospitalized patients with COVID-19, affecting their health outcomes.</data>
      <data key="d9">health impact,symptomatology</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Public Health Emergency">
      <data key="d7">1.0</data>
      <data key="d8">COVID-19 is classified as a Public Health Emergency due to its high transmissibility and worldwide impact.</data>
      <data key="d9">global crisis,transmissibility</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="REGEN-COV">
      <data key="d7">1.0</data>
      <data key="d8">REGEN-COV has demonstrated efficacy in reducing hospitalization or death in non-hospitalized COVID-19 patients.</data>
      <data key="d9">efficacy,treatment</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Reports of Suspected Adverse Reaction">
      <data key="d7">1.0</data>
      <data key="d8">Reports of suspected adverse reactions are documents that detail safety issues associated with COVID-19 vaccines.</data>
      <data key="d9">safety reporting,vaccine monitoring</data>
      <data key="d10">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="Randomised Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Randomised clinical trials are critical methods used to study the efficacy of vaccines against COVID-19.</data>
      <data key="d9">research methodology,vaccine research</data>
      <data key="d10">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="LAMP Assays">
      <data key="d7">1.0</data>
      <data key="d8">LAMP assays provide a rapid diagnostic method for detecting COVID-19.</data>
      <data key="d9">diagnostic method,rapid testing</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19" target="CRISPR-Cas13-based Diagnosis">
      <data key="d7">1.0</data>
      <data key="d8">The CRISPR-Cas13-based method is a rapid innovation for diagnosing COVID-19.</data>
      <data key="d9">diagnostic innovation,rapid testing</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="Real-Time PCR Technology" target="Viral Envelope">
      <data key="d7">1.0</data>
      <data key="d8">Real-Time PCR Technology detects the presence of viral Envelope RNA from SARS-CoV-2.</data>
      <data key="d9">detection method,target</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="Real-Time PCR Technology" target="Nucleocapsid">
      <data key="d7">1.0</data>
      <data key="d8">Real-Time PCR Technology also targets the Nucleocapsid for detection of SARS-CoV-2 RNA.</data>
      <data key="d9">detection method,target</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="P681H" target="SARS-CoV-2">
      <data key="d7">1.0</data>
      <data key="d8">P681H is a mutation in SARS-CoV-2 known for its influence on transmission rates.</data>
      <data key="d9">mutation characteristic,transmissibility</data>
      <data key="d10">chunk-b494139a91f9118736292a4317ea00c8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="Interleukin-6 Receptor Antagonists">
      <data key="d7">1.0</data>
      <data key="d8">Tocilizumab is an example of an interleukin-6 receptor antagonist used in treating critically ill COVID-19 patients.</data>
      <data key="d9">medication class,treatment approach</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="REMAP-CAP">
      <data key="d7">1.0</data>
      <data key="d8">Tocilizumab improved survival rates in patients according to findings from the REMAP-CAP study.</data>
      <data key="d9">clinical trial,survival rates</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="FDA">
      <data key="d7">1.0</data>
      <data key="d8">Tocilizumab received FDA approval for use as an immunotherapy against severe COVID-19 symptomatology.</data>
      <data key="d9">approval,regulatory process</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="COVINTOC">
      <data key="d7">2.0</data>
      <data key="d8">Tocilizumab is studied in the COVINTOC trial for its effects on cytokine release syndrome in COVID-19 patients.&lt;SEP&gt;Tocilizumab is being evaluated in the COVINTOC trial for its effectiveness in treating COVID-19 cytokine release syndrome.</data>
      <data key="d9">COVID-19 cytokine release,clinical trial,research involvement,treatment evaluation</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b&lt;SEP&gt;chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="Remap-Cap">
      <data key="d7">1.0</data>
      <data key="d8">Remap-Cap trial evaluated the effectiveness of Tocilizumab for improving outcomes in Covid-19 patients.</data>
      <data key="d9">clinical trial,treatment evaluation</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="India">
      <data key="d7">1.0</data>
      <data key="d8">Tocilizumab is being studied in India within the context of the COVINTOC trial for COVID-19 treatment.</data>
      <data key="d9">regional trial,treatment context</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="Pharm J">
      <data key="d7">1.0</data>
      <data key="d8">Pharm J recommends considering tocilizumab in the treatment of hospitalized COVID-19 patients.</data>
      <data key="d9">clinical guidance,treatment recommendation</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="Clin Drug Investig">
      <data key="d7">1.0</data>
      <data key="d8">Clin Drug Investig outlines the rational use of tocilizumab for COVID-19 pneumonia treatment.</data>
      <data key="d9">publication support,rational treatment</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Tocilizumab" target="REMAP-CAP Trial">
      <data key="d7">1.0</data>
      <data key="d8">The REMAP-CAP trial demonstrated that Tocilizumab improved survival rates in hospitalized COVID-19 patients.</data>
      <data key="d9">clinical evaluation,survival improvement</data>
      <data key="d10">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="COVINTOC" target="Soin AS">
      <data key="d7">1.0</data>
      <data key="d8">Soin AS is involved as an author in the COVINTOC trial focusing on tocilizumab treatment for COVID-19.</data>
      <data key="d9">author involvement,clinical research</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="COVINTOC" target="Kumar K">
      <data key="d7">1.0</data>
      <data key="d8">Kumar K contributed as an author to the COVINTOC trial assessing the efficacy of tocilizumab.</data>
      <data key="d9">author involvement,clinical research</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="COVINTOC" target="Choudhary NS">
      <data key="d7">1.0</data>
      <data key="d8">Choudhary NS participated as an author in the COVINTOC trial for COVID-19 treatment.</data>
      <data key="d9">author involvement,clinical research</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Zhang S" target="Clin Drug Investig">
      <data key="d7">1.0</data>
      <data key="d8">Zhang S contributed to the discussion on tocillizumab published in Clin Drug Investig.</data>
      <data key="d9">publication contribution,research dissemination</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="REGEN-COV" target="FDA">
      <data key="d7">2.0</data>
      <data key="d8">The FDA approved REGEN-COV for treating mild to moderate Covid-19 cases in patients.&lt;SEP&gt;REGEN-COV received FDA approval for treating mild to moderate COVID-19 cases in patients at high risk.</data>
      <data key="d9">approval,therapy,treatment authorization</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="REGEN-COV" target="Imdevimab">
      <data key="d7">2.0</data>
      <data key="d8">Imdevimab is included in REGEN-COV, assisting in treatment efficacy against Covid-19.&lt;SEP&gt;Imdevimab is also part of the REGEN-COV monoclonal antibody cocktail designed for treating COVID-19.</data>
      <data key="d9">combination therapy,component,monoclonal antibody cocktail,therapeutic effect</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="REGEN-COV" target="Casirivimab">
      <data key="d7">2.0</data>
      <data key="d8">Casirivimab is a component of REGEN-COV, which helps reduce hospitalizations in Covid-19 patients.&lt;SEP&gt;Casirivimab is a key component of the monoclonal antibody cocktail REGEN-COV for COVID-19 treatment.</data>
      <data key="d9">combination therapy,component,monoclonal antibody cocktail,therapeutic effect</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="Gordon CJ" target="J Biol Chem">
      <data key="d7">1.0</data>
      <data key="d8">Gordon CJ contributed to research published in J Biol Chem regarding the mutagenesis of SARS-CoV-2.</data>
      <data key="d9">publication contribution,research dissemination</data>
      <data key="d10">chunk-ce5654da6d9426c044b695106c4aa2b8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791285</data>
      <data key="d13" />
    </edge>
    <edge source="FDA" target="BNT162b2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The FDA granted authorization for the BNT162b2 vaccine for use in adolescents, ensuring regulatory compliance and safety.</data>
      <data key="d9">authorization,regulation</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="FDA" target="Pfizer-BioNTech COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The FDA authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use to combat the pandemic.</data>
      <data key="d9">emergency use,vaccine authorization</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="FDA" target="CoronaVac">
      <data key="d7">1.0</data>
      <data key="d8">The FDA is responsible for evaluating the safety and efficacy of the CoronaVac vaccine before approval.</data>
      <data key="d9">safety evaluation,vaccine regulation</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273 Vaccine" target="Phase I Clinical Trial">
      <data key="d7">1.0</data>
      <data key="d8">The mRNA-1273 vaccine is tested in a Phase I clinical trial to evaluate its immune response and safety among participants.</data>
      <data key="d9">immune response,testing</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273 Vaccine" target="COVID-19 mRNA Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">The mRNA-1273 vaccine is classified as a COVID-19 mRNA vaccine, which aims to provide an immune response against the virus.</data>
      <data key="d9">immune strategy,vaccine category</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 Vaccine" target="India Variant (B.1.617.2)">
      <data key="d7">1.0</data>
      <data key="d8">The emergence of the India variant has led to a reduction in the effectiveness of the BNT162b2 vaccine to 87.9%.</data>
      <data key="d9">effectiveness,variant impact</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 Vaccine" target="COVID-19 mRNA Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">The BNT162b2 vaccine is also categorized under COVID-19 mRNA vaccines, targeting similar immune responses against the virus.</data>
      <data key="d9">immune strategy,vaccine category</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 Vaccine" target="Health Care Personnel">
      <data key="d7">1.0</data>
      <data key="d8">The effectiveness of the BNT162b2 vaccine was estimated among health care personnel in a study.</data>
      <data key="d9">study group,vaccine effectiveness</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 Vaccine" target="B.1.617.2 (Delta) Variant">
      <data key="d7">1.0</data>
      <data key="d8">The BNT162b2 vaccine's effectiveness against the B.1.617.2 (Delta) variant was evaluated in subsequent studies.</data>
      <data key="d9">vaccine assessment,variant effectiveness</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791319</data>
      <data key="d13" />
    </edge>
    <edge source="Phase I Clinical Trial" target="COVID-19 Vaccine (Vero Cell) Inactivated">
      <data key="d7">1.0</data>
      <data key="d8">Phase I Clinical Trial evaluated the safety of the COVID-19 Vaccine (Vero Cell) Inactivated in 144 healthy participants.</data>
      <data key="d9">initial testing,safety evaluation</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="Inactivated Virus Vaccines" target="Live Attenuated Virus Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Inactivated virus vaccines are considered safer compared to live attenuated virus vaccines, which may revert to pathogenic forms.</data>
      <data key="d9">safety,vaccine strategy</data>
      <data key="d10">chunk-2415f0ecad61f32f0f796518d46fff67</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Inactivated Virus Vaccines" target="WHO">
      <data key="d7">1.0</data>
      <data key="d8">WHO monitors the development and clinical phases of inactivated virus vaccines for COVID-19.</data>
      <data key="d9">clinical phase,vaccine oversight</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Cui J" target="Nat Rev Microbiol">
      <data key="d7">1.0</data>
      <data key="d8">Cui J is one of the authors of the research published in Nat Rev Microbiol regarding pathogenic coronaviruses.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Cui J" target="Shi ZL">
      <data key="d7">1.0</data>
      <data key="d8">Cui J and Shi ZL collaborated on research regarding the origin and evolution of pathogenic coronaviruses.</data>
      <data key="d9">co-authorship,coronavirus research</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Li F" target="Nat Rev Microbiol">
      <data key="d7">1.0</data>
      <data key="d8">Li F is a co-author of the research on pathogenic coronaviruses published in Nat Rev Microbiol.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Shi ZL" target="Nat Rev Microbiol">
      <data key="d7">1.0</data>
      <data key="d8">Shi ZL contributed to the research on pathogenic coronaviruses published in Nat Rev Microbiol.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="Chan JF" target="Lancet">
      <data key="d7">1.0</data>
      <data key="d8">Chan JF is an author of the study published in Lancet discussing a pneumonia cluster tied to the 2019 novel coronavirus.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Chan JF" target="Genomic Characterization">
      <data key="d7">1.0</data>
      <data key="d8">Chan JF contributed to the research on genomic characterization of the novel human-pathogenic coronavirus.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="Chan JF" target="Yuan S">
      <data key="d7">1.0</data>
      <data key="d8">Chan JF and Yuan S co-authored a study on pneumonia associated with the novel coronavirus.</data>
      <data key="d9">co-authorship,pneumonia study</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Phan LT" target="Nguyen TV">
      <data key="d7">1.0</data>
      <data key="d8">Phan LT and Nguyen TV collaborated on research regarding human-to-human transmission of the novel coronavirus.</data>
      <data key="d9">co-authorship,coronavirus transmission</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Triveri A">
      <data key="d7">1.0</data>
      <data key="d8">Triveri A is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d9">research contribution,study authorship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Serapian SA">
      <data key="d7">1.0</data>
      <data key="d8">Serapian SA is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d9">research contribution,study authorship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Marchetti F">
      <data key="d7">1.0</data>
      <data key="d8">Marchetti F is an author involved in the study of SARS-CoV-2 spike protein mutations and their escape from antibodies.</data>
      <data key="d9">research contribution,study authorship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791277</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="LAMP">
      <data key="d7">1.0</data>
      <data key="d8">LAMP is considered a reliable and efficient alternative for SARS-CoV-2 detection.</data>
      <data key="d9">diagnostic method,efficiency</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791279</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="CRISPR">
      <data key="d7">1.0</data>
      <data key="d8">CRISPR technology provides a novel method for targeting specific genes of the SARS-CoV-2 virus in diagnostics.</data>
      <data key="d9">diagnostic innovation,gene targeting</data>
      <data key="d10">chunk-ab3e854c0000cad5901402bd6d215800</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791280</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="COVID-19 Variants">
      <data key="d7">2.0</data>
      <data key="d8">SARS-CoV-2 is the virus responsible for the emergence of COVID-19 variants as discussed in the review.&lt;SEP&gt;COVID-19 variants are evolving strains of the SARS-CoV-2 virus that impact diagnosis and vaccine development.</data>
      <data key="d9">disease impact,research focus,virus evolution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5&lt;SEP&gt;chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="NVX-CoV2373">
      <data key="d7">1.0</data>
      <data key="d8">NVX-CoV2373 is designed to provide immunity against the SARS-CoV-2 virus.</data>
      <data key="d9">disease prevention,vaccination target</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791288</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="International Committee on Taxonomy of Viruses">
      <data key="d7">1.0</data>
      <data key="d8">The International Committee on Taxonomy of Viruses formally named SARS-CoV-2 and classified it within the Coronaviridae family.</data>
      <data key="d9">naming,virus classification</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Viral Epidemic">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 is responsible for the viral epidemic and outbreak of COVID-19.</data>
      <data key="d9">cause,outbreak</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Nucleocapsid Protein">
      <data key="d7">2.0</data>
      <data key="d8">Nucleocapsid protein is one of the key structural proteins contributing to the virulence of the SARS-CoV-2 virus.&lt;SEP&gt;The nucleocapsid protein (N) is a key structural component of the SARS-CoV-2 virus that determines its virulence.</data>
      <data key="d9">structural component,virulence,virulence factor</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Membrane Glycoprotein">
      <data key="d7">2.0</data>
      <data key="d8">Membrane glycoprotein is essential for the functionality and virulence of the SARS-CoV-2 virus.&lt;SEP&gt;Membrane glycoprotein (M) is a vital structural component of SARS-CoV-2 that aids in its functionality.</data>
      <data key="d9">functionality,structural component,virulence factor</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Spike Glycoprotein">
      <data key="d7">2.0</data>
      <data key="d8">Spike glycoprotein is pivotal in enabling the SARS-CoV-2 virus to initiate infection in host cells.&lt;SEP&gt;Spike glycoprotein (S) is a critical feature of the SARS-CoV-2 virus that enables it to enter human host cells.</data>
      <data key="d9">cell entry,infection initiation,structural component,structural feature</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4&lt;SEP&gt;chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="PCR Fragment">
      <data key="d7">1.0</data>
      <data key="d8">The PCR fragment is capable of detecting and identifying variants of SARS-CoV-2.</data>
      <data key="d9">detection,identification</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Immuno-Assay">
      <data key="d7">1.0</data>
      <data key="d8">Immuno-assays are utilized for detecting SARS-CoV-2 infections through various assays.</data>
      <data key="d9">detection method,infection identification</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Anti-SARS-CoV-2 Antibody">
      <data key="d7">1.0</data>
      <data key="d8">Anti-SARS-CoV-2 antibodies develop post-infection and are used for detection during later stages.</data>
      <data key="d9">immune response,post-infection detection</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="SARS-CoV-2 Variants of Concern (VOCs)">
      <data key="d7">1.0</data>
      <data key="d8">Monitoring of SARS-CoV-2 is crucial for identifying and addressing the emergence of new variants of concern.</data>
      <data key="d9">monitoring,virus variation</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="ChAdOx1 nCoV-19">
      <data key="d7">1.0</data>
      <data key="d8">The ChAdOx1 nCoV-19 vaccine is being studied for its safety and effectiveness against SARS-CoV-2.</data>
      <data key="d9">safety study,vaccine trial</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Science Translational Medicine">
      <data key="d7">1.0</data>
      <data key="d8">Studies on various antivirals that inhibit SARS-CoV-2 were published in Science Translational Medicine.</data>
      <data key="d9">antiviral research,virus inhibition</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Omicron">
      <data key="d7">1.0</data>
      <data key="d8">Omicron is a novel variant of the SARS-CoV-2 virus that has implications for diagnostics and vaccination.</data>
      <data key="d9">variant emergence,viral mutation</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Spike Protein">
      <data key="d7">2.0</data>
      <data key="d8">SARS-CoV-2 utilizes the spike protein for binding to host cells, making it a key target for vaccine development.&lt;SEP&gt;The spike protein is a critical component that allows SARS-CoV-2 to infect human cells.</data>
      <data key="d9">infection mechanism,vaccine target,viral structure,virus structure</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Acute Respiratory Distress Syndromes">
      <data key="d7">2.0</data>
      <data key="d8">SARS-CoV-2 may lead to Acute Respiratory Distress Syndromes as a severe consequence of infection.&lt;SEP&gt;SARS-CoV-2 infections can lead to Acute Respiratory Distress Syndromes, highlighting the virus's severe health implications.</data>
      <data key="d9">complications,disease outcome,health impact,infection consequence</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Virulence">
      <data key="d7">1.0</data>
      <data key="d8">The virulence of the SARS-CoV-2 virus relates to its ability to cause significant disease in infected individuals.</data>
      <data key="d9">disease severity,pathogenicity</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Diagnostic Methods">
      <data key="d7">1.0</data>
      <data key="d8">The evolution of SARS-CoV-2 variants necessitates advancements in diagnostic methods for accurate detection of infections.</data>
      <data key="d9">infection detection,testing approach</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="ChAdOx1 nCoV-19 Vaccine">
      <data key="d7">2.0</data>
      <data key="d8">The ChAdOx1 nCoV-19 vaccine is developed specifically to provide immunity against SARS-CoV-2.&lt;SEP&gt;The ChAdOx1 nCoV-19 vaccine is designed to elicit an immune response against SARS-CoV-2, aiming to thwart COVID-19.</data>
      <data key="d9">disease prevention,vaccine purpose,vaccine targeting,virus target</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="BBIBP-CorV">
      <data key="d7">2.0</data>
      <data key="d8">BBIBP-CorV provides protection against SARS-CoV-2 by inducing high levels of neutralizing antibodies.&lt;SEP&gt;BBIBP-CorV is specifically developed to provide immunity against the SARS-CoV-2 virus.</data>
      <data key="d9">immunogenicity,protection,vaccine target,virus</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Amino Acid Mutations">
      <data key="d7">1.0</data>
      <data key="d8">The SARS-CoV-2 virus exhibits amino acid mutations that can affect its virulence and transmission properties.</data>
      <data key="d9">mutation impact,viral evolution</data>
      <data key="d10">chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="RBD Region">
      <data key="d7">1.0</data>
      <data key="d8">The RBD region of the SARS-CoV-2 virus is critical for its ability to bind to human cell receptors, influencing infection rates.</data>
      <data key="d9">binding,viral structure</data>
      <data key="d10">chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Gam-COVID-Vac">
      <data key="d7">3.0</data>
      <data key="d8">Gam-COVID-Vac is a vaccine specifically designed to target the SARS-CoV-2 virus.&lt;SEP&gt;Gam-COVID-Vac is developed to specifically combat the SARS-CoV-2 virus.&lt;SEP&gt;Gam-COVID-Vac has been noted to efficiently neutralize the spike protein from SARS-CoV-2 variants.</data>
      <data key="d9">immune response,targeted virus,vaccine development,vaccine effectiveness,vaccine target,viral neutralization</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="La Rosa G">
      <data key="d7">1.0</data>
      <data key="d8">La Rosa G's work focuses on rapid screening for SARS-CoV-2 variants using nested RT-PCR assays.</data>
      <data key="d9">research contribution,variant detection</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Banada P">
      <data key="d7">1.0</data>
      <data key="d8">Banada P's research includes developing assays to rapidly screen for SARS-CoV-2 variants.</data>
      <data key="d9">assay development,variant screening</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="COVID-19 Vaccination">
      <data key="d7">1.0</data>
      <data key="d8">COVID-19 vaccination aims to provide immunity against the SARS-CoV-2 virus.</data>
      <data key="d9">vaccination objective,virus target</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Computational Approaches">
      <data key="d7">1.0</data>
      <data key="d8">Computational approaches are utilized to analyze the impact of SARS-CoV-2 variants on the effectiveness of vaccines.</data>
      <data key="d9">vaccine predictiveness,virus analysis</data>
      <data key="d10">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Transmissibility">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 variants exhibit varying levels of transmissibility among populations.</data>
      <data key="d9">pathogenicity,virus characteristic</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Severity">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 variants affect the severity of illness in infected individuals.</data>
      <data key="d9">health impact,virus characteristic</data>
      <data key="d10">chunk-5cb5916ca321946236db8aad9fa33a94</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="J Phys Chem Lett">
      <data key="d7">1.0</data>
      <data key="d8">J Phys Chem Lett published research on dynamics simulations related to epitope prediction for SARS-CoV-2.</data>
      <data key="d9">epitope prediction,scientific research</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Angiotensin-Converting Enzyme 2 (ACE2)">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 utilizes ACE2 as a receptor to gain entry into human cells.</data>
      <data key="d9">cellular interaction,viral entry</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="SARS-CoV-2 Spike Protein">
      <data key="d7">1.0</data>
      <data key="d8">Monoclonal antibodies target the SARS-CoV-2 spike protein to reduce the virus's ability to evade the immune system.</data>
      <data key="d9">immune response,target interaction</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Sputnik V Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The Sputnik V vaccine demonstrated neutralizing activity against SARS-CoV-2 variants.</data>
      <data key="d9">neutralization,vaccine efficacy</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Central Nervous System (CNS)">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 shows potential to invade the CNS, raising concerns about neurological effects.</data>
      <data key="d9">disease association,neuro-invasion</data>
      <data key="d10">chunk-1c7d4256e04a0834c64b7e62ef5d3416</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="L452R">
      <data key="d7">1.0</data>
      <data key="d8">The L452R mutation in the spike protein of SARS-CoV-2 has implications for treatment resistance to monoclonal antibodies.</data>
      <data key="d9">mutation impact,treatment resistance</data>
      <data key="d10">chunk-dc9977325cdee13a132c8b548d9e9b97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791316</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Antiviral Res">
      <data key="d7">1.0</data>
      <data key="d8">Antiviral Res published research on the genetic conservation of SARS-CoV-2 RNA replication complex.</data>
      <data key="d9">genetic research,viral replication</data>
      <data key="d10">chunk-164002d25ffd9cbe6d0d28236e7610f6</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="COVID-19 vaccines">
      <data key="d7">1.0</data>
      <data key="d8">The purpose of the COVID-19 vaccines, including BNT162b2 and mRNA-1273, is to prevent infection by the SARS-CoV-2 virus.</data>
      <data key="d9">vaccine purpose,virus prevention</data>
      <data key="d10">chunk-ad9d995908432109592f45ab0eade340</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="AZD1222">
      <data key="d7">1.0</data>
      <data key="d8">AZD1222 is developed to combat the SARS-CoV-2 virus.</data>
      <data key="d9">target virus,vaccine development</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Protein Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Protein vaccines are designed to induce an immune response against the SARS-CoV-2 virus.</data>
      <data key="d9">target virus,vaccine design</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Next-Generation Gene Sequencing">
      <data key="d7">1.0</data>
      <data key="d8">Next-Generation Gene Sequencing is employed to detect SARS-CoV-2 and help in understanding its epidemiology.</data>
      <data key="d9">detection method,epidemiological study</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Anti-SARS-CoV-2 Antibody-Based Detection">
      <data key="d7">1.0</data>
      <data key="d8">Anti-SARS-CoV-2 antibody-based detection techniques target antibodies developed against SARS-CoV-2 infection.</data>
      <data key="d9">antibody response,infection detection</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791330</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Enzyme Linked Immunosorbent Assays (ELISA)">
      <data key="d7">1.0</data>
      <data key="d8">Enzyme Linked Immunosorbent Assays (ELISA) are reliable for detecting SARS-CoV-2 infections.</data>
      <data key="d9">assay reliability,infection detection</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791330</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="PCR Melting Temperature Assays">
      <data key="d7">1.0</data>
      <data key="d8">PCR melting temperature assays serve as a quicker alternative for detecting SARS-CoV-2 compared to sequencing methods.</data>
      <data key="d9">detection comparability,sequencing alternative</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="SARS-CoV-2 Antigen">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 Antigens are identified during testing for the presence of the SARS-CoV-2 virus.</data>
      <data key="d9">disease detection,protein identification</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Immunofluorescent Assays">
      <data key="d7">1.0</data>
      <data key="d8">Immunofluorescent Assays are utilized to detect SARS-CoV-2 by identifying specific antigens associated with the virus.</data>
      <data key="d9">antigen detection,diagnostic method</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Immunochromatographic Assays">
      <data key="d7">2.0</data>
      <data key="d8">Immunochromatographic Assays are used for detecting SARS-CoV-2 infections by identifying viral antigens.&lt;SEP&gt;Immunochromatographic assays are used for the detection of antibodies against SARS-CoV-2.</data>
      <data key="d9">antibody testing,antigen detection,detection method,diagnostic method</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb&lt;SEP&gt;chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Chemiluminescent Immunoassays">
      <data key="d7">1.0</data>
      <data key="d8">Chemiluminescent Immunoassays are used to identify SARS-CoV-2 infections by targeting antigens present.</data>
      <data key="d9">antigen detection,diagnostic method</data>
      <data key="d10">chunk-42afc66a510e32c7e7356f907c3ef8fb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Diagnostics">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 is central to the development of diagnostics discussed in the review article.</data>
      <data key="d9">research focus,virus detection</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Al Kaabi N">
      <data key="d7">1.0</data>
      <data key="d8">Al Kaabi N contributed to research on the effectiveness of inactivated SARS-CoV-2 vaccines in clinical trials.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Antibodies">
      <data key="d7">1.0</data>
      <data key="d8">Antibodies are generated specifically in response to the SARS-CoV-2 viral antigens.</data>
      <data key="d9">immunity,viral response</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Chemiluminescence Assays">
      <data key="d7">1.0</data>
      <data key="d8">Chemiluminescence assays are employed to detect antibodies specific to SARS-CoV-2.</data>
      <data key="d9">antibody testing,detection method</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="ELISA">
      <data key="d7">1.0</data>
      <data key="d8">ELISA is utilized to identify antibodies generated against the SARS-CoV-2 antigen.</data>
      <data key="d9">antibody testing,detection method</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Chloroquine">
      <data key="d7">2.0</data>
      <data key="d8">Chloroquine has been reported to show effectiveness against SARS-CoV-2 infections.&lt;SEP&gt;Chloroquine was studied for its potential efficacy against SARS-CoV-2 but lacks conclusive supportive evidence.</data>
      <data key="d9">antiviral effect,efficacy evaluation,evaluation,therapeutic research</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3&lt;SEP&gt;chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Remdesivir Triphosphate">
      <data key="d7">1.0</data>
      <data key="d8">Remdesivir triphosphate resembles RNA of the coronavirus and disrupts viral genome replication.</data>
      <data key="d9">antiviral effect,mechanism of action</data>
      <data key="d10">chunk-2b577370572f3abc47d20a85c1e6bec3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Transplant Recipients">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 presents a risk of breakthrough infections among adult transplant recipients.</data>
      <data key="d9">clinical concern,infection risk</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="new variants">
      <data key="d7">1.0</data>
      <data key="d8">The emergence of new SARS-CoV-2 variants necessitates ongoing evaluation of treatment efficacy and adaptations in therapy.</data>
      <data key="d9">treatment evaluation,variant emergence</data>
      <data key="d10">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Vaccines are developed to provide immunity against SARS-CoV-2 and its variants, raising efficacy questions amid variant emergence.</data>
      <data key="d9">efficacy,immunization</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2" target="COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">SARS-CoV-2 is the target virus for COVID-19 vaccines, which aim to generate an immune response against it.</data>
      <data key="d9">vaccine efficacy,viral target</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791340</data>
      <data key="d13" />
    </edge>
    <edge source="Wang D" target="JAMA">
      <data key="d7">1.0</data>
      <data key="d8">Wang D authored the research regarding clinical characteristics of patients with pneumonia caused by the 2019 novel coronavirus, published in JAMA.</data>
      <data key="d9">author contribution,research publication</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791286</data>
      <data key="d13" />
    </edge>
    <edge source="Wang D" target="Hu B">
      <data key="d7">1.0</data>
      <data key="d8">Wang D and Hu B co-authored research on the clinical characteristics of COVID-19 patients in Wuhan.</data>
      <data key="d9">COVID-19 study,co-authorship</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791317</data>
      <data key="d13" />
    </edge>
    <edge source="Wang D" target="138 Hospitalized Patients">
      <data key="d7">1.0</data>
      <data key="d8">Wang D conducted research on the clinical characteristics of 138 hospitalized patients with COVID-19 in Wuhan.</data>
      <data key="d9">clinical research,patient study</data>
      <data key="d10">chunk-aca59a50b858aa1e41e7e9acf7e566d2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Variants" target="Diagnostics">
      <data key="d7">1.0</data>
      <data key="d8">Emerging COVID-19 variants pose challenges to diagnostics as discussed in the review.</data>
      <data key="d9">challenge,research focus</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Dina Moustafa Abo El-Ella" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Dina Moustafa Abo El-Ella is affiliated with the Translational Cancer Research Facility and is involved in research on COVID-19.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="Dina Moustafa Abo El-Ella" target="National Center for Cancer Care and Research">
      <data key="d7">1.0</data>
      <data key="d8">Dina Moustafa Abo El-Ella contributes to research efforts at the National Center for Cancer Care and Research on COVID-19.</data>
      <data key="d9">authorship,research contribution</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Takwa Bedhiafi" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Takwa Bedhiafi is a co-author associated with the research at the Translational Cancer Research Facility focusing on COVID-19 variants.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791288</data>
      <data key="d13" />
    </edge>
    <edge source="Takwa Bedhiafi" target="Hamad Medical Corporation">
      <data key="d7">1.0</data>
      <data key="d8">Takwa Bedhiafi is associated with Hamad Medical Corporation and contributes to research on COVID-19.</data>
      <data key="d9">authorship,research contribution</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="Afsheen Raza" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Afsheen Raza is a co-author working at the Translational Cancer Research Facility, contributing to COVID-19 research.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="Mariam Ali Yousuf Al-Nesf" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Mariam Ali Yousuf Al-Nesf is affiliated with the Translational Cancer Research Facility, contributing to research on COVID-19 variants.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="Ali Ait Hssain" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Ali Ait Hssain is associated with the Translational Cancer Research Facility, involved in studies on COVID-19 variants.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="Shahab Uddin" target="Hamad General Hospital">
      <data key="d7">1.0</data>
      <data key="d8">Shahab Uddin works in the Allergy and Immunology Section at Hamad General Hospital and is involved in research on COVID-19 variants.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="Shahab Uddin" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">Shahab Uddin provided intellectual input for the manuscript.</data>
      <data key="d9">author,intellectual input</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791319</data>
      <data key="d13" />
    </edge>
    <edge source="Said Dermime" target="Translational Cancer Research Facility">
      <data key="d7">1.0</data>
      <data key="d8">Said Dermime is affiliated with the Translational Cancer Research Facility, contributing to the study of COVID-19 variants.</data>
      <data key="d9">author affiliation,research contribution</data>
      <data key="d10">chunk-0783a0a835b268a035494c1cf8ad3ee5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="Said Dermime" target="Hamad Medical Corporation">
      <data key="d7">1.0</data>
      <data key="d8">Said Dermime is associated with Hamad Medical Corporation in the field of health research.</data>
      <data key="d9">health research,professional affiliation</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="Said Dermime" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">Said Dermime contributed intellectual input to the manuscript.</data>
      <data key="d9">author,intellectual input</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791319</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Novavax">
      <data key="d7">1.0</data>
      <data key="d8">Novavax is the organization responsible for the development of NVX-CoV2373.</data>
      <data key="d9">organizational involvement,vaccine development</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791287</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Matrix-M">
      <data key="d7">2.0</data>
      <data key="d8">Matrix-M is used as an adjuvant in the formulation of the NVX-CoV2373 vaccine to enhance immune responses.&lt;SEP&gt;The NVX-CoV2373 vaccine utilizes Matrix-M as an adjuvant to enhance the immune response.</data>
      <data key="d9">formulation,immune enhancement,vaccine formulation</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04&lt;SEP&gt;chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791288</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Phase 1-2 Clinical Trial">
      <data key="d7">1.0</data>
      <data key="d8">Phase 1-2 clinical trials are conducted to evaluate the safety and effectiveness of NVX-CoV2373 in humans.</data>
      <data key="d9">clinical evaluation,vaccine safety</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791288</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Protein Subunit Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">NVX-CoV2373 is categorized as a protein subunit vaccine due to its formulation and mechanism of action.</data>
      <data key="d9">vaccine category,vaccine type</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Baculovirus-Spodoptera Frugiperda (Sf9)">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine is produced using the Baculovirus-Spodoptera frugiperda (Sf9) insect cell expression system.</data>
      <data key="d9">production method,vaccine development</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="T Cell Response">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine elicits a T cell response as part of its effectiveness against SARS-CoV-2.</data>
      <data key="d9">immune response capability,vaccination effect</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="B Cell Response">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine induces a B cell response, producing antibodies against SARS-CoV-2.</data>
      <data key="d9">immune response capability,vaccination effect</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Cynomolgus Macaque">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine was tested for protection against SARS-CoV-2 in cynomolgus macaques.</data>
      <data key="d9">animal study,vaccine research</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Keech CMD">
      <data key="d7">1.0</data>
      <data key="d8">Keech CMD has contributed to trials related to the NVX-CoV2373 COVID-19 vaccine.</data>
      <data key="d9">research contribution,vaccine trial</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791296</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Heath PT">
      <data key="d7">1.0</data>
      <data key="d8">Heath PT is involved in the study of safety and efficacy related to the NVX-CoV2373 vaccine.</data>
      <data key="d9">safety study,vaccine research</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="New England Journal of Medicine">
      <data key="d7">1.0</data>
      <data key="d8">Research on the safety and efficacy of NVX-CoV2373 COVID-19 vaccine was published in the New England Journal of Medicine.</data>
      <data key="d9">journal publication,vaccine study</data>
      <data key="d10">chunk-24854732d58a0cfe449336f2148986eb</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Covid-19 Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Covid-19 vaccines, including NVX-CoV2373, are crucial for preventing coronavirus infection.</data>
      <data key="d9">infection prevention,vaccine development</data>
      <data key="d10">chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Nonhuman Primate Models">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine was initially tested for safety and immunogenicity in nonhuman primate models.</data>
      <data key="d9">immunogenicity testing,vaccine safety</data>
      <data key="d10">chunk-6537690b487b6e3ab7d5ee5af21c0f15</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791318</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="United Kingdom">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine is being tested in phase 3 trials in the United Kingdom.</data>
      <data key="d9">location,vaccine trial</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Northern Ireland">
      <data key="d7">1.0</data>
      <data key="d8">Northern Ireland is a location included in the phase 3 trials of the NVX-CoV2373 vaccine.</data>
      <data key="d9">location,vaccine trial</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="NVX-CoV2373" target="Comorbidities">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine is reported to be effective among participants with comorbidities.</data>
      <data key="d9">participant health,vaccine efficacy</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1-2 Clinical Trial" target="United Kingdom">
      <data key="d7">1.0</data>
      <data key="d8">The ongoing trials for NVX-CoV2373 include participation from the United Kingdom.</data>
      <data key="d9">research participation,trial location</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1-2 Clinical Trial" target="Northern Ireland">
      <data key="d7">1.0</data>
      <data key="d8">The ongoing trials for NVX-CoV2373 include participation from Northern Ireland.</data>
      <data key="d9">research participation,trial location</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1-2 Clinical Trial" target="Mexico">
      <data key="d7">1.0</data>
      <data key="d8">The ongoing trials for NVX-CoV2373 include participation from Mexico.</data>
      <data key="d9">research participation,trial location</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791289</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1-2 Clinical Trial" target="Puerto Rico">
      <data key="d7">1.0</data>
      <data key="d8">The ongoing trials for NVX-CoV2373 include participation from Puerto Rico.</data>
      <data key="d9">research participation,trial location</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1-2 Clinical Trial" target="United States of America">
      <data key="d7">1.0</data>
      <data key="d8">The ongoing trials for NVX-CoV2373 include participation from the United States of America.</data>
      <data key="d9">research participation,trial location</data>
      <data key="d10">chunk-c5934df4a227a1b2ad45cbefd136bd04</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="QF" target="VP">
      <data key="d7">1.0</data>
      <data key="d8">QF and VP collaborated on the preparation of figures for the manuscript.</data>
      <data key="d9">collaboration,manuscript preparation</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791290</data>
      <data key="d13" />
    </edge>
    <edge source="QF" target="AR">
      <data key="d7">1.0</data>
      <data key="d8">AR critically revised and organized the manuscript contributed by QF and others.</data>
      <data key="d9">manuscript,review</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="QF" target="LZ">
      <data key="d7">1.0</data>
      <data key="d8">LZ provided intellectual input and reviewed the manuscript authored by QF.</data>
      <data key="d9">intellectual contribution,manuscript review</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="QF" target="Disclosure Statement">
      <data key="d7">1.0</data>
      <data key="d8">The disclosure statement notes that QF reported no potential conflicts of interest.</data>
      <data key="d9">authors,conflict of interest</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="QF" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">QF contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791320</data>
      <data key="d13" />
    </edge>
    <edge source="MM" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">MM contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791321</data>
      <data key="d13" />
    </edge>
    <edge source="SM" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">SM contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791321</data>
      <data key="d13" />
    </edge>
    <edge source="NT" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">NT contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791321</data>
      <data key="d13" />
    </edge>
    <edge source="DM" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">DM contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791322</data>
      <data key="d13" />
    </edge>
    <edge source="TB" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">TB contributed to the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791322</data>
      <data key="d13" />
    </edge>
    <edge source="VP" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">VP prepared the figures for graphical illustration in the manuscript.</data>
      <data key="d9">figure preparation,graphical illustration</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791323</data>
      <data key="d13" />
    </edge>
    <edge source="AR" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">AR critically revised and organized the manuscript.</data>
      <data key="d9">editing,revision</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791323</data>
      <data key="d13" />
    </edge>
    <edge source="LZ" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">LZ provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791323</data>
      <data key="d13" />
    </edge>
    <edge source="MOM" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">MOM provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="MAN" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">MAN provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="AA" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">AA provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="HM" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">HM provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="MB" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">MB provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791325</data>
      <data key="d13" />
    </edge>
    <edge source="SU" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">SU provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="SD" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">SD provided intellectual input and reviewed the manuscript.</data>
      <data key="d9">intellectual input,review</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Zhu N" target="Novel Coronavirus">
      <data key="d7">1.0</data>
      <data key="d8">Zhu N contributed to the research on a novel coronavirus from patients with pneumonia in China.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="Guan WJ" target="Coronavirus Disease 2019">
      <data key="d7">1.0</data>
      <data key="d8">Guan WJ contributed to the research on clinical characteristics of coronavirus disease 2019 in China.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="Huang C" target="Novel Coronavirus">
      <data key="d7">1.0</data>
      <data key="d8">Huang C contributed to the research on clinical features of patients infected with the novel coronavirus.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791291</data>
      <data key="d13" />
    </edge>
    <edge source="Lu R" target="Genomic Characterization">
      <data key="d7">1.0</data>
      <data key="d8">Lu R contributed to the research on genomic epidemiology of the novel coronavirus.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="Tyrrell DA" target="Cultivation of Viruses">
      <data key="d7">1.0</data>
      <data key="d8">Tyrrell DA contributed to the research on the cultivation of viruses from patients with colds.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="Tyrrell DA" target="Bynoe ML">
      <data key="d7">1.0</data>
      <data key="d8">Tyrrell DA and Bynoe ML collaborated on research focusing on the cultivation of viruses from patients with colds.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Perlman S" target="Coronaviruses">
      <data key="d7">1.0</data>
      <data key="d8">Perlman S contributed to the research on coronaviruses over the decades.</data>
      <data key="d9">manuscript,research contribution</data>
      <data key="d10">chunk-cc5ee4ccea3edd4e63785b4c4aa8e45e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791292</data>
      <data key="d13" />
    </edge>
    <edge source="Martin MA" target="VanInsberghe D">
      <data key="d7">1.0</data>
      <data key="d8">Martin MA and VanInsberghe D worked together on insights related to SARS-CoV-2 sequences.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Martin MA" target="Koelle K">
      <data key="d7">1.0</data>
      <data key="d8">Martin MA and Koelle K are co-authors on research about SARS-CoV-2 sequences.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="World Health Organization" target="COVID-19 Candidate Vaccines">
      <data key="d7">2.0</data>
      <data key="d8">The World Health Organization monitors and reports on various COVID-19 candidate vaccines' development.&lt;SEP&gt;The World Health Organization monitors the landscape of COVID-19 candidate vaccines.</data>
      <data key="d9">global health initiative,pandemic response,vaccine oversight,vaccine tracking</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="World Health Organization" target="AZD1222 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The AZD1222 vaccine received approval from the World Health Organization for use in various countries.</data>
      <data key="d9">public health,vaccine approval</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="Tyrell and Bynoe" target="Coronaviridae">
      <data key="d7">1.0</data>
      <data key="d8">Tyrell and Bynoe were the researchers who first identified the Coronaviridae family of viruses.</data>
      <data key="d9">discovery,virus classification</data>
      <data key="d10">chunk-8da47fd3ab04bfda61202cc5b44306a4</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="Chung JR" target="Influenza Incidence Surveillance Project">
      <data key="d7">2.0</data>
      <data key="d8">Chung JR is an author for studies focused on assessing the effectiveness of influenza vaccines conducted by the project.&lt;SEP&gt;Chung JR is referenced in connection with the Influenza Incidence Surveillance Project in influenza vaccine studies.</data>
      <data key="d9">collaboration,research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="Flannery B" target="US Influenza Vaccine Effectiveness Network">
      <data key="d7">1.0</data>
      <data key="d8">Flannery B's work relates to the US Influenza Vaccine Effectiveness Network focusing on vaccine performance.</data>
      <data key="d9">research involvement,vaccination</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="Flannery B" target="Safety">
      <data key="d7">1.0</data>
      <data key="d8">Flannery B's research involves evaluating the safety of vaccines, particularly human papillomavirus vaccines.</data>
      <data key="d9">research focus,vaccine safety</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Ambrose CS" target="Influenza Incidence Surveillance Project">
      <data key="d7">1.0</data>
      <data key="d8">Ambrose CS is an author involved in documenting the effectiveness of vaccines within the project.</data>
      <data key="d9">research contribution,vaccine effectiveness</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Jiang R" target="Vaccine">
      <data key="d7">2.0</data>
      <data key="d8">Jiang R conducted research evaluating the immunogenicity and safety of a specific vaccine.&lt;SEP&gt;Jiang R has contributed to the clinical study of the inactivated poliomyelitis vaccine.</data>
      <data key="d9">clinical study,immunogenicity,research,vaccine development</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8&lt;SEP&gt;chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="Jiang R" target="Phase IV Clinical Trial">
      <data key="d7">1.0</data>
      <data key="d8">Jiang R participated in a Phase IV clinical trial assessing the safety of inactivated poliomyelitis vaccine.</data>
      <data key="d9">safety assessment,vaccine study</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Human Papillomavirus Vaccines" target="Drug Safety">
      <data key="d7">1.0</data>
      <data key="d8">The safety of Human Papillomavirus Vaccines has been reviewed in the Drug Safety journal.</data>
      <data key="d9">publication,safety review</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791293</data>
      <data key="d13" />
    </edge>
    <edge source="CoronaVac" target="Sinovac Biotech Ltd">
      <data key="d7">1.0</data>
      <data key="d8">Sinovac Biotech Ltd developed the CoronaVac vaccine as an inactivated approach to combat COVID-19.</data>
      <data key="d9">COVID-19 response,vaccine production</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="medRxiv" target="Puvar AP">
      <data key="d7">1.0</data>
      <data key="d8">Puvar AP's research on a PCR-based method for detecting Omicron variant was shared on medRxiv.</data>
      <data key="d9">PCR detection method,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac Vaccine" target="China">
      <data key="d7">2.0</data>
      <data key="d8">The Sinovac vaccine is administered in China to combat COVID-19, supported by phase-iii trial results.&lt;SEP&gt;The Sinovac Vaccine was developed in China and is a subject of clinical trial results reporting.</data>
      <data key="d9">disease combat,research location,vaccine administration,vaccine development</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac Vaccine" target="Phase-III Trial Results">
      <data key="d7">1.0</data>
      <data key="d8">Phase-III trial results evaluate the efficacy and safety of the Sinovac vaccine in combating COVID-19.</data>
      <data key="d9">trial results,vaccine evaluation</data>
      <data key="d10">chunk-0c6a11e5028c19780f412657d5fa29c5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Immunogenicity" target="Safety">
      <data key="d7">1.0</data>
      <data key="d8">The immunogenicity and safety of the inactivated poliomyelitis vaccine were evaluated in clinical trials.</data>
      <data key="d9">clinical assessment,vaccine evaluation</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="Immunogenicity" target="Phase IV Clinical Trial">
      <data key="d7">1.0</data>
      <data key="d8">The Phase IV Clinical Trial aims to assess immunogenicity in a large population for the poliomyelitis vaccine.</data>
      <data key="d9">experimental design,vaccine assessment</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="Immunogenicity" target="Clinical Effectiveness Study">
      <data key="d7">1.0</data>
      <data key="d8">Immunogenicity is a key focus within the Clinical Effectiveness Study assessing vaccine performance.</data>
      <data key="d9">immune response,vaccine evaluation</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Immuno-Assay" target="Enzyme Linked Immunosorbent Assays (ELISA)">
      <data key="d7">1.0</data>
      <data key="d8">ELISA is a specific form of immuno-assay used to detect SARS-CoV-2 antigens.</data>
      <data key="d9">infection detection,specific method</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="Immuno-Assay" target="Clinical Specimens">
      <data key="d7">1.0</data>
      <data key="d8">Clinical specimens are used as sample sources for immuno-assays in the detection of SARS-CoV-2 infection.</data>
      <data key="d9">detection method,sample source</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="Immuno-Assay" target="Novel Sensor and Biosensor Technologies">
      <data key="d7">1.0</data>
      <data key="d8">Research into novel sensor and biosensor technologies aims to improve the sensitivity of immuno-assays for SARS-CoV-2 detection.</data>
      <data key="d9">research focus,sensitivity enhancement</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791296</data>
      <data key="d13" />
    </edge>
    <edge source="Anti-SARS-CoV-2 Antibody" target="IgM">
      <data key="d7">1.0</data>
      <data key="d8">IgM is measured to assess the immune response against SARS-CoV-2 and help with diagnosis.</data>
      <data key="d9">diagnostic tool,immune measurement</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791295</data>
      <data key="d13" />
    </edge>
    <edge source="Anti-SARS-CoV-2 Antibody" target="IgG">
      <data key="d7">1.0</data>
      <data key="d8">IgG is measured alongside IgM to evaluate the humoral immune response in SARS-CoV-2 infection.</data>
      <data key="d9">diagnostic tool,immune measurement</data>
      <data key="d10">chunk-90dfb33ebd8b6695b6eb243fc4a55781</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791296</data>
      <data key="d13" />
    </edge>
    <edge source="Cynomolgus Macaque" target="NVX-CoV2373 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine was tested in cynomolgus macaques for efficacy against SARS-CoV-2.</data>
      <data key="d9">animal study,vaccine testing</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="Oxford-AstraZeneca COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The Lancet published studies regarding the efficacy and side effects of the Oxford-AstraZeneca COVID-19 vaccine.</data>
      <data key="d9">medical publication,research</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The Lancet published findings regarding the safety and efficacy of the rAd26 and rAd5 vector-based COVID-19 vaccine.</data>
      <data key="d9">research publication,trial findings</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="mRNA Rabies Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The Lancet published results concerning the safety and immunogenicity of the mRNA rabies vaccine.</data>
      <data key="d9">clinical trial results,research publication</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="Folegatti PM">
      <data key="d7">1.0</data>
      <data key="d8">Findings from Folegatti PM's research on ChAdOx1 nCoV-19 vaccine have been published in The Lancet to inform the medical community.</data>
      <data key="d9">publication,research dissemination</data>
      <data key="d10">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="Russia">
      <data key="d7">1.0</data>
      <data key="d8">Lancet published findings on the safety and efficacy of the COVID-19 vaccine based on studies conducted in Russia.</data>
      <data key="d9">publication,vaccine study</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="rAd26 and rAd5">
      <data key="d7">1.0</data>
      <data key="d8">Lancet published findings regarding the safety and immunogenicity of the rAd26 and rAd5 vector-based COVID-19 vaccine formulations.</data>
      <data key="d9">publication,vaccine study</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="Lancet" target="COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Lancet publishes critical research findings on COVID-19 vaccines, including efficacy studies.</data>
      <data key="d9">publication,research findings</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791340</data>
      <data key="d13" />
    </edge>
    <edge source="Keech CMD" target="Matrix-M Adjuvant">
      <data key="d7">1.0</data>
      <data key="d8">Keech CMD researched the use of Matrix-M adjuvant to enhance immune responses in vaccinations.</data>
      <data key="d9">immune response,vaccine enhancement</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac" target="COVID-19 Vaccine (Vero Cell) Inactivated">
      <data key="d7">1.0</data>
      <data key="d8">The COVID-19 Vaccine (Vero Cell) Inactivated was developed by Sinovac using inactivated SARS-CoV-2 virus.</data>
      <data key="d9">pharmaceutical production,vaccine development</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791297</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac" target="China">
      <data key="d7">1.0</data>
      <data key="d8">Sinovac is based in China, where it produces the COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d9">company location,vaccine production</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac" target="Sinopharm">
      <data key="d7">1.0</data>
      <data key="d8">Sinovac and Sinopharm are both pharmaceutical companies from China involved in the development of inactivated viral vaccines.</data>
      <data key="d9">industry competitors,vaccine development</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="Sinopharm" target="BBIBP-CorV">
      <data key="d7">2.0</data>
      <data key="d8">BBIBP-CorV was developed by Sinopharm as an inactivated virus COVID-19 vaccine.&lt;SEP&gt;BBIBP-CorV is a vaccine developed by Sinopharm, indicating a direct organizational connection.</data>
      <data key="d9">development,organizational relationship,vaccine creation,vaccine development</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Sinopharm" target="Argentina">
      <data key="d7">1.0</data>
      <data key="d8">Sinopharm conducted a phase III trial for its vaccine in Argentina.</data>
      <data key="d9">research trial,vaccine development</data>
      <data key="d10">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="WHO">
      <data key="d7">1.0</data>
      <data key="d8">The development of the COVID-19 Vaccine (Vero Cell) Inactivated is monitored by the WHO for safety and efficacy.</data>
      <data key="d9">health organization,vaccine approval</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Brazil">
      <data key="d7">2.0</data>
      <data key="d8">Brazil is one of the countries participating in clinical trials for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Brazil reported an efficacy rate of 53% for the COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d9">clinical trials,efficacy reporting,vaccine testing,vaccine trials</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Turkey">
      <data key="d7">2.0</data>
      <data key="d8">Turkey has conducted randomized double-blinded placebo control studies for the COVID-19 Vaccine (Vero Cell) Inactivated.&lt;SEP&gt;Turkey reported an efficacy rate of 83% for the COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d9">clinical trials,efficacy reporting,placebo control study,vaccine trials</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c&lt;SEP&gt;chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Macaca Mulatta">
      <data key="d7">1.0</data>
      <data key="d8">The vaccine's safety evaluation involves preclinical testing on Macaca mulatta to ensure its effectiveness against COVID-19.</data>
      <data key="d9">preclinical testing,safety evaluation</data>
      <data key="d10">chunk-306854c102d9f44210a9fd90efc41b9c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Phase II Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase II Clinical Trials assessed the efficacy of the COVID-19 Vaccine (Vero Cell) Inactivated with an expanded participant group.</data>
      <data key="d9">efficacy testing,participant assessment</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Hypersensitivity">
      <data key="d7">1.0</data>
      <data key="d8">The safety profile of the COVID-19 Vaccine (Vero Cell) Inactivated indicates very few cases of hypersensitivity.</data>
      <data key="d9">adverse reaction,safety profile</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="Two-Dose Immunization Schedule">
      <data key="d7">1.0</data>
      <data key="d8">The COVID-19 Vaccine (Vero Cell) Inactivated is administered following a Two-Dose Immunization Schedule to ensure maximum efficacy.</data>
      <data key="d9">administration method,vaccine strategy</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell) Inactivated" target="COVID-19 Vaccine (Vero Cell)">
      <data key="d7">1.0</data>
      <data key="d8">COVID-19 Vaccine (Vero Cell) is a general term that includes the specific formulation known as COVID-19 Vaccine (Vero Cell) Inactivated.</data>
      <data key="d9">specific formulation,vaccine type</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Brazil" target="Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Brazil hosted clinical trials for the COVID-19 Vaccine (Vero Cell) to evaluate its efficacy.</data>
      <data key="d9">efficacy assessment,trial location</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="Turkey" target="Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Turkey conducted clinical trials for the COVID-19 Vaccine (Vero Cell) and reported its efficacy rate.</data>
      <data key="d9">efficacy assessment,trial location</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="China" target="BBIBP-CorV Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The BBIBP-CorV vaccine was developed and tested in China.</data>
      <data key="d9">development location,vaccine trial</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="China" target="Algeria">
      <data key="d7">1.0</data>
      <data key="d8">Algeria received a donation of 200,000 doses of the anti-COVID-19 vaccine from China.</data>
      <data key="d9">international aid,vaccine donation</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="China" target="Serbia">
      <data key="d7">1.0</data>
      <data key="d8">Serbia received a million doses of the Sinopharm COVID-19 vaccine from China.</data>
      <data key="d9">international aid,vaccine donation</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Hamad Bin Khalifa University">
      <data key="d7">1.0</data>
      <data key="d8">Hamad Medical Corporation is affiliated with Hamad Bin Khalifa University in health and life sciences research.</data>
      <data key="d9">healthcare research,institutional collaboration</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="University of Bern">
      <data key="d7">1.0</data>
      <data key="d8">The University of Bern collaborates with Hamad Medical Corporation in biomedical research.</data>
      <data key="d9">biomedical studies,research partnership</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="University of Oxford">
      <data key="d7">1.0</data>
      <data key="d8">The University of Oxford is involved with Hamad Medical Corporation on biomedical research initiatives.</data>
      <data key="d9">medical advancement,research collaboration</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791298</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Maysaloun Merhi">
      <data key="d7">1.0</data>
      <data key="d8">Maysaloun Merhi contributes to the biomedical research work at Hamad Medical Corporation.</data>
      <data key="d9">biomedical study,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Sarra Mestiri">
      <data key="d7">1.0</data>
      <data key="d8">Sarra Mestiri is involved in the research conducted at Hamad Medical Corporation.</data>
      <data key="d9">health sciences,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Nassiba Taib">
      <data key="d7">1.0</data>
      <data key="d8">Nassiba Taib is contributing to the research on COVID-19 at Hamad Medical Corporation.</data>
      <data key="d9">immunology,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Lobna Al-Zaidan">
      <data key="d7">1.0</data>
      <data key="d8">Lobna Al-Zaidan is involved in health research projects at Hamad Medical Corporation.</data>
      <data key="d9">health research,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Mona O. Mohsen">
      <data key="d7">1.0</data>
      <data key="d8">Mona O. Mohsen is part of the biomedical research team at Hamad Medical Corporation.</data>
      <data key="d9">biomedical field,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Hadi Mohamad Yassine">
      <data key="d7">1.0</data>
      <data key="d8">Hadi Mohamad Yassine participates in immunology studies at Hamad Medical Corporation.</data>
      <data key="d9">immunological studies,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Martin F. Bachmann">
      <data key="d7">1.0</data>
      <data key="d8">Martin F. Bachmann is linked to biomedical research activities at Hamad Medical Corporation.</data>
      <data key="d9">biomedical research,research contribution</data>
      <data key="d10">chunk-1bd5e90caf2bb8e64acc9e5ab28dcff2</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Hamad Medical Corporation" target="Doha">
      <data key="d7">1.0</data>
      <data key="d8">Doha is the location for the healthcare initiatives provided by Hamad Medical Corporation.</data>
      <data key="d9">geographical location,healthcare services</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Chimpanzee Vectors" target="Ebola Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Chimpanzee vectors are utilized in the development of the Ebola vaccine to enhance immune responses.</data>
      <data key="d9">methodology,vaccine development</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791299</data>
      <data key="d13" />
    </edge>
    <edge source="Chimpanzee Vectors" target="Malaria Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Chimpanzee vectors are employed in creating the malaria vaccine to induce protective immune responses.</data>
      <data key="d9">methodology,vaccine development</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="Chimpanzee Vectors" target="HIV Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Chimpanzee vectors are instrumental in the development of the HIV vaccine, targeting virus-specific immune responses.</data>
      <data key="d9">methodology,vaccine development</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="Chimpanzee Vectors" target="Crohn Disease Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Chimpanzee vectors are used to develop a vaccine for Crohn disease, demonstrating flexibility in vaccine applications.</data>
      <data key="d9">methodology,vaccine development</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="Clinical Trials">
      <data key="d7">2.0</data>
      <data key="d8">Clinical trials assess the safety and immune response of the AZD1222 vaccine in participants.&lt;SEP&gt;Clinical trials were conducted to assess the safety and efficacy of the AZD1222 vaccine among participants.</data>
      <data key="d9">efficacy,immunogenicity,safety assessment,safety testing</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791300</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="European Countries">
      <data key="d7">1.0</data>
      <data key="d8">European countries suspended the AZD1222 vaccine due to reported adverse events such as thrombocytopenia.</data>
      <data key="d9">adverse events,vaccine suspension</data>
      <data key="d10">chunk-0d061c21fc85caf7325966660f802be7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="UK">
      <data key="d7">1.0</data>
      <data key="d8">The UK made a decision to prioritize the use of the AZD1222 vaccine amidst safety concerns.</data>
      <data key="d9">medical decision,vaccine usage</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="European Medicines Agency">
      <data key="d7">2.0</data>
      <data key="d8">The European Medicines Agency monitors the safety and evaluates the AZD1222 vaccine related to adverse events.&lt;SEP&gt;The European Medicines Agency assesses the safety of the AZD1222 vaccine and monitors reported adverse effects.</data>
      <data key="d9">safety assessment,safety monitoring,vaccine evaluation,vaccine regulation</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551&lt;SEP&gt;chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="Thrombocytopenia">
      <data key="d7">1.0</data>
      <data key="d8">Thrombocytopenia is reported as an adverse effect associated with the AZD1222 vaccine usage.</data>
      <data key="d9">adverse effect,vaccine safety</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="WHO">
      <data key="d7">1.0</data>
      <data key="d8">The AZD1222 vaccine has been approved by the WHO for use in many countries.</data>
      <data key="d9">approval,endorsement</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222 Vaccine" target="Thrombosis">
      <data key="d7">1.0</data>
      <data key="d8">The AZD1222 vaccine has been linked to reports of thrombosis and other adverse events.</data>
      <data key="d9">health concerns,side effects</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Clinical Trials" target="COVID-19 Vaccine (Vero Cell)">
      <data key="d7">1.0</data>
      <data key="d8">Clinical trials are conducted to assess the safety and efficacy of the COVID-19 Vaccine (Vero Cell).</data>
      <data key="d9">efficacy testing,safety evaluation</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="Falzone L" target="Current Diagnostic Methods">
      <data key="d7">1.0</data>
      <data key="d8">Falzone L contributed to the review of current methods for diagnosing COVID-19 infection.</data>
      <data key="d9">COVID-19 diagnosis,research contribution</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Falzone L" target="Int J Mol Med">
      <data key="d7">1.0</data>
      <data key="d8">Falzone L's research on COVID-19 diagnosis was published in the International Journal of Molecular Medicine.</data>
      <data key="d9">COVID-19 diagnosis,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Falzone L" target="Gattuso G">
      <data key="d7">1.0</data>
      <data key="d8">Falzone L and Gattuso G are co-authors on innovative methods for COVID-19 diagnosis.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Falzone L" target="Tsatsakis A">
      <data key="d7">1.0</data>
      <data key="d8">Falzone L and Tsatsakis A contributed to the review on COVID-19 diagnostic methods.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Alpdagtas S" target="APL Bioeng">
      <data key="d7">1.0</data>
      <data key="d8">Alpdagtas S's evaluation of diagnostic methods for COVID-19 appeared in APL Bioengineering.</data>
      <data key="d9">COVID-19 diagnostics,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Alpdagtas S" target="Ilhan E">
      <data key="d7">1.0</data>
      <data key="d8">Alpdagtas S and Ilhan E collaborated on evaluating current COVID-19 diagnostic methods.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Alpdagtas S" target="Uysal E">
      <data key="d7">1.0</data>
      <data key="d8">Alpdagtas S and Uysal E are co-authors on the evaluation of diagnostic methods for COVID-19.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Tsang NNY" target="Lancet Infect Dis">
      <data key="d7">1.0</data>
      <data key="d8">Tsang NNY's systematic review on SARS-CoV-2 RT-PCR testing was published in The Lancet Infectious Diseases.</data>
      <data key="d9">SARS-CoV-2 testing,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Tsang NNY" target="So HC">
      <data key="d7">1.0</data>
      <data key="d8">Tsang NNY and So HC co-authored a systematic review on SARS-CoV-2 testing approaches.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Tsang NNY" target="Ng KY">
      <data key="d7">1.0</data>
      <data key="d8">Tsang NNY and Ng KY worked together on a systematic review of different sampling approaches for SARS-CoV-2 RT-PCR testing.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Tahan S" target="J Clin Microbiol">
      <data key="d7">1.0</data>
      <data key="d8">Tahan S's study on the SARS-CoV-2 E gene variant and viral detection was published in the Journal of Clinical Microbiology.</data>
      <data key="d9">research publication,viral detection assay</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Tahan S" target="Parikh BA">
      <data key="d7">1.0</data>
      <data key="d8">Tahan S and Parikh BA are co-authors on research discussing SARS-CoV-2 E gene variant impact on detection methods.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Tahan S" target="Droit L">
      <data key="d7">1.0</data>
      <data key="d8">Tahan S and Droit L collaborated on a study about how SARS-CoV-2 E gene variant affects detection.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Mautner L" target="Rapid Detection Methods">
      <data key="d7">1.0</data>
      <data key="d8">Mautner L is developing rapid detection methods for SARS-CoV-2 using RT-LAMP.</data>
      <data key="d9">COVID-19 detection,research development</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Mautner L" target="Virol J">
      <data key="d7">1.0</data>
      <data key="d8">Mautner L's research on rapid detection of SARS-CoV-2 using RT-LAMP was published in Virology Journal.</data>
      <data key="d9">rapid detection research,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Mautner L" target="Baillie CK">
      <data key="d7">1.0</data>
      <data key="d8">Mautner L and Baillie CK worked together on rapid detection methods for SARS-CoV-2.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="Mautner L" target="Herold HM">
      <data key="d7">1.0</data>
      <data key="d8">Mautner L and Herold HM are co-authors on studies about rapid point-of-care detection of SARS-CoV-2.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Broughton JP" target="CRISPR-Cas12 Detection">
      <data key="d7">1.0</data>
      <data key="d8">Broughton JP is studying CRISPR-Cas12-based detection for SARS-CoV-2.</data>
      <data key="d9">SARS-CoV-2 detection,research contribution</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Broughton JP" target="Nat Biotechnol">
      <data key="d7">1.0</data>
      <data key="d8">Broughton JP's study on CRISPR-Cas12-based detection of SARS-CoV-2 was published in Nature Biotechnology.</data>
      <data key="d9">CRISPR detection method,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="Broughton JP" target="Deng X">
      <data key="d7">1.0</data>
      <data key="d8">Broughton JP and Deng X collaborated on research regarding CRISPR-Cas12 detection of SARS-CoV-2.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Broughton JP" target="Yu G">
      <data key="d7">1.0</data>
      <data key="d8">Broughton JP and Yu G are co-authors on the study about SARS-CoV-2 detection using CRISPR-Cas12.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Puvar AP" target="Chaudhari AM">
      <data key="d7">1.0</data>
      <data key="d8">Puvar AP and Chaudhari AM are co-authors on a PCR-based method for detecting the Omicron variant.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Puvar AP" target="Travadi T">
      <data key="d7">1.0</data>
      <data key="d8">Puvar AP and Travadi T collaborated on a study focusing on detecting the Omicron variant of SARS-CoV-2.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Zelyas N" target="Microbiol Spectr">
      <data key="d7">1.0</data>
      <data key="d8">Zelyas N's study on PCR assays for SARS-CoV-2 variant detection was published in Microbiology Spectrum.</data>
      <data key="d9">research publication,variant detection response</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791301</data>
      <data key="d13" />
    </edge>
    <edge source="Zelyas N" target="Pabbaraju K">
      <data key="d7">1.0</data>
      <data key="d8">Zelyas N and Pabbaraju K co-authored research examining rapid responses to the B.1.1.7 variant.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Zelyas N" target="Croxen MA">
      <data key="d7">1.0</data>
      <data key="d8">Zelyas N and Croxen MA worked together on studies concerning rapid detection methods for SARS-CoV-2 variants.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Giovacchini N" target="Int J Infect Dis">
      <data key="d7">1.0</data>
      <data key="d8">Giovacchini N's research on rapid screening for SARS-CoV-2 variants was published in The International Journal of Infectious Diseases.</data>
      <data key="d9">research publication,screening method</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="Giovacchini N" target="Coppi M">
      <data key="d7">1.0</data>
      <data key="d8">Giovacchini N and Coppi M collaborated on research about screening methods for SARS-CoV-2 variants.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="Giovacchini N" target="Aiezza N">
      <data key="d7">1.0</data>
      <data key="d8">Giovacchini N and Aiezza N worked together on studies regarding rapid screening for SARS-CoV-2 variants.</data>
      <data key="d9">research collaboration,study authorship</data>
      <data key="d10">chunk-62c1a16d82b02fe9ac82ef46c947532d</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791329</data>
      <data key="d13" />
    </edge>
    <edge source="WHO" target="Variants of Interest">
      <data key="d7">2.0</data>
      <data key="d8">WHO classifies certain SARS-CoV-2 variants as Variants of Interest based on mutation impacts.&lt;SEP&gt;The WHO classifies certain SARS-CoV-2 variants as Variants of Interest based on their epidemiological significance.</data>
      <data key="d9">classification,pandemic response,public health</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="WHO" target="Variants of Concern">
      <data key="d7">2.0</data>
      <data key="d8">WHO identifies specific variants as Variants of Concern due to their significant impact on transmissibility and treatment response.&lt;SEP&gt;The WHO also identifies Variants of Concern as having strong evidence of increased transmissibility and severity.</data>
      <data key="d9">classification,pandemic response,public health</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b&lt;SEP&gt;chunk-d57b3ea41472c432630e5f05c35f581f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="WHO" target="Greek Alphabet">
      <data key="d7">1.0</data>
      <data key="d8">WHO suggests the use of the Greek Alphabet for uniformly naming and tracking emerging SARS-CoV-2 variants.</data>
      <data key="d9">nomenclature system,tracking</data>
      <data key="d10">chunk-0bfad39f2750956a99fee789e546ca9b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="La Rosa G" target="Water Res">
      <data key="d7">1.0</data>
      <data key="d8">La Rosa G's research on rapid screening for SARS-CoV-2 in water samples was published in Water Research.</data>
      <data key="d9">environmental sample detection,research publication</data>
      <data key="d10">chunk-cb4a59d1dc3e66480494a802eb5f562f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="Kashir J" target="LAMP Assays">
      <data key="d7">1.0</data>
      <data key="d8">Kashir J developed LAMP assays aimed at rapid diagnostics for COVID-19.</data>
      <data key="d9">COVID-19,diagnostic development</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="J Clin Microbiol" target="PCR Melting-Temperature Assay">
      <data key="d7">1.0</data>
      <data key="d8">The J Clin Microbiol published research on a rapid PCR melting-temperature assay for screening SARS-CoV-2 variants.</data>
      <data key="d9">rapid screening,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="Int J Infect Dis" target="Rapid Screening for SARS-CoV-2 Variants">
      <data key="d7">1.0</data>
      <data key="d8">The Int J Infect Dis published research detailing methods for rapid screening of SARS-CoV-2 variants.</data>
      <data key="d9">research publication,variant detection</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV Vaccine" target="Xia S">
      <data key="d7">1.0</data>
      <data key="d8">Xia S contributed to the research regarding the BBIBP-CorV vaccine as part of a study on safety and immunogenicity outcomes.</data>
      <data key="d9">author contribution,research</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV Vaccine" target="Duan K">
      <data key="d7">1.0</data>
      <data key="d8">Duan K contributed to the research regarding the BBIBP-CorV vaccine regarding safety and immunogenicity outcomes.</data>
      <data key="d9">author contribution,research</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV Vaccine" target="Zhang Y">
      <data key="d7">1.0</data>
      <data key="d8">Zhang Y contributed to the research of the BBIBP-CorV vaccine focusing on safety and immunogenicity outcomes.</data>
      <data key="d9">author contribution,research</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV Vaccine" target="Al Kaabi N">
      <data key="d7">1.0</data>
      <data key="d8">Al Kaabi N was involved in the research and clinical trial concerning the BBIBP-CorV vaccine.</data>
      <data key="d9">author contribution,research</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="UAE Ministry of Health" target="Algeria">
      <data key="d7">1.0</data>
      <data key="d8">Algeria received a donation of vaccines from the UAE Ministry of Health.</data>
      <data key="d9">international health collaboration,vaccine donation</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791302</data>
      <data key="d13" />
    </edge>
    <edge source="Algeria" target="Sinopharm COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Algeria received a donation of Sinopharm COVID-19 vaccine doses from China.</data>
      <data key="d9">international support,vaccine donation</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Morocco" target="Sinopharm Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Morocco received half a million doses of the Sinopharm COVID-19 vaccine for its vaccination campaign.</data>
      <data key="d9">international supply,vaccine acquisition</data>
      <data key="d10">chunk-fbd439f210751f278e08778f5add0bb7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="Morocco" target="Sinopharm COVID-19 Vaccine">
      <data key="d7">3.0</data>
      <data key="d8">The Sinopharm COVID-19 vaccine was received by Morocco as part of vaccine distribution efforts to combat COVID-19.&lt;SEP&gt;Morocco received half a million doses of the Sinopharm COVID-19 vaccine as part of its vaccination efforts.&lt;SEP&gt;Morocco received a supply of the Sinopharm COVID-19 vaccine as part of international support efforts.</data>
      <data key="d9">international aid,vaccination effort,vaccine distribution,vaccine donation,vaccine supply</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-0c6a11e5028c19780f412657d5fa29c5&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="ChAdOx1 nCoV-19 Vaccine" target="Phase 1/2 Trial">
      <data key="d7">1.0</data>
      <data key="d8">The safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine were assessed through a Phase 1/2 trial.</data>
      <data key="d9">clinical testing,vaccine evaluation</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="ChAdOx1 nCoV-19 Vaccine" target="Folegatti PM">
      <data key="d7">2.0</data>
      <data key="d8">Folegatti PM contributed to evaluating the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in clinical trials.&lt;SEP&gt;Folegatti PM conducted a study to evaluate the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine.</data>
      <data key="d9">immunogenicity,research involvement,vaccine evaluation,vaccine study</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Oxford/AstraZeneca Vaccine" target="COVID-19 Vaccine Tracker">
      <data key="d7">2.0</data>
      <data key="d8">The COVID-19 vaccine tracker includes information on the Oxford/AstraZeneca vaccine.&lt;SEP&gt;The COVID-19 Vaccine Tracker provides updates and information regarding the Oxford/AstraZeneca vaccine's development and deployment.</data>
      <data key="d9">data reporting,tracking resource,vaccination information,vaccine information</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791303</data>
      <data key="d13" />
    </edge>
    <edge source="Oxford/AstraZeneca Vaccine" target="Blood Clots">
      <data key="d7">1.0</data>
      <data key="d8">Blood clots have been reported as a safety concern related to the use of the Oxford/AstraZeneca vaccine.</data>
      <data key="d9">health issue,safety concern</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Oxford/AstraZeneca Vaccine" target="Thromboembolism">
      <data key="d7">2.0</data>
      <data key="d8">Thromboembolism is noted as a potential side effect following vaccination with the Oxford/AstraZeneca vaccine.&lt;SEP&gt;Thromboembolism has been raised as a potential side effect linked to the Oxford/AstraZeneca vaccine in various case reports.</data>
      <data key="d9">adverse reaction,safety concerns,side effect,side effects</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06&lt;SEP&gt;chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Oxford/AstraZeneca Vaccine" target="Emergency Use Authorization">
      <data key="d7">1.0</data>
      <data key="d8">The Oxford/AstraZeneca vaccine received Emergency Use Authorization to facilitate its rapid deployment during the COVID-19 pandemic.</data>
      <data key="d9">public health,regulatory approval</data>
      <data key="d10">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Thromboembolism" target="Oxford-AstraZeneca COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Thromboembolism is examined as a potential adverse effect associated with the Oxford-AstraZeneca COVID-19 vaccine.</data>
      <data key="d9">adverse effect,vaccine concern</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="BMJ" target="Oxford-AstraZeneca">
      <data key="d7">1.0</data>
      <data key="d8">BMJ published findings from a study on the Oxford-AstraZeneca COVID-19 vaccine conducted in Denmark and Norway.</data>
      <data key="d9">publication,vaccine study</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="Folegatti PM" target="Ewer KJ">
      <data key="d7">1.0</data>
      <data key="d8">Folegatti PM and Ewer KJ collaborated on studies focusing on the safety and immunogenicity of COVID-19 vaccines.</data>
      <data key="d9">collaboration,vaccine research</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Folegatti PM" target="Aley PK">
      <data key="d7">1.0</data>
      <data key="d8">Folegatti PM and Aley PK worked together on research pertaining to the ChAdOx1 nCoV-19 vaccine's safety.</data>
      <data key="d9">research contribution,vaccine safety</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Ewer KJ" target="Viral Vectors as Vaccine Platforms">
      <data key="d7">1.0</data>
      <data key="d8">Ewer KJ conducts research investigating the role of viral vectors in vaccines, focusing on their immunogenicity and effectiveness.</data>
      <data key="d9">research investigation,vaccine efficacy</data>
      <data key="d10">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Guo J" target="Mondal M">
      <data key="d7">1.0</data>
      <data key="d8">Guo J and Mondal M collaborated in the development of novel vaccine vectors using chimpanzee adenoviruses.</data>
      <data key="d9">collaboration,vaccine vector development</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Guo J" target="Development of Novel Vaccine Vectors">
      <data key="d7">1.0</data>
      <data key="d8">Guo J's research focuses on developing novel vaccine vectors, particularly in conjunction with other listed researchers.</data>
      <data key="d9">research collaboration,vaccine technology</data>
      <data key="d10">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Lambe T" target="Rollier CS">
      <data key="d7">1.0</data>
      <data key="d8">Lambe T and Rollier CS contributed to research on viral vectors as vaccine platforms.</data>
      <data key="d9">research collaboration,vaccine platforms</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Pottegrd A" target="Lund LC">
      <data key="d7">1.0</data>
      <data key="d8">Pottegrd A and Lund LC are involved in studying the safety of the Oxford-AstraZeneca vaccine regarding thromboembolic events.</data>
      <data key="d9">safety evaluation,vaccine side effects</data>
      <data key="d10">chunk-5627384c44748846e3ebfabc500b2f06</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791304</data>
      <data key="d13" />
    </edge>
    <edge source="Pottegrd A" target="Oxford-AstraZeneca COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Pottegrd A conducted research on the effects of the Oxford-AstraZeneca COVID-19 vaccine in Denmark and Norway.</data>
      <data key="d9">research involvement,vaccine efficacy</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Pottegrd A" target="Oxford-AstraZeneca Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Pottegrd A's research investigates safety concerns associated with the Oxford-AstraZeneca vaccine, particularly arterial events.</data>
      <data key="d9">safety study,vaccine complications</data>
      <data key="d10">chunk-1f5bd39f94801f6e3906bc498e399298</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="United Arab Emirates (UAE)">
      <data key="d7">2.0</data>
      <data key="d8">The UAE has shown that BBIBP-CorV is 78.1% effective against symptomatic cases and 100% effective against severe cases.&lt;SEP&gt;The United Arab Emirates provided efficacy data for the BBIBP-CorV vaccine after clinical trials.</data>
      <data key="d9">efficacy reporting,vaccine study,vaccine trials</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="Bahrain">
      <data key="d7">3.0</data>
      <data key="d8">Bahrain is mentioned as a location where efficacy data for BBIBP-CorV has been reported.&lt;SEP&gt;Bahrain reported the efficacy of the BBIBP-CorV vaccine against symptomatic and severe COVID-19 cases.&lt;SEP&gt;Bahrain contributed to the reporting of efficacy data concerning the BBIBP-CorV vaccine.</data>
      <data key="d9">efficacy reporting,public health,vaccine efficacy,vaccine study,vaccine trials</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40&lt;SEP&gt;chunk-34095163b30b47116fce3d2618689be5&lt;SEP&gt;chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791305</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="Phase I Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase I trials were conducted to evaluate the safety of the BBIBP-CorV vaccine on 192 adults.</data>
      <data key="d9">clinical trials,vaccine testing</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="Phase II Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase II trials were performed to assess the immunogenicity and efficacy of the BBIBP-CorV vaccine on 448 adults.</data>
      <data key="d9">clinical trials,vaccine testing</data>
      <data key="d10">chunk-5b5dbe63f945f3d4429f1f540c762c40</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="UAE">
      <data key="d7">1.0</data>
      <data key="d8">The UAE announced interim results of a vaccine demonstrating 86% efficacy.</data>
      <data key="d9">public health,vaccine efficacy</data>
      <data key="d10">chunk-34095163b30b47116fce3d2618689be5</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="Argentina">
      <data key="d7">1.0</data>
      <data key="d8">Argentina's clinical trials showed differing effectiveness of BBIBP-CorV compared to other COVID-19 vaccines.</data>
      <data key="d9">clinical trials,comparative study</data>
      <data key="d10">chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="SOTRs (Solid Organ Transplant Recipients)">
      <data key="d7">1.0</data>
      <data key="d8">Solid organ transplant recipients (SOTRs) were included in studies assessing the immunogenic response to the BBIBP-CorV vaccine.</data>
      <data key="d9">immunological study,vaccine testing</data>
      <data key="d10">chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="BBIBP-CorV" target="Phase III Trials">
      <data key="d7">1.0</data>
      <data key="d8">BBIBP-CorV is undergoing Phase III trials to assess its long-term safety and efficacy.</data>
      <data key="d9">clinical assessment,long-term evaluation</data>
      <data key="d10">chunk-1f62dd8f4fa706f61d214740d4aca4e3</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222" target="CD4 T Cell Response">
      <data key="d7">1.0</data>
      <data key="d8">AZD1222 vaccine induces a significant CD4 T cell response during vaccination.</data>
      <data key="d9">immune response,vaccine efficacy</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222" target="Antibody Dependent Cellular Cytotoxicity">
      <data key="d7">1.0</data>
      <data key="d8">AZD1222 triggers Antibody Dependent Cellular Cytotoxicity as part of the immune response against SARS-CoV-2.</data>
      <data key="d9">immune mechanism,vaccine response</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222" target="CD8 T Cell Response">
      <data key="d7">1.0</data>
      <data key="d8">AZD1222 is reported to induce a potent CD8 T cell response in vaccinated individuals.</data>
      <data key="d9">immune mechanism,vaccine efficacy</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="AZD1222" target="Neutralizing Antibodies">
      <data key="d7">1.0</data>
      <data key="d8">The AZD1222 vaccine is used to generate neutralizing antibodies against SARS-CoV-2 and emerging variants.</data>
      <data key="d9">immune response,vaccine</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine" target="DV">
      <data key="d7">1.0</data>
      <data key="d8">DV is involved in the study of the safety and efficacy of the COVID-19 vaccine.</data>
      <data key="d9">research,vaccine study</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine" target="Sputnik V">
      <data key="d7">1.0</data>
      <data key="d8">Sputnik V is categorized as a type of COVID-19 vaccine with neutralizing activity against variants.</data>
      <data key="d9">immune response,vaccine development</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine" target="mRNA Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines represent a new class of technology in the fight against COVID-19.</data>
      <data key="d9">new class,vaccine technology</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine" target="BioNTech">
      <data key="d7">1.0</data>
      <data key="d8">BioNTech collaborates with Pfizer on the BNT162b2 mRNA COVID-19 vaccine.</data>
      <data key="d9">product development,vaccine collaboration</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791340</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine" target="C4591001 Clinical Trial Group">
      <data key="d7">1.0</data>
      <data key="d8">The C4591001 Clinical Trial Group conducts clinical research focused on the efficacy of COVID-19 vaccines.</data>
      <data key="d9">clinical research,vaccine trials</data>
      <data key="d10">chunk-442deee46860f108f0c5389563ea0e97</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791341</data>
      <data key="d13" />
    </edge>
    <edge source="National Center for Cancer Care and Research" target="Queenie Fernandes">
      <data key="d7">1.0</data>
      <data key="d8">Queenie Fernandes contributes to the research at the National Center for Cancer Care and Research regarding COVID-19.</data>
      <data key="d9">authorship,research contribution</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="National Center for Cancer Care and Research" target="Varghese Philipose Inchakalody">
      <data key="d7">1.0</data>
      <data key="d8">Varghese Philipose Inchakalody is involved in the research on COVID-19 variants at the National Center for Cancer Care and Research.</data>
      <data key="d9">authorship,research contribution</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="Gam-COVID-Vac" target="rAd26">
      <data key="d7">1.0</data>
      <data key="d8">rAd26 is a component of the Gam-COVID-Vac vaccine designed to elicit an immune response.</data>
      <data key="d9">recombinant vector,vaccine component</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="Gam-COVID-Vac" target="rAd5">
      <data key="d7">1.0</data>
      <data key="d8">rAd5 acts as the second vector in the Gam-COVID-Vac vaccine formulation.</data>
      <data key="d9">recombinant vector,vaccine component</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Gam-COVID-Vac" target="Phase 1/2 Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase 1/2 clinical trials assessed the safety and immune response efficacy of the Gam-COVID-Vac vaccine.</data>
      <data key="d9">clinical assessment,vaccine efficacy</data>
      <data key="d10">chunk-2baf1f4f2648db88606de10f45be0551</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Gam-COVID-Vac" target="SARS-CoV-2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Gam-COVID-Vac has shown the ability to neutralize variants of SARS-CoV-2, indicating potential cross-protection.</data>
      <data key="d9">cross-protection,strain neutralization</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1/2 Clinical Trials" target="SARS-CoV-2 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Phase 1/2 clinical trials are conducted to assess the safety and immunogenicity of the SARS-CoV-2 vaccine.</data>
      <data key="d9">clinical testing,vaccine assessment</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1/2 Clinical Trials" target="IgG Titre">
      <data key="d7">1.0</data>
      <data key="d8">IgG titre is measured in Phase 1/2 clinical trials to evaluate the immune response to the SARS-CoV-2 vaccine.</data>
      <data key="d9">immune response measurement,vaccine effectiveness</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1/2 Clinical Trials" target="Neutralizing Antibodies">
      <data key="d7">1.0</data>
      <data key="d8">Neutralizing antibodies are assessed during Phase 1/2 clinical trials to gauge the effectiveness of the vaccine.</data>
      <data key="d9">immune response measurement,vaccine evaluation</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Water Research" target="Rapid Screening for SARS-CoV-2 Variants">
      <data key="d7">1.0</data>
      <data key="d8">Water Research published studies focusing on detecting SARS-CoV-2 variants in both clinical and environmental samples.</data>
      <data key="d9">environmental detection,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="Gao D" target="CRISPR-Cas13-based diagnostics">
      <data key="d7">1.0</data>
      <data key="d8">Gao D contributed to the sensitive CRISPR-Cas13-based diagnostics for detecting SARS-CoV-2.</data>
      <data key="d9">research involvement,virus detection</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Diagnostics" target="SARS-CoV-2 Protein Detection">
      <data key="d7">1.0</data>
      <data key="d8">Diagnostics featured research on the detection methods for SARS-CoV-2 proteins.</data>
      <data key="d9">diagnostic methods,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="ELISA Test" target="SARS-CoV-2 Proteins">
      <data key="d7">1.0</data>
      <data key="d8">The ELISA test is developed to detect specific proteins associated with SARS-CoV-2 infection.</data>
      <data key="d9">detection method,protein analysis</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="Automated Western Immunoblotting" target="SARS-CoV-2 Antibodies">
      <data key="d7">1.0</data>
      <data key="d8">Automated Western immunoblotting is utilized in the detection of anti-SARS-CoV-2 antibodies.</data>
      <data key="d9">antibody analysis,detection method</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="Automated Western Immunoblotting" target="Eur J Clin Microbiol Infect Dis">
      <data key="d7">1.0</data>
      <data key="d8">Eur J Clin Microbiol Infect Dis published a study on automated Western immunoblotting for detecting anti-SARS-CoV-2 antibodies.</data>
      <data key="d9">antibody detection,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="Robinson J" target="Drug Treatment Options">
      <data key="d7">1.0</data>
      <data key="d8">Robinson J provides insights on available drug treatment options for COVID-19.</data>
      <data key="d9">COVID-19,treatment discussion</data>
      <data key="d10">chunk-461b6d7ef70b2aad9e56e16a8eb85ed7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791306</data>
      <data key="d13" />
    </edge>
    <edge source="Sinopharm COVID-19 Vaccine" target="Serbia">
      <data key="d7">1.0</data>
      <data key="d8">Serbia received a substantial supply of Sinopharm COVID-19 vaccine doses from China.</data>
      <data key="d9">international aid,vaccine supply</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccination" target="Transplant Recipients">
      <data key="d7">1.0</data>
      <data key="d8">Transplant recipients are studied to evaluate the clinical effectiveness of COVID-19 vaccination.</data>
      <data key="d9">population study,vaccine efficacy</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Transplant Recipients" target="Clinical Effectiveness Study">
      <data key="d7">2.0</data>
      <data key="d8">Transplant recipients are being studied in the Clinical Effectiveness Study regarding the effectiveness of COVID-19 vaccination.&lt;SEP&gt;The Clinical Effectiveness Study focuses on the efficacy of COVID-19 vaccinations in transplant recipients.</data>
      <data key="d9">research focus,research subject,vaccine assessment,vaccine efficacy</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b&lt;SEP&gt;chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791307</data>
      <data key="d13" />
    </edge>
    <edge source="Clinical Effectiveness Study" target="Breakthrough Infections">
      <data key="d7">1.0</data>
      <data key="d8">Breakthrough infections are analyzed as part of the Clinical Effectiveness Study of COVID-19 vaccinations.</data>
      <data key="d9">adverse outcomes,vaccine analysis</data>
      <data key="d10">chunk-f94d02beebab98a3e864c2779b99040b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Clinical Effectiveness Study" target="Qin CX">
      <data key="d7">1.0</data>
      <data key="d8">Qin CX is involved in the Clinical Effectiveness Study related to the risk of SARS-CoV-2 infections in transplant recipients.</data>
      <data key="d9">research involvement,study focus</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Sarilumab" target="REMAP-CAP">
      <data key="d7">1.0</data>
      <data key="d8">Sarilumab demonstrated a reduction in mortality in COVID-19 hospitalized patients in the REMAP-CAP trial.</data>
      <data key="d9">clinical trial,survival rates</data>
      <data key="d10">chunk-f542171328bc39729060fbc8ff577681</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791308</data>
      <data key="d13" />
    </edge>
    <edge source="Sarilumab" target="Remap-Cap">
      <data key="d7">1.0</data>
      <data key="d8">Remap-Cap trial assessed Sarilumab's effectiveness in enhancing survival rates among Covid-19 patients.</data>
      <data key="d9">clinical trial,treatment evaluation</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Sarilumab" target="REMAP-CAP Trial">
      <data key="d7">1.0</data>
      <data key="d8">The REMAP-CAP trial showed that Sarilumab also improved outcomes and survival rates in COVID-19 patients.</data>
      <data key="d9">clinical evaluation,survival improvement</data>
      <data key="d10">chunk-27fd707fb557046d91dccc6a9c1e15fd</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Denmark" target="Oxford-AstraZeneca">
      <data key="d7">1.0</data>
      <data key="d8">Denmark was a location where a study evaluated the effects of the Oxford-AstraZeneca vaccine.</data>
      <data key="d9">study location,vaccine evaluation</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="Norway" target="Oxford-AstraZeneca">
      <data key="d7">1.0</data>
      <data key="d8">Norway was a location included in the study evaluating the effects of the Oxford-AstraZeneca vaccine.</data>
      <data key="d9">study location,vaccine evaluation</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="Logunov DY" target="rAd26 and rAd5 Vector-Based COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Logunov DY studied the safety and immunogenicity of the rAd26 and rAd5 vector-based COVID-19 vaccine in Russia.</data>
      <data key="d9">study involvement,vaccine safety</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Anywaine Z" target="Ebola Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Anywaine Z was involved in the clinical trial studying the safety and immunogenicity of the Ebola vaccines in Uganda and Tanzania.</data>
      <data key="d9">clinical trial,vaccine safety</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Uganda" target="Ebola Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">A clinical trial for the Ebola vaccines took place in Uganda as part of a 2-dose heterologous vaccination regimen.</data>
      <data key="d9">clinical trial,study location</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791336</data>
      <data key="d13" />
    </edge>
    <edge source="Williams K" target="Respiratory Syncytial Virus Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Williams K was involved in the phase 1 safety and immunogenicity study of the respiratory syncytial virus vaccine.</data>
      <data key="d9">study involvement,vaccine safety</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1/2 Studies" target="rAd26 and rAd5 Vector-Based COVID-19 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">Phase 1/2 studies were conducted to assess the safety and immunogenicity of the rAd26 and rAd5 vector-based COVID-19 vaccine.</data>
      <data key="d9">clinical trial,vaccine assessment</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Heterologous Prime-Boost Vaccination" target="Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Heterologous prime-boost vaccination methodology was evaluated for the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines in clinical trials.</data>
      <data key="d9">immune response,vaccination method</data>
      <data key="d10">chunk-35fdd1bda3fea15e577ab68819cc4db8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791309</data>
      <data key="d13" />
    </edge>
    <edge source="Solid Organ Transplant Recipients (SOTRs)" target="Neutralizing Antibodies">
      <data key="d7">1.0</data>
      <data key="d8">SOTRs have shown a development of neutralizing antibodies upon vaccination, although often with weaker responses compared to the general population.</data>
      <data key="d9">immune response,vaccine effectiveness</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Solid Organ Transplant Recipients (SOTRs)" target="Breakthrough Disease">
      <data key="d7">1.0</data>
      <data key="d8">Solid organ transplant recipients (SOTRs) are more likely to experience breakthrough disease despite being fully vaccinated compared to the general population.</data>
      <data key="d9">infection risk,vulnerability</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="Computational Approaches" target="Emerging Variants of Concern (VOCs)">
      <data key="d7">1.0</data>
      <data key="d8">Computational approaches assist in predicting the impact of VOCs on the efficacy of COVID-19 vaccines.</data>
      <data key="d9">modeling,prediction</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="rAd26-S" target="rAd5-S">
      <data key="d7">1.0</data>
      <data key="d8">rAd26-S and rAd5-S were administered in a specific regimen during the clinical trials.</data>
      <data key="d9">dosing regimen,vaccine combination</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Participants" target="Phase 1 Trials">
      <data key="d7">1.0</data>
      <data key="d8">Participants received a single intramuscular dose of rAd26-S or rAd5-S in Phase 1 Trials.</data>
      <data key="d9">trial involvement,vaccine testing</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="Participants" target="Phase 2 Trials">
      <data key="d7">1.0</data>
      <data key="d8">Participants were administrated doses of rAd26-S and rAd5-S in Phase 2 Trials following Phase 1.</data>
      <data key="d9">trial involvement,vaccine progression</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1 Trials" target="No Severe Adverse Reactions">
      <data key="d7">1.0</data>
      <data key="d8">Results from Phase 1 Trials indicated no severe adverse reactions among participants post-vaccination.</data>
      <data key="d9">safety assessment,vaccine trials</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 2 Trials" target="Phase 3 Trials">
      <data key="d7">1.0</data>
      <data key="d8">Results from Phase 2 Trials informed the larger Phase 3 Trials conducted on nearly 22,000 adults.</data>
      <data key="d9">clinical evaluation,vaccine efficacy</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 1" target="Phase 2">
      <data key="d7">1.0</data>
      <data key="d8">Phase 1 results informed the progression to Phase 2 trials for further assessment of the vaccine.</data>
      <data key="d9">trial progression,vaccine development</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791310</data>
      <data key="d13" />
    </edge>
    <edge source="Phase 2" target="Phase 3">
      <data key="d7">1.0</data>
      <data key="d8">Phase 2 findings determined the expansion of trials into Phase 3 for larger population evaluation.</data>
      <data key="d9">clinical evaluation,vaccine assessment</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Patterson TF" target="ACTT-2 Study">
      <data key="d7">1.0</data>
      <data key="d8">Patterson TF is associated with the ACTT-2 Study focused on COVID-19 therapies.</data>
      <data key="d9">clinical trials,research involvement</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Magro G" target="Virus Research">
      <data key="d7">1.0</data>
      <data key="d8">Magro G's work on COVID-19 therapies was published in Virus Research.</data>
      <data key="d9">COVID-19 review,research publication</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Chu CM" target="Thorax">
      <data key="d7">1.0</data>
      <data key="d8">Chu CM's findings on Lopinavir/Ritonavir for SARS were published in Thorax.</data>
      <data key="d9">SARS treatment,research publication</data>
      <data key="d10">chunk-a2bf94dfda652964087a535f4138f69b</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Human Coronavirus 229E" target="Neurotropism">
      <data key="d7">1.0</data>
      <data key="d8">Research highlights the neurotropic properties of Human Coronavirus 229E, impacting neurological health.</data>
      <data key="d9">infection study,viral behavior</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="Human Coronavirus OC43" target="Neurons">
      <data key="d7">1.0</data>
      <data key="d8">Human Coronavirus OC43 has been shown to propagate from neuron to neuron via axonal transport mechanisms.</data>
      <data key="d9">axonal propagation,infection mechanism</data>
      <data key="d10">chunk-a06be5698bde2a8fa0e5e10b2d87875c</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791312</data>
      <data key="d13" />
    </edge>
    <edge source="NHS Guidance" target="Remark-Cap">
      <data key="d7">1.0</data>
      <data key="d8">NHS Guidance recommends Tocilizumab and Sarilumab for treating Covid-19 in hospitalized patients.</data>
      <data key="d9">protocol,treatment recommendation</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="Casirivimab" target="Imdevimab">
      <data key="d7">1.0</data>
      <data key="d8">Casirivimab is part of a combination with Imdevimab to form the REGEN-COV treatment.</data>
      <data key="d9">Covid-19 treatment,combination therapy</data>
      <data key="d10">chunk-f773b3825a5d702479233be92ad1c099</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791313</data>
      <data key="d13" />
    </edge>
    <edge source="rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine" target="Clinical Trial">
      <data key="d7">1.0</data>
      <data key="d8">The rAd26 and rAd5 vector-based COVID-19 vaccine is being tested in a phase-3 clinical trial to evaluate its safety and efficacy.</data>
      <data key="d9">phase-3 study,vaccine testing</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="Sputnik V Vaccine" target="rAd26 and rAd5">
      <data key="d7">1.0</data>
      <data key="d8">The immunogenicity of the Sputnik V Vaccine was evaluated alongside rAd26 and rAd5 vectors during vaccine studies.</data>
      <data key="d9">immunogenicity,vaccine comparison</data>
      <data key="d10">chunk-d300ad0251280be6e2b2d713e9ee6b72</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="mRNA-1273 SARS-CoV-2 Vaccine" target="Moderna">
      <data key="d7">1.0</data>
      <data key="d8">Moderna developed the mRNA-1273 vaccine specifically against SARS-CoV-2.</data>
      <data key="d9">company,vaccine development</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 mRNA COVID-19 Vaccine" target="BioNTech">
      <data key="d7">1.0</data>
      <data key="d8">BioNTech collaborated with Pfizer in developing the BNT162b2 mRNA COVID-19 vaccine.</data>
      <data key="d9">collaboration,vaccine development</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="BNT162b2 mRNA COVID-19 Vaccine" target="Pfizer">
      <data key="d7">1.0</data>
      <data key="d8">Pfizer worked with BioNTech in the development of the BNT162b2 mRNA COVID-19 vaccine.</data>
      <data key="d9">collaboration,vaccine development</data>
      <data key="d10">chunk-daf403b571f1733c8c38249ab48ad963</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791314</data>
      <data key="d13" />
    </edge>
    <edge source="Lipid Nanoparticles" target="mRNA Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">mRNA vaccines utilize lipid nanoparticles to encapsulate mRNA for effective delivery into human cells.</data>
      <data key="d9">delivery method,vaccine technology</data>
      <data key="d10">chunk-c9bb134c549ef99824593cc9b842ed83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Q. Fernandes" target="Manuscript">
      <data key="d7">1.0</data>
      <data key="d8">Q. Fernandes wrote the initial draft of the manuscript.</data>
      <data key="d9">author contribution,draft</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791319</data>
      <data key="d13" />
    </edge>
    <edge source="Virus" target="Therapeutic Strategies">
      <data key="d7">1.0</data>
      <data key="d8">Research on the virus informs the development of therapeutic strategies to enhance treatment options.</data>
      <data key="d9">research focus,treatment improvement</data>
      <data key="d10">chunk-05b47fbb959b906a23f529ac6d753a35</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791319</data>
      <data key="d13" />
    </edge>
    <edge source="E154K" target="G142D">
      <data key="d7">1.0</data>
      <data key="d8">E154K and G142D are mutations of SARS-CoV-2 studied in relation to the effectiveness of antibody treatments.</data>
      <data key="d9">antibody study,viral mutation</data>
      <data key="d10">chunk-f6003fc73508a55817ade571f6742383</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791324</data>
      <data key="d13" />
    </edge>
    <edge source="Sinovac Biotech Ltd" target="COVID-19 Vaccine (Vero Cell)">
      <data key="d7">1.0</data>
      <data key="d8">Sinovac Biotech Ltd is the developer and producer of the COVID-19 Vaccine (Vero Cell).</data>
      <data key="d9">production,vaccine development</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791330</data>
      <data key="d13" />
    </edge>
    <edge source="Whole Virus Vaccines" target="Influenza">
      <data key="d7">1.0</data>
      <data key="d8">Whole virus vaccines have been successfully used for the prevention of influenza.</data>
      <data key="d9">prevention,vaccine strategy</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Whole Virus Vaccines" target="Poliomyelitis">
      <data key="d7">1.0</data>
      <data key="d8">Whole virus vaccines are one of the strategies for producing vaccines to prevent poliomyelitis.</data>
      <data key="d9">prevention,vaccine strategy</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Whole Virus Vaccines" target="Human Papillomavirus Infections">
      <data key="d7">1.0</data>
      <data key="d8">Whole virus vaccines have been utilized to prevent human papillomavirus infections.</data>
      <data key="d9">prevention,vaccine strategy</data>
      <data key="d10">chunk-76b896a58b69e219292e8f85429f28c9</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Neutralizing Antibodies" target="Emerging Variants of Concern (VOCs)">
      <data key="d7">1.0</data>
      <data key="d8">Neutralizing antibodies play a critical role in combating emerging variants of concern after vaccination.</data>
      <data key="d9">antibody response,vaccine efficacy</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="V-2 Mutagenesis" target="RNA Template">
      <data key="d7">1.0</data>
      <data key="d8">V-2 mutagenesis utilizes an RNA template as a foundational element for introducing mutations.</data>
      <data key="d9">methodology,scientific process</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Tian JH" target="Spike Glycoprotein Vaccine Candidate NVX-CoV2373">
      <data key="d7">1.0</data>
      <data key="d8">Tian JH studied the immunogenicity of the NVX-CoV2373 vaccine candidate.</data>
      <data key="d9">research study,vaccine development</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791326</data>
      <data key="d13" />
    </edge>
    <edge source="Baboon" target="NevX-CoV2373 Vaccine">
      <data key="d7">1.0</data>
      <data key="d8">The NVX-CoV2373 vaccine assessed immunogenicity in baboons as part of research.</data>
      <data key="d9">immunogenicity,vaccine study</data>
      <data key="d10">chunk-c0e6aa9f0875f979985d2e25e365e6ae</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791327</data>
      <data key="d13" />
    </edge>
    <edge source="Safety" target="Revenko H">
      <data key="d7">1.0</data>
      <data key="d8">Revenko H's work focuses on assessing immunity related to vaccines in the context of health research.</data>
      <data key="d9">health research,immunity assessment</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell)" target="SARS-CoV-2 (CN2 strain)">
      <data key="d7">1.0</data>
      <data key="d8">COVID-19 Vaccine (Vero Cell) aims to prevent infections caused by the SARS-CoV-2 (CN2 strain).</data>
      <data key="d9">infection prevention,vaccine target</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791330</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell)" target="Aluminium Hydroxide">
      <data key="d7">1.0</data>
      <data key="d8">Aluminium Hydroxide is an adjuvant incorporated in the COVID-19 Vaccine (Vero Cell) to enhance immune response.</data>
      <data key="d9">adjuvant role,vaccine formulation</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791331</data>
      <data key="d13" />
    </edge>
    <edge source="COVID-19 Vaccine (Vero Cell)" target="Rhesus Macaca Mulatta">
      <data key="d7">1.0</data>
      <data key="d8">Rhesus Macaca Mulatta were used in safety evaluations for the COVID-19 Vaccine (Vero Cell).</data>
      <data key="d9">animal testing,safety evaluation</data>
      <data key="d10">chunk-aaaa5fb757f39e3e664c7d9b45847f8f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="Therapeutics" target="Vaccines">
      <data key="d7">1.0</data>
      <data key="d8">Vaccines and therapeutics are both critical to the prevention and treatment of COVID-19 as examined in the article.</data>
      <data key="d9">preventive measures,research focus</data>
      <data key="d10">chunk-ce3bd37fe1aaaf4844a65730510fce83</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791332</data>
      <data key="d13" />
    </edge>
    <edge source="Vaccines" target="Immuno-Compromised Individuals">
      <data key="d7">1.0</data>
      <data key="d8">Vaccines present challenges in generating robust immune responses in immuno-compromised individuals, impacting their overall efficacy.</data>
      <data key="d9">immune response,vaccination challenges</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="Neutrophils" target="Infected Cells">
      <data key="d7">1.0</data>
      <data key="d8">Neutrophils recognize and eliminate infected cells as part of the immune response.</data>
      <data key="d9">cell elimination,immune response</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791333</data>
      <data key="d13" />
    </edge>
    <edge source="Eosinophils" target="Infected Cells">
      <data key="d7">1.0</data>
      <data key="d8">Eosinophils target and eliminate infected cells in the immune process.</data>
      <data key="d9">cell elimination,immune response</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="Macrophages" target="Infected Cells">
      <data key="d7">1.0</data>
      <data key="d8">Macrophages help identify and destroy infected cells in the immune response.</data>
      <data key="d9">cell elimination,immune response</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="NK Cells" target="Infected Cells">
      <data key="d7">1.0</data>
      <data key="d8">NK cells recognize and eliminate infected cells as part of the body's immune defense.</data>
      <data key="d9">cell elimination,immune response</data>
      <data key="d10">chunk-0f6cf3a778132d5b8450f1b918dd5c9f</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 VOC-alpha" target="Allplex SARS-CoV-2/FluA/FluB/ RSV Assay">
      <data key="d7">1.0</data>
      <data key="d8">The Allplex assay is used for rapid screening and diagnosis of the SARS-CoV-2 VOC-alpha variant.</data>
      <data key="d9">diagnostic method,variant detection</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 VOC-alpha" target="Nested RT-PCR Assays">
      <data key="d7">1.0</data>
      <data key="d8">Nested RT-PCR assays are designed for detecting SARS-CoV-2 variants of concern, including VOC-alpha.</data>
      <data key="d9">clinical application,variant detection</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791334</data>
      <data key="d13" />
    </edge>
    <edge source="Intervirology" target="Detection of Coronaviruses">
      <data key="d7">1.0</data>
      <data key="d8">Intervirology published findings on detecting various coronaviruses.</data>
      <data key="d9">coronavirus detection,research publication</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="Infect Genet Evol" target="Sanger-based Screening">
      <data key="d7">1.0</data>
      <data key="d8">Infect Genet Evol published a study on a Sanger-based approach for screening SARS-CoV-2 variants.</data>
      <data key="d9">research publication,variant detection</data>
      <data key="d10">chunk-2e048a55e60c5424d16722fffe73116e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791335</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Vaccine" target="Recombinant Adenovirus Type 26">
      <data key="d7">1.0</data>
      <data key="d8">The SARS-CoV-2 vaccine is formulated using Recombinant Adenovirus Type 26 as a key component.</data>
      <data key="d9">vaccine formulation,viral vector</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Vaccine" target="Recombinant Adenovirus Type 5">
      <data key="d7">1.0</data>
      <data key="d8">The SARS-CoV-2 vaccine includes Recombinant Adenovirus Type 5 as an essential vector.</data>
      <data key="d9">vaccine formulation,viral vector</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791337</data>
      <data key="d13" />
    </edge>
    <edge source="SARS-CoV-2 Vaccine" target="Phase 3 Clinical Trials">
      <data key="d7">1.0</data>
      <data key="d8">Phase 3 clinical trials evaluate the effectiveness and safety of the SARS-CoV-2 vaccine on a large scale.</data>
      <data key="d9">broader participant group,efficacy evaluation</data>
      <data key="d10">chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Frozen Formulation" target="Lyophilized Formulation">
      <data key="d7">2.0</data>
      <data key="d8">The frozen formulation of the SARS-CoV-2 vaccine is considered more effective than the lyophilized formulation based on immune response data from clinical trials.&lt;SEP&gt;The frozen formulation was found to be more effective than the lyophilized variant in terms of immune response metrics.</data>
      <data key="d9">efficacy analysis,efficiency comparison,vaccine comparison,vaccine effectiveness</data>
      <data key="d10">chunk-504266ce396b2ee303462fca7cecde6e&lt;SEP&gt;chunk-a218174a04fc9428ffade976a83e2c22</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791311</data>
      <data key="d13" />
    </edge>
    <edge source="Aslam S" target="Immunogenicity Study">
      <data key="d7">1.0</data>
      <data key="d8">Aslam S is involved in the Immunogenicity Study focusing on the effectiveness of COVID-19 vaccinations in transplant recipients.</data>
      <data key="d9">research involvement,vaccine effectiveness</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Adler E" target="Immunogenicity Study">
      <data key="d7">1.0</data>
      <data key="d8">Adler E participates in the Immunogenicity Study assessing the immune response in transplant recipients after vaccination.</data>
      <data key="d9">research involvement,vaccine effectiveness</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Mekeel K" target="Immunogenicity Study">
      <data key="d7">1.0</data>
      <data key="d8">Mekeel K is a participant in the Immunogenicity Study concerning COVID-19 vaccinations in transplant patients.</data>
      <data key="d9">research involvement,vaccine effectiveness</data>
      <data key="d10">chunk-c5d32d4ea33d3f509cec33af4a70a104</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791338</data>
      <data key="d13" />
    </edge>
    <edge source="Emerging Variants of Concern (VOCs)" target="CAPTURE Study">
      <data key="d7">1.0</data>
      <data key="d8">The CAPTURE study indicates the presence of neutralizing antibodies against novel VOCs in certain patient populations following vaccination.</data>
      <data key="d9">study,vaccine impact</data>
      <data key="d10">chunk-79e80c342197e54d6b5f6d848763a310</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791339</data>
      <data key="d13" />
    </edge>
    <edge source="Gu J" target="SARS">
      <data key="d7">1.0</data>
      <data key="d8">Gu J is an author who researched multiple organ infections and pathogenesis associated with Severe Acute Respiratory Syndrome (SARS).</data>
      <data key="d9">research contribution,study authorship</data>
      <data key="d10">chunk-98ac72e5523a2d04c4d2212f1d927f7e</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791276</data>
      <data key="d13" />
    </edge>
    <edge source="Athletics Championship" target="Noah Carter">
      <data key="d7">1.0</data>
      <data key="d8">Noah Carter's participation in the World Athletics Championship is marked by his record-breaking performance.</data>
      <data key="d9">athlete achievement,sporting event</data>
      <data key="d10">chunk-a18a5bbab5af25bc2490ee22a56c55a8</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791294</data>
      <data key="d13" />
    </edge>
    <edge source="Noah Carter" target="Influenza Vaccine Effectiveness Network">
      <data key="d7">1.0</data>
      <data key="d8">Noah Carter is involved in studies assessing the effectiveness of vaccines within the network.</data>
      <data key="d9">research involvement,vaccine effectiveness</data>
      <data key="d10">chunk-f849139a3171d7c3bad48d83b0e56bf7</data>
      <data key="d11">Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis_extracted.json</data>
      <data key="d12">1761791328</data>
      <data key="d13" />
    </edge>
  </graph>
</graphml>
